
<html lang="en"     class="pb-page"  data-request-id="8bdfdb82-8565-4e49-85be-3e3cf81da764"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2017.60.issue-8;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.6b01197"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects" /></meta><meta name="dc.Creator" content="Yasuhiro  Wada" /></meta><meta name="dc.Creator" content="Seiji  Nakano" /></meta><meta name="dc.Creator" content="Akifumi  Morimoto" /></meta><meta name="dc.Creator" content="Ken-ichi  Kasahara" /></meta><meta name="dc.Creator" content="Takahiko  Hayashi" /></meta><meta name="dc.Creator" content="Yoshio  Takada" /></meta><meta name="dc.Creator" content="Hiroko  Suzuki" /></meta><meta name="dc.Creator" content="Michiko  Niwa-Sakai" /></meta><meta name="dc.Creator" content="Shigeki  Ohashi" /></meta><meta name="dc.Creator" content="Mutsuhiro  Mori" /></meta><meta name="dc.Creator" content="Takatsugu  Hirokawa" /></meta><meta name="dc.Creator" content="Satoshi  Shuto" /></meta><meta name="dc.Description" content="We previously discovered that indazole derivative 8 was a highly selective β3-adrenergic receptor (β3-AR) agonist, but it appeared to be metabolically unstable. To improve metabolic stability, furt..." /></meta><meta name="Description" content="We previously discovered that indazole derivative 8 was a highly selective β3-adrenergic receptor (β3-AR) agonist, but it appeared to be metabolically unstable. To improve metabolic stability, furt..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 11, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01197" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01197" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01197" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01197" /></link>
        
    
    

<title>Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01197" /></meta><meta property="og:title" content="Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0014.jpeg" /></meta><meta property="og:description" content="We previously discovered that indazole derivative 8 was a highly selective β3-adrenergic receptor (β3-AR) agonist, but it appeared to be metabolically unstable. To improve metabolic stability, further optimization of this scaffold was carried out. We focused on the sulfonamide moiety of this scaffold, which resulted in the discovery of compound 15 as a highly potent β3-AR agonist (EC50 = 18 nM) being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3 &gt; 556-fold). Compound 15 showed dose-dependent β3-AR-mediated responses in marmoset urinary bladder smooth muscle, had a desirable metabolic stability and pharmacokinetic profile (Cmax and AUC), and did not obviously affect heart rate or mean blood pressure when administered intravenously (3 mg/kg) to anesthetized rats. Thus, compound 15 is a highly potent, selective, and orally available β3-AR agonist, which may serve as a candidate drug for the treatment of overactive bladder without off-target-based cardiovascular side effects." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01197"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01197">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01197&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01197&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01197&amp;href=/doi/10.1021/acs.jmedchem.6b01197" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3252-3265</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01711" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01536" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel Indazole Derivatives as Orally Available β<sub>3</sub>-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yasuhiro++Wada">Yasuhiro Wada</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-5988-2912" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Seiji++Nakano">Seiji Nakano</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Akifumi++Morimoto">Akifumi Morimoto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ken-ichi++Kasahara">Ken-ichi Kasahara</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takahiko++Hayashi">Takahiko Hayashi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yoshio++Takada">Yoshio Takada</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroko++Suzuki">Hiroko Suzuki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michiko++Niwa-Sakai">Michiko Niwa-Sakai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shigeki++Ohashi">Shigeki Ohashi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mutsuhiro++Mori">Mutsuhiro Mori</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takatsugu++Hirokawa">Takatsugu Hirokawa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Satoshi++Shuto">Satoshi Shuto</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-7850-8064" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div><div class="aff-info" id="aff2"><span class="aff-text"><sup>‡</sup>Faculty of Pharmaceutical Sciences and <sup>§</sup>Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∥</span> <span class="aff-text">Molecular Profiling Research Center for Drug Discovery (molprof), National Institute of Advanced Industrial Science and Technology (AIST), 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">⊥</span> <span class="aff-text">Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan</span></div><div class="corresp-info"><strong>*</strong>For Y.W.: phone, +81-558-76-8494; fax, +81-558-76-5755; E-mail, <a href="/cdn-cgi/l/email-protection#14637570753a6d64547b793a7567757c7d397f7567717d3a777b3a7e64"><span class="__cf_email__" data-cfemail="82f5e3e6e3acfbf2c2edeface3f1e3eaebafe9e3f1e7ebace1edace8f2">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For S.S.: phone/fax, +81-11-706-3769; E-mail, <a href="/cdn-cgi/l/email-protection#95e6fde0d5e5fdf4e7f8bbfdfafee0f1f4fcbbf4f6bbffe5"><span class="__cf_email__" data-cfemail="44372c3104342c2536296a2c2b2f3120252d6a25276a2e34">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01197&amp;href=/doi/10.1021%2Facs.jmedchem.6b01197" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3252–3265</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 29, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 August 2016</li><li><span class="item_label"><b>Published</b> online</span>11 April 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 April 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01197" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01197</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3252%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYasuhiro%2BWada%252C%2BSeiji%2BNakano%252C%2BAkifumi%2BMorimoto%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D8%26contentID%3Dacs.jmedchem.6b01197%26title%3DDiscovery%2Bof%2BNovel%2BIndazole%2BDerivatives%2Bas%2BOrally%2BAvailable%2B%25CE%25B23-Adrenergic%2BReceptor%2BAgonists%2BLacking%2BOff-Target-Based%2BCardiovascular%2BSide%2BEffects%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3265%26publicationDate%3DApril%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01197"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1404</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01197" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yasuhiro&quot;,&quot;last_name&quot;:&quot;Wada&quot;},{&quot;first_name&quot;:&quot;Seiji&quot;,&quot;last_name&quot;:&quot;Nakano&quot;},{&quot;first_name&quot;:&quot;Akifumi&quot;,&quot;last_name&quot;:&quot;Morimoto&quot;},{&quot;first_name&quot;:&quot;Ken-ichi&quot;,&quot;last_name&quot;:&quot;Kasahara&quot;},{&quot;first_name&quot;:&quot;Takahiko&quot;,&quot;last_name&quot;:&quot;Hayashi&quot;},{&quot;first_name&quot;:&quot;Yoshio&quot;,&quot;last_name&quot;:&quot;Takada&quot;},{&quot;first_name&quot;:&quot;Hiroko&quot;,&quot;last_name&quot;:&quot;Suzuki&quot;},{&quot;first_name&quot;:&quot;Michiko&quot;,&quot;last_name&quot;:&quot;Niwa-Sakai&quot;},{&quot;first_name&quot;:&quot;Shigeki&quot;,&quot;last_name&quot;:&quot;Ohashi&quot;},{&quot;first_name&quot;:&quot;Mutsuhiro&quot;,&quot;last_name&quot;:&quot;Mori&quot;},{&quot;first_name&quot;:&quot;Takatsugu&quot;,&quot;last_name&quot;:&quot;Hirokawa&quot;},{&quot;first_name&quot;:&quot;Satoshi&quot;,&quot;last_name&quot;:&quot;Shuto&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;3252-3265&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01197&quot;},&quot;abstract&quot;:&quot;We previously discovered that indazole derivative 8 was a highly selective β3-adrenergic receptor (β3-AR) agonist, but it appeared to be metabolically unstable. To improve metabolic stability, further optimization of this scaffold was carried out. We focused on the sulfonamide moiety of this scaffold, which resulted in the discovery of compound 15 as a highly potent β3-AR agonist (EC50 = 18 nM) being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3 &gt; 556-fold). Compound 15 showed dose-dependent β3-AR-mediated responses in marmoset urinary bladder smooth muscle, had a desirable metabolic stability and pharmacokinetic profile (Cmax and AUC), and did not obviously affect heart rate or mean blood pressure when administered intravenously (3 mg/kg) to anesthetized rats. Thus, compound 15 is a highly potent, selective, and orally available β3-AR agonist, which may serve as a candidate drug for the treatment of overactive bladder without off-target-based cardiovascular side effects.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01197&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01197" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01197&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01197" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01197&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01197" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01197&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01197&amp;href=/doi/10.1021/acs.jmedchem.6b01197" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01197" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01197" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01197%26sid%3Dliteratum%253Aachs%26pmid%3D28355078%26genre%3Darticle%26aulast%3DWada%26date%3D2017%26atitle%3DDiscovery%2Bof%2BNovel%2BIndazole%2BDerivatives%2Bas%2BOrally%2BAvailable%2B%25CE%25B23-Adrenergic%2BReceptor%2BAgonists%2BLacking%2BOff-Target-Based%2BCardiovascular%2BSide%2BEffects%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D8%26spage%3D3252%26epage%3D3265%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290716" title="Sulfones">Sulfones</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/jmcmar.2017.60.issue-8/20170427/jmcmar.2017.60.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We previously discovered that indazole derivative <b>8</b> was a highly selective β<sub>3</sub>-adrenergic receptor (β<sub>3</sub>-AR) agonist, but it appeared to be metabolically unstable. To improve metabolic stability, further optimization of this scaffold was carried out. We focused on the sulfonamide moiety of this scaffold, which resulted in the discovery of compound <b>15</b> as a highly potent β<sub>3</sub>-AR agonist (EC<sub>50</sub> = 18 nM) being inactive to β<sub>1</sub>-, β<sub>2</sub>-, and α<sub>1A</sub>-AR (β<sub>1</sub>/β<sub>3</sub>, β<sub>2</sub>/β<sub>3</sub>, and α<sub>1A</sub>/β<sub>3</sub> > 556-fold). Compound <b>15</b> showed dose-dependent β<sub>3</sub>-AR-mediated responses in marmoset urinary bladder smooth muscle, had a desirable metabolic stability and pharmacokinetic profile (<i>C</i><sub>max</sub> and AUC), and did not obviously affect heart rate or mean blood pressure when administered intravenously (3 mg/kg) to anesthetized rats. Thus, compound <b>15</b> is a highly potent, selective, and orally available β<sub>3</sub>-AR agonist, which may serve as a candidate drug for the treatment of overactive bladder without off-target-based cardiovascular side effects.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82056" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82056" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The International Union of Pharmacology recognizes three adrenergic receptor (AR) subfamilies, the α<sub>1</sub>-, α<sub>2</sub>-, and β-AR subfamilies, with β<sub>1</sub>-, β<sub>2</sub>-, and β<sub>3</sub>-ARs as members of the latter.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The β<sub>1</sub>-AR is the dominant receptor in heart and adipose tissue, whereas the β<sub>2</sub>-AR is responsible for relaxation of vascular, uterine, and airway smooth muscle.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The β<sub>3</sub>-AR mediates metabolic effects such as lipolysis and thermogenesis in adipose tissues.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Given that β<sub>3</sub>-AR mRNA is present in human white fat, gall bladder, stomach, small intestine, prostate, and urinary bladder detrusor,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> this particular receptor represents an attractive target for drug discovery efforts that may culminate in the development of potent and selective β<sub>3</sub>-AR agonists.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Because many β<sub>3</sub>-AR agonists induce weight loss in obese animals and exert antidiabetic effects in rodent models of type 2 diabetes, these agonists were investigated in clinical trials for the treatment of obesity and/or diabetes.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> However, these agonists failed during early clinical investigations, likely because the expression pattern of β<sub>3</sub>-AR in most animal species differs considerably from that in humans, particularly in adipose tissues.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Moreover, many of the agonists also showed either poor pharmacokinetic (PK) profiles and/or cardiovascular adverse effects due to a lack of selectivity for the β<sub>3</sub>-AR over β<sub>1</sub>- and β<sub>2</sub>-ARs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> However, these earlier β<sub>3</sub>-AR agonists were observed to relax isolated rat and human detrusor muscle strips and to increase bladder capacity in rats.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Therefore, pharmaceutical companies have recently been endeavoring to discover potent, selective, and orally bioavailable β<sub>3</sub>-AR agonists for the treatment of overactive bladder (OAB).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">OAB is defined as urgency with or without urinary incontinence, usually associated with frequency and nocturia.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Population-based estimations demonstrated that OAB affects 11.8% of adults and that its rates are similar between men and women and increase with age.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> OAB can be extremely distressing to the patient and has been shown to negatively affect quality of life.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> OAB is associated with enhanced voiding frequency, increased risk of depression, sleep disorders, skin infections, and falls with fractures.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Detrusor overactivity is a urodynamic observation characterized by involuntary detrusor contractions during the filling phase that may be spontaneous or provoked.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Muscarinic antagonists have been used as first-line treatment drugs for OAB for many years.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> These drugs demonstrate improvement in continence, number of micturitions, and urgency.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> However, they are associated with mechanistic side effects such as dry mouth, constipation, and blurred vision, and in rare instances with urinary retention.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> A recent study found that the persistence rates with pharmacotherapy for OAB were ≤35% for 12 months after the initial prescription of muscarinic antagonists.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The side effects can be related to the limitation of their long-term adherence in the pharmacotherapy of OAB, at least to some extent.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Therefore, alternative drugs are sought to both avoid adverse effects and provide more potent therapeutic options. The β<sub>3</sub>-AR agonists have emerged as a promising class of such drugs because this class may be less prone toward inducing adverse effects in comparison with muscarinic antagonists.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">Clinical studies have examined several β<sub>3</sub>-AR agonists such as <b>1</b> (mirabegron, YM-178),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a><b>2</b> (solabegron, GW427353),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a><b>3</b> (ritobegron, KUC-7483),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and <b>4</b> (vibegron, MK-4618),<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> which are shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>. In 2012, Mirabegron was approved for the treatment of OAB,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and its treatment showed significant efficacy for OAB and resulted in a lower dry mouth incidence compared to muscarinic antagonists.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> However, treatment with mirabegron caused hypertension and increased heart rate (HR) in both animals and healthy individuals.<a onclick="showRef(event, 'ref19 ref24'); return false;" href="javascript:void(0);" class="ref ref19 ref24">(19, 24)</a> We hypothesize that the increased HR resulting from treatment with mirabegron is at least partially induced via activation of the β<sub>1</sub>-AR,<a onclick="showRef(event, 'cit24a'); return false;" href="javascript:void(0);" class="ref cit24a">(24a)</a> and accordingly, highly selective novel β<sub>3</sub>-AR agonists would be effective drugs for the treatment of OAB without the risk of such cardiovascular side effects as increased HR. In contrast to mirabegron, which inhibits CYP2D6 and generally should not be coadministered with CYP2D6 substrates,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> highly selective novel β<sub>3</sub>-AR agonists should be inactive to CYP enzymes.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of <b>1</b>, <b>2</b>, <b>3</b>, and <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In our previous publication, we reported on novel indazole derivatives, represented by compound <b>8</b>, which exhibited a highly selective β<sub>3</sub>-AR agonistic activity without cardiovascular side effects.<a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">(10c)</a> However, PK studies of <b>8</b> in rats indicated that it was metabolically unstable and had poor PK properties (<i>C</i><sub>max</sub> and AUC). On the basis of these findings, we performed a structure–activity relationship (SAR) study of the sulfonamide moiety of the indazole derivatives to improve the metabolic stability while maintaining the excellent selectivity over α<sub>1A</sub>-AR and obtained the optimized compound <b>15</b>, which had more desirable PK properties than <b>8</b> in rats. We also conducted a docking study at the β<sub>3</sub>-AR binding site, which identified the structural features required for high affinity for the β<sub>3</sub>-AR as well as high selectivity for the β<sub>3</sub>-AR over α<sub>1A</sub>-, β<sub>1</sub>-, and β<sub>2</sub>-ARs. Thus, we have successfully identified compound <b>15</b> as a highly potent, selective, and orally available β<sub>3</sub>-AR agonist lacking cardiovascular side effects.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37577" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37577" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Characteristics of Compound <b>8</b></h3><div class="NLM_p">We evaluated the in vitro ADME and PK profiles of four 3-substituted indazole β<sub>3</sub>-AR agonists <b>5</b>–<b>8</b> previously reported by us.<a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">(10c)</a> As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, the human unbound microsomal intrinsic clearance (hCL<sub>int,u</sub>) and the rat unbound microsomal intrinsic clearance (rCL<sub>int,u</sub>) for <b>7</b> and <b>8</b> were determined to be unacceptably higher (thereby indicating greater metabolic instability) than <b>5</b> even though <b>7</b> and <b>8</b> possessed excellent β<sub>3</sub>-AR selectivity while <b>5</b> was poorly selective for the β<sub>3</sub>-AR over α<sub>1A</sub>-AR. Furthermore, <b>8</b> showed an undesirable PK profile (<i>C</i><sub>max</sub> and AUC) in rats compared with <b>5</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). On the other hand, <b>8</b> had moderate MDCK cell monolayer permeability and good solubility in aqueous solutions at a pH 1.2 and pH 6.8 (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The low <i>C</i><sub>max</sub> and AUC of <b>8</b> may be due to its metabolic instability.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. AR Agonist Activity and in Vitro Metabolic Stability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">The results are shown as the mean ± SEM (<i>n</i> = 3) or are presented as the average of two experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">IA (intrinsic activity): maximum response induced by isoproterenol was defined as 100%.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">IA: maximum response induced by norepinephrine was defined as 100%.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro ADME and in Vivo Pharmacokinetics in Rats</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0009.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>5</b></th><th class="colsep0 rowsep0" align="center"><b>8</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">R</td><td class="colsep0 rowsep0" align="center">–Me</td><td class="colsep0 rowsep0" align="center">–<i>i</i>-Pr</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="center">Physicochemical Properties and in Vitro ADME Profiles</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">metabolic stability<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hCL<sub>int,u</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="center"><10</td><td class="colsep0 rowsep0" align="center">193</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rCL<sub>int,u</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="center">103</td><td class="colsep0 rowsep0" align="center">211</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDCK (× 10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="center">2.4</td><td class="colsep0 rowsep0" align="center">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 1.2 solution (μM)</td><td class="colsep0 rowsep0" align="center">285</td><td class="colsep0 rowsep0" align="center">295</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 6.8 solution (μM)</td><td class="colsep0 rowsep0" align="center">273</td><td class="colsep0 rowsep0" align="center">267</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="center">Pharmacokinetics Parameters in Rats<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5 mg/kg<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/mL)</td><td class="colsep0 rowsep0" align="center">0.107 ± 0.034</td><td class="colsep0 rowsep0" align="center">0.0452</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μg·h/mL)</td><td class="colsep0 rowsep0" align="center">0.542 ± 0.065</td><td class="colsep0 rowsep0" align="center">0.200</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The results are shown as the mean ± SD (<i>n</i> = 3) or are presented as the average of two experiments.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Compounds were administered orally to rats in solution with saline or water.</p></div></div></div><div class="NLM_p">These previous results indicated that the selectivity of our indazole compounds for the β<sub>3</sub>-AR and α<sub>1A</sub>-AR changed depending on the substituent at the 3-positon. Therefore, when ordered in terms of their selectivity for the β<sub>3</sub>-AR over α<sub>1A</sub>-AR, the indazole compounds ranked as follows: <i>iso</i>-propyl (<b>8</b>) > cyclobutyl (<b>7</b>) > ethyl (<b>6</b>) > methyl (<b>5</b>). In contrast, the rank order of these compounds in terms of their metabolic stability (hCL<sub>int,u</sub>) was as follows: methyl (<b>5</b>) > ethyl (<b>6</b>) > <i>iso</i>-propyl (<b>8</b>) > cyclobutyl (<b>7</b>). Thus, highly selective compounds (<b>7</b> and <b>8</b>) showed poor metabolic stability.</div><div class="NLM_p">Our aim was to improve the metabolic stability of these compounds while maintaining highly selective β<sub>3</sub>-AR agonist activity. In sulfonamide-containing AR agonists, the α<sub>1A</sub>- or β<sub>3</sub>-AR agonistic activity can be manipulated by changing the sulfonamide structure.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Therefore, we decided to optimize the metabolically stable 3-methyl indazole derivative <b>5</b> by modifying its sulfonamide moiety in order to improve its β<sub>3</sub>-AR agonistic selectivity over α<sub>1A</sub>-AR.</div><div class="NLM_p">Altenbach et al. reported a SAR study on potent sulfonamide-containing α<sub>1A</sub>-AR agonist <b>9</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>),<a onclick="showRef(event, 'cit26a'); return false;" href="javascript:void(0);" class="ref cit26a">(26a)</a> for which increases in the size of the aliphatic group (R<sup>1</sup>) of the sulfonamide resulted in decreased α<sub>1A</sub>-AR potency while aromatic substitution of the sulfonamide made the compounds inactive to α<sub>1A</sub>-AR.<a onclick="showRef(event, 'cit26a'); return false;" href="javascript:void(0);" class="ref cit26a">(26a)</a> On the other hand, when Sawa et al. compared aliphatic sulfonamide <b>10a</b> with aromatic sulfonamide <b>10b</b>, the β<sub>3</sub>-AR agonistic potency of <b>10b</b> was higher than that of <b>10a</b>.<a onclick="showRef(event, 'cit26b'); return false;" href="javascript:void(0);" class="ref cit26b">(26b)</a> Taking these findings into account, we hypothesized that changing the size of the substitution on the sulfonamide of compound <b>5</b> would improve selectivity for β<sub>3</sub>-AR agonistic activity over α<sub>1A</sub>-AR without sacrificing its desirable human microsome, rat microsome, and rat PK profile (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design strategy of sulfonamide moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> SAR of the Sulfonamide Moiety</h3><div class="NLM_p">Agonistic activities for the β<sub>3</sub>-AR of analogues of <b>5</b>, which were modified at the sulfonamide moiety, are shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Replacement of the methyl substituent of <b>5</b> with an <i>n</i>-Pr (<b>12</b>) slightly increased β<sub>3</sub>-AR agonistic potency (<b>5</b>, EC<sub>50</sub> = 21 nM vs <b>12</b>, EC<sub>50</sub> = 6.5 nM). However, by replacing the methyl substituent with <i>i</i>-Pr (<b>13</b>), the β<sub>3</sub>-AR agonistic activity was decreased (<b>5</b>, EC<sub>50</sub> = 21 nM vs <b>13</b>, EC<sub>50</sub> = 70 nM). We next synthesized and evaluated compounds with a cycloalkyl substitution; replacement with a cyclopropyl or cyclobutyl group increased β<sub>3</sub>-AR agonistic potency (<b>13</b>, EC<sub>50</sub> = 70 nM vs <b>14</b>, EC<sub>50</sub> = 43 nM; <b>15</b>, EC<sub>50</sub> = 18 nM). However, replacement with a cyclopentyl group (<b>16</b>) decreased potency (<b>13</b>, EC<sub>50</sub> = 70 nM vs <b>16</b>, EC<sub>50</sub> = 309 nM). On the other hand, the phenyl sulfonamide derivative <b>17</b> (EC<sub>50</sub> = 3.9 nM) showed higher potency than the alkyl congeners. Thus, in order of their β<sub>3</sub>-AR agonist activity, the compounds were ranked as follows: <b>17</b> > <b>12</b> > <b>15</b>, <b>5</b> > <b>14</b> > <b>13</b> > <b>16</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Human β<sub>3</sub>- and α<sub>1A</sub>-AR Agonistic Activities<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0010.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0011.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">The results are shown as the mean ± SEM (<i>n</i> = 3) or are presented as the average of two experiments.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Human β<sub>3</sub>- or α<sub>1A</sub>-AR agonist assay, ref <a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">10c</a>.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">IA (intrinsic activity): maximum response induced by isoproterenol was defined as 100%.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">IA: maximum response induced by norepinephrine was defined as 100%. NT: not tested.</p></div></div><div></div></div><div class="NLM_p">The agonistic potency of these compounds for the α<sub>1A</sub>-AR is also summarized in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Although replacement of the methyl substituent with an <i>n</i>-Pr did not change activity (<b>5</b>, EC<sub>50</sub> = 219 nM vs <b>12</b>, EC<sub>50</sub> = 163 nM), replacement with <i>i</i>-Pr (<b>13</b>) and cyclopropyl (<b>14</b>) showed remarkably weakened agonistic activity for the α<sub>1A</sub>-AR (<b>13</b>, EC<sub>50</sub> = 1757 nM; <b>14</b>, EC<sub>50</sub> = 1250 nM). Finally, the change to a cyclobutyl (<b>15</b>), cyclopentyl (<b>16</b>), or phenyl (<b>17</b>) group made these compounds inactive to α<sub>1A</sub>-AR (all EC<sub>50</sub> > 10000 nM). Thus, in order of α<sub>1A</sub>-AR agonist activity, the compounds were ranked as <b>5</b>, <b>12</b> > <b>13</b>, <b>14</b> ≫ <b>15</b>, <b>16</b>, <b>17</b>.</div><div class="NLM_p">On the basis of their agonistic potencies for the β<sub>3</sub>- and α<sub>1A</sub>-ARs, these compounds were ranked in terms of their selectivity for β<sub>3</sub>-AR over α<sub>1A</sub>-AR as follows: <b>17</b> > <b>15</b> ≫ <b>12</b>, <b>13</b>, <b>14</b>, <b>16</b> > <b>5</b>. The most selective, <b>15</b> and <b>17</b>, were next evaluated for β<sub>1</sub>-AR and β<sub>2</sub>-AR agonistic activities, and the results indicated that both compounds were inactive to these two AR subtypes (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Thus, <b>15</b> and <b>17</b> were identified as highly selective β<sub>3</sub>-AR agonists and were selected for the next pharmacological and ADME evaluation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Summary of Human β- and α<sub>1</sub>-ARs Agonistic Activities<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">β<sub>3</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center">β<sub>1</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center">β<sub>2</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center">α<sub>1A</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IA (%)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IA (%)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IA (%)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IA (%)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="center">13 ± 1.5</td><td class="colsep0 rowsep0" align="center">69</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">11.9</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">5.6</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">9.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b><a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">18 ± 2.6</td><td class="colsep0 rowsep0" align="center">105</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center">3.9 ± 0.067</td><td class="colsep0 rowsep0" align="center">85</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">isoproterenol</td><td class="colsep0 rowsep0" align="center">86 ± 3.7</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">3.2 ± 0.29</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">13 ± 3.0</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">norepinephrine</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">9.1 ± 0.52</td><td class="colsep0 rowsep0" align="center">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">The results are shown as the mean ± SEM (<i>n</i> = 3) or are presented as the average of two experiments.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Human β<sub>1</sub>-, β<sub>2</sub>-, β<sub>3</sub>- or α<sub>1A</sub>-AR agonist assay, ref <a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">10c</a>.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">IA (intrinsic activity): maximum response induced by isoproterenol was defined as 100%.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">IA: maximum response induced by norepinephrine was defined as 100%.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Compound <b>15</b> exhibited insignificant agonistic activity for α<sub>1B</sub>-AR and α<sub>1D</sub>-AR (EC<sub>50</sub> > 10000 nM). NT: not tested.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> ADME Profiles</h3><div class="NLM_p">ADME profiles of <b>15</b> and <b>17</b> as well as <b>8</b> in vitro are summarized in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. Although human microsomal clearance of <b>15</b> was excellent (hCL<sub>int,u</sub> = 57 mL/min/kg), that of <b>17</b> was not acceptable (hCL<sub>int,u</sub> = 464 mL/min/kg, 8-fold worse than <b>15</b>). Rat microsomal clearance of <b>15</b> was also acceptable (rCL<sub>int,u</sub> = 52 mL/min/kg, 4-fold better than <b>8</b>). Both <b>15</b> and <b>17</b> had moderate MDCK cell monolayer permeability and good solubility in pH 1.2 and pH 6.8 solutions. Compound <b>15</b> also had improved <i>C</i><sub>max</sub>, AUC and half-life values in comparison with <b>8</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro ADME and In Vivo Pharmacokinetics of <b>8</b>, <b>15</b>, and <b>17</b> in Rats</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0012.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0013.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">The results are shown as the mean ± SD (<i>n</i> = 3) or are presented as the average of two experiments.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Compounds were administered orally to rats in solution with saline or water. NT: not tested.</p></div></div><div></div></div><div class="NLM_p last">Compound <b>15</b> was next evaluated with a panel of cytochrome P450 enzymes, where it showed only insignificant inhibition of the CYPs (<34% inhibition at 10 μM against CYP1A2, 2B6, 2C19, 2C8, 2C9, 2D6, and 3A4). In the same evaluation, <b>1</b> showed a significant inhibition of 87% at 10 μM against CYP2D6. The low inhibitory capacity of <b>15</b> against CYPs suggests that <b>15</b> has a much lower risk of drug–drug interactions than <b>1</b> when coadministered with CYP-metabolized drugs.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Cardiovascular Safety Profiles and Pharmacology</h3><div class="NLM_p">We compared the cardiovascular safety profile of <b>15</b>, which has highly selective β<sub>3</sub>-AR agonistic activity and an excellent ADME profile, with the clinical drug <b>1</b>. As shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, <b>1</b> (iv, 3 mg/kg) clearly increased HR and decreased mean blood pressure (MBP) in anesthetized rats. In the same evaluation, compound <b>15</b> (iv, 3 mg/kg) tended to increase HR and decrease MBP less than <b>1</b> as a preliminary experiment.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> These data indicate that <b>15</b> possesses a desirable cardiovascular safety profile, likely due to its minimal off-target activities; it is highly active to the β<sub>3</sub>-AR but completely inactive to all other α<sub>1</sub>- and β-ARs.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Effects of Intravenous Administration of <b>15</b> on HR and MBP in Anaesthetized Rats<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">HR</th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">MBP</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">N</th><th class="colsep0 rowsep0" align="center" char="±">increase (%)</th><th class="colsep0 rowsep0" align="center">decrease (%)</th><th class="colsep0 rowsep0" align="center" char="±">increase (%)</th><th class="colsep0 rowsep0" align="center" char="±">decrease (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">saline</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.9</td><td class="colsep0 rowsep0" align="center">4.5 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">5.4 ± 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char="±">10.0 ± 2.5</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">38.3 ± 3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 0.4</td><td class="colsep0 rowsep0" align="center">0.9 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">12.9 ± 0.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Compounds were administered intravenously to rats (3 mg/kg) and HR and MBP recorded for 30 min. Maximum increase or decrease of HR or MBP is shown as the percentage change relative to baseline. The results are shown as the mean ± SEM. See ref <a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">10c</a> for further details of the experimental method. ND: not detected.</p></div></div></div><div class="NLM_p">Next, we investigated the effect of <b>15</b> on the relaxation of urinary bladder smooth muscle strips from marmosets.<a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">(10c)</a> As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, <b>15</b> fully relaxed isolated marmoset urinary bladder smooth muscle that was precontracted with KCl, and its efficacy was similar to that of the nonselective β-AR agonist isoproterenol.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Relaxation of marmoset urinary bladder smooth muscle by <b>15</b>. Each point represents the mean of two experiments. See ref <a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">10c</a> for further details of the experimental method.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of its excellent β<sub>3</sub>-AR selectivity, oral availability, low risk of drug–drug interactions, and favorable relaxation effect on marmoset urinary bladder smooth muscle, the optimized compound <b>15</b> was identified as a candidate drug for the treatment of OAB without cardiovascular side effects.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div class="NLM_p">The synthesis of compounds <b>12</b>–<b>17</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Aminoalcohol <b>20</b> was prepared by coupling (<i>R</i>)-2-(3-nitrophenyl)oxirane <b>18</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> with benzylamine <b>19</b> in 2-PrOH. Protection of the hydroxyl of <b>20</b> with triethylsilyl chloride (TESCl) and imidazole afforded <b>21</b>. Hydrogenolysis of <b>21</b> reduced the nitro group and deprotected <i>N</i>-Bn, and the alkyl amine was protected by using Boc<sub>2</sub>O and then the <i>O</i>-Bn group was deprotected under hydrogenolysis conditions to afford alcohol <b>22</b>. Mitsunobu reaction of <b>22</b> and <b>23</b><a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">(10c)</a> using DMEAD<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and triphenylphosphine proceeded to give the aniline <b>24</b>. Coupling of a sulfonyl chloride with aniline <b>24</b> and subsequent deprotection of Boc and TES groups afforded the corresponding target compounds <b>12</b>–<b>17</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-PrOH, reflux; (b) TESCl, imidazole, DMF, rt; (c) H<sub>2</sub>, 10% Pd/C, EtOH, 50 °C; (d) Boc<sub>2</sub>O, THF, rt; (e) H<sub>2</sub>, 20% Pd(OH)<sub>2</sub>/C, THF, MeOH, 50 °C; (f) DMEAD, PPh<sub>3</sub>, toluene, rt; (g) R<sup>1</sup>-SO<sub>2</sub>Cl (R<sup>1</sup> = <i>n</i>-Pr, cyclopropyl, cyclobutyl, or phenyl), pyridine, CH<sub>2</sub>Cl<sub>2</sub> or R<sup>1</sup>-SO<sub>2</sub>Cl (R<sup>1</sup> = <i>i</i>-Pr or cyclopentyl), DBU, CH<sub>2</sub>Cl<sub>2</sub>, rt. (h) For <b>12</b>–<b>14</b>, <b>16</b>, and <b>17</b>: 4 M HCl in dioxane, rt. for <b>15</b>:<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> 1 M TBAF in THF, THF, rt then 4 M HCl in dioxane, rt.</p></p></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Docking Study to Characterize β<sub>3</sub>-AR Agonistic Activity and Selectivity over α<sub>1A</sub>-, β<sub>1</sub>-, and β<sub>2</sub>-ARs</h3><div class="NLM_p">A docking study of the indazole series of the agonists was undertaken in order to understand the SAR underlying the β<sub>3</sub>- and α<sub>1A</sub>-AR agonistic activities. No crystal structure of the β<sub>3</sub>-AR is known; therefore, we constructed a homology model of the β<sub>3</sub>-AR. Previous studies showed that β<sub>3</sub>-AR homology models, which were constructed using the crystal structure of the β<sub>2</sub>-AR, were useful for providing structural insight into ligand binding conformation, performing QSAR analyses, and conducting in silico drug discovery.<a onclick="showRef(event, 'cit10a cit10d ref31'); return false;" href="javascript:void(0);" class="ref cit10a cit10d ref31">(10a, 10d, 31)</a> Recent resolutions of the β<sub>2</sub>-AR active conformation<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> allowed us to generate more accurate models of the β<sub>3</sub>-AR with β<sub>3</sub>-AR agonist using homology modeling and docking simulation. We constructed an in silico homology model of the β<sub>3</sub>-AR based on the β<sub>2</sub>-AR active conformation (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3P0G">3P0G</a>). The β<sub>3</sub>-AR sequence was aligned with the β<sub>1</sub>-, β<sub>2</sub>-, and α<sub>1A</sub>-ARs using MOE 2015 software (Chemical Computing Group, Montreal, Canada), and the alignment was refined manually to better match the position of amino acids with the corresponding β<sub>2</sub>-AR structure (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_003.pdf" class="ext-link">Figure S1</a>, Supporting Information). The sequence identity between β<sub>3</sub>- and β<sub>2</sub>-ARs is 55.7% based on sequence alignment.<a onclick="showRef(event, 'cit31b'); return false;" href="javascript:void(0);" class="ref cit31b">(31b)</a></div><div class="NLM_p">First, we constructed a homology model of the β<sub>3</sub>-AR with compound <b>17</b>, which is the most potent β<sub>3</sub>-AR agonist in the indazole series. Using this model, we performed a docking simulation with a structurally diverse indazole series of eight compounds, which included the previously reported compounds,<a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">(10c)</a> in addition to another series that consisted of KUC-7322 (active form of compound <b>3</b>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> two analogues of <b>10</b>,<a onclick="showRef(event, 'cit26b'); return false;" href="javascript:void(0);" class="ref cit26b">(26b)</a> and isoproterenol. Previously, our group used a similar strategy for a docking simulation to characterize the histamine H<sub>3</sub> receptor binding mode.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The correlation between the calculated docking score and the −pEC<sub>50</sub> was determined. As shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, a strong correlation was observed between docking score and −pEC<sub>50</sub> (<i>R</i> = 0.67 for all 12 compounds; <i>R</i> = 0.90 for the eight indazole compounds). These results show that the homology model and docking pose of the ligand are in agreement with the SAR. To further validate the docking pose of compound <b>15</b>, which offers the best profile for potency, selectivity, and ADME within our indazole series, a molecular dynamics (MD) simulation was performed. An enormous difference between the pose suggested by docking and final ligand pose after a MD simulation has been reported in spite of a high docking score.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> To examine temporal changes in compound <b>15</b> with the β<sub>3</sub>-AR during 20 ns of the MD simulation, the root-mean-square deviation (RMSD) was calculated for compound <b>15</b> and the β<sub>3</sub>-AR throughout the simulation time (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_003.pdf" class="ext-link">Figure S2</a> in Supporting Information). The time series of the RMSD of compound <b>15</b> show that the binding mode is overall stable. Accordingly, compound <b>15</b> with the β<sub>3</sub>-AR after the MD refinement was further evaluated for its interaction with and selectivity for the β<sub>3</sub>-AR over α<sub>1A</sub>-, β<sub>1</sub>-, and β<sub>2</sub>-ARs.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plot of docking score calculated by Glide extra precision (XP) based on the compound <b>17</b> β<sub>3</sub>-AR model versus experimental agonistic activity (−pEC<sub>50</sub>) for eight indazole analogues (diamonds) and four other compounds (circles). The coefficient of determination, <i>R</i><sup>2</sup>, was 0.45 for the docking scores and −pEC<sub>50</sub> values of all 12 compounds. See Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_003.pdf" class="ext-link">Table S1</a>) for individual −pEC<sub>50</sub> values and docking scores.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The proposed binding mode of compound <b>15</b> with the β<sub>3</sub>-AR after the MD refinement is shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A. The obtained mode suggested that compound <b>15</b> interacts with the three key conserved residues, Asp117 (transmembrane [TM] 3), Ser208 (TM5), and Asn332 (TM7), as observed in the crystal structure of the BI-167107−β<sub>2</sub>-AR complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3P0G">3P0G</a>). An additional hydrogen bonding was predicted between the indazole NH of compound <b>15</b> and backbone of Cys196 (extracellular loop [ECL] 2); the indazole moiety participates in hydrophobic interactions with residues Leu97 (TM2), Leu329 (TM7), and Trp333 (TM7) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A,B). Moreover, hydrogen bonding also occurred between the sulfonamide carbonyl oxygen and Asn312 (TM6), a T-shaped π–π interaction was predicted between the phenyl ring and Phe309 (TM6), and the cyclobutane moiety occupied a hydrophobic pocket formed by residues Val118 (TM3), Ile173 (TM4), and Tyr204 (TM5) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A,B).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Proposed model of compound <b>15</b> binding to the homology model of β<sub>3</sub>-AR after MD refinement. Receptor residues within 4.0 Å of compound <b>15</b> are represented by lines. Compound <b>15</b> is shown as a ball and stick model. All nonpolar hydrogen atoms of the receptor residues are omitted for clarity. Hydrogen bonding and salt bridges to side chains of Asn117, Ser208, Asn312, and Asn332 are depicted by blue dots. Hydrogen bonding to the backbone of Cys196 is also depicted by blue dots. (B) Schematic representation of the interactions between compound <b>15</b> and β<sub>3</sub>-AR residues using the Maestro Ligand Interaction Diagram module (Schrödinger, LLC, Portland, OR, USA). Hydrogen bonding is indicated with dashed arrows, salt bridge with purple lines, cation−π interactions with red lines, and π–π interactions with green lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next examined selectivity for the β<sub>3</sub>-AR over α<sub>1A</sub>-AR based on the proposed β<sub>3</sub>-AR binding model of compound <b>15</b> and the sequence alignment with the α<sub>1A</sub>-AR. Previously, we reported that the selectivity of different indazole 3-moieties for the β<sub>3</sub>-AR over α<sub>1A</sub>-AR was ranked as follows: <i>i</i>-Pr (<b>8</b>) > cyclobutyl (<b>7</b>) > ethyl (<b>6</b>) > −Me (<b>5</b>) > −CH<sub>2</sub>OH.<a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">(10c)</a> These results suggest that a hydrophobic substituent effectively induces improved selectivity for the β<sub>3</sub>-AR over α<sub>1A</sub>-AR. The indazole moiety participates in hydrophobic interactions with residues Leu97 (TM2), Leu329 (TM7), and Trp333 (TM7) of the β<sub>3</sub>-AR in the binding model. The residue Leu329 is not conserved in the α<sub>1A</sub>-AR; in α<sub>1A</sub>-AR, these residues are mutated to the hydrophilic residue Lys309. Therefore, the environment of this pocket in the α<sub>1A</sub>-AR might be more hydrophilic than that in the β<sub>3</sub>-AR. Thus, the SAR results on selectivity for the β<sub>3</sub>-AR over α<sub>1A</sub>-AR are supported by the results obtained from our docking model of the β<sub>3</sub>-AR. On the other hand, when compared by their selectivity for the β<sub>3</sub>-AR over α<sub>1A</sub>-AR, the substituents at the sulfonamide moiety were ordered as follows: phenyl (<b>17</b>) > cyclobutyl (<b>15</b>) ≫ <i>n</i>-propyl (<b>12</b>) > methyl (<b>5</b>) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). This ordering suggests that a more bulky substituent improves selectivity for the β<sub>3</sub>-AR over α<sub>1A</sub>-AR. The cyclobutyl substituent displayed hydrophobic interactions with Val118 (TM3), Ile173 (TM4), and Tyr204 (TM5) in β<sub>3</sub>-AR homology modeling. The residue Ile173 is not conserved and is replaced with Leu162 in the α<sub>1A</sub>-AR. Moreover, Phe198, Ala199, and Ser200 of ECL2, which is located proximal to the sulfone group of the sulfonamide in the β<sub>3</sub>-AR, are not conserved in the α<sub>1A</sub>-AR; in the α<sub>1A</sub>-AR, these residues correspond to Ile178, Asn179, and Glu180, respectively. Interactions of α<sub>1A</sub>-AR’s residues with the cyclobutyl substituent and sulfone group may thus differ significantly from those of β<sub>3</sub>-AR’s residues based on differences in their overall size, protonation potential, charge density, and overall hydrogen bond-forming ability with neighboring residues or ligands. Consequently, these differences may account for the selectivity of β<sub>3</sub>-AR over α<sub>1A</sub>-AR agonistic activity in our indazole analogues.</div><div class="NLM_p last">We also considered the selectivity for the β<sub>3</sub>-AR over β<sub>1</sub>- and β<sub>2</sub>-ARs based on the proposed β<sub>3</sub>-AR binding model of compound <b>15</b>. As previously observed by Edmondon et al.,<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> the Ala197 (ECL2) residue of β<sub>3</sub>-AR is a critical component for selectivity for activation of β<sub>3</sub>-AR over binding to β<sub>1</sub>- and β<sub>2</sub>-ARs. The indazole moiety of compound <b>15</b> formed a hydrogen-bonding interaction with the backbone of Cys196, and the Ala197 residue is located proximal to the indazole NH group (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). The Ala197 replaces an Asp residue in β<sub>1</sub>- and β<sub>2</sub>-ARs (Asp217 in β<sub>1</sub>-AR, Asp192 in β<sub>2</sub>-ARs). The Asp residue in β<sub>1</sub>- and β<sub>2</sub>-ARs may lead to unfavorable interactions with this hydrogen-bonding with respect to both electrostatic interactions and size. Therefore, compound <b>15</b> is likely to show high selectivity for the β<sub>3</sub>-AR over β<sub>1</sub>- and β<sub>2</sub>-ARs.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We successfully developed the highly potent and selective β<sub>3</sub>-AR agonist <b>15</b>, which possesses a desirable metabolic stability and PK profile. Compound <b>15</b> showed dose-dependent β<sub>3</sub>-AR-mediated responses in marmoset urinary bladder smooth muscle and exhibited an excellent cardiovascular safety profile. These promising characteristics are likely due to its minimal off-target effects: <b>15</b> is highly active toward only the β<sub>3</sub>-AR and completely inactive toward all other α- and β-ARs. Furthermore, <b>15</b> is likely to have a lower risk of drug–drug interactions due to its low inhibition of CYPs. Thus, compound <b>15</b> could be a drug candidate for the treatment of OAB without cardiovascular side effects. Detailed pharmacology of <b>15</b> will be reported in a future pharmacology paper. We also developed a docking model of the β<sub>3</sub>-AR with <b>15</b> and related β<sub>3</sub>-AR agonists, which identified the structural features required for highly selective binding to the β<sub>3</sub>-AR over α<sub>1A</sub>-, β<sub>1</sub>-, and β<sub>2</sub>-ARs and which could therefore be useful for the design of other potent β<sub>3</sub>-AR agonists.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Methods</h3><div class="NLM_p">All reagents and solvents were purchased from commercial sources and were used as received. Anhydrous solvents were obtained from commercial sources. Thin layer chromatography (TLC) was carried out using Merck GmbH precoated silica gel 60 F<sub>254</sub> (Darmstadt, Germany). Chromatography on silica gel was carried out using prepacked silica gel cartridges (Yamazen Hi-Flash column silica gel, Purifpack-Si series, or Biotage KP-Sil series) and the indicated solvent system (Yamazen Multi Prep YFLC, a Moritex Purif-α2 (50F) or Quad1 preparative isolation system). <sup>1</sup>H NMR spectra were recorded on either a JEOL AL-300 (300 MHz) or a Bruker BIOPIN AVANCE III HD (400 MHz), with chemical shifts reported in δ values (ppm) relative to trimethylsilane. Electrospray ionization (ESI) high-resolution mass spectra (HRMS) were recorded using a Thermo Scientific Orbitrap Velos Pro (Waltham, MA, USA). Liquid chromatography–mass spectrometry (LC/MS) data were recorded using a Waters single quadrupole type mass spectrometer UPLC/SQD system (Milford, MA, USA) with an ESI method. All the final compounds were purified to ≥95% purity, as determined by high-performance liquid chromatography (HPLC). The HPLC method conditions were as follows: YMC Meteoric Core C18 column (Kyoto, Japan), 2.7 μm, 3.0 mm × 50 mm, 40 °C; solvent A consisting of water (10 mM ammonium acetate); solvent B consisting of acetonitrile; 1.0 mL/min flow rate; linear mobile phase gradient of 10–95% B (2 min), 95% B (2 min), 10% B (2 min); photodiode array detection (254 nm). None of the final compounds were recognized as PAINS compounds.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> All animal experiments were approved by the Committee on Ethics in Animal Experiments of Asahi Kasei Pharma Corporation.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (<i>R</i>)-<i>N</i>-(3-(1-Hydroxy-2-((2-((3-methyl-1<i>H</i>-indazol-6-yl)oxy)ethyl)amino)ethyl)phenyl)propane-1-sulfonamide (<b>12</b>)</h4><div class="NLM_p last">To a solution of <b>24</b> (95 mg, 0.15 mmol) and pyridine (75 μL, 0.9 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added propane-1-sulfonyl chloride (86 mg, 0.6 mmol) at room temperature, and the solution was shaken (600 min<sup>–1</sup>) overnight. The mixture was purified by flash column chromatography (4:3 <i>n</i>-hexane/ethyl acetate). The sulfonamide product was diluted with MTBE (100 μL), and 4 M HCl in 1,4-dioxane (1.5 mL, 6.0 mmol) was added at room temperature. The mixture was shaken (600 min<sup>–1</sup>) overnight, and nitrogen gas was blown into the reaction solution to evaporate the solvent. The residue was dried to give compound <b>12</b> (40.9 mg, 0.095 mmol, 63% yield) as dihydrochloride salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.93 (3H, t, <i>J</i> = 7.6), 1.68 (2H, quin, <i>J</i> = 7.6), 2.44 (3H, s), 3.03–3.09 (1H, m), 3.07 (2H, t, <i>J</i> = 7.6), 3.23–3.27 (1H, m), 3.46 (2H, t, <i>J</i> = 5.1), 4.33–4.37 (2H, m), 4.99 (1H, dd, <i>J</i> = 2.2, 10.2), 6.21 (1H, brs), 6.77 (1H, dd, <i>J</i> = 1.8, 8.7), 6.90 (1H, d, <i>J</i> = 1.8), 7.11 (1H, d, <i>J</i> = 7.8), 7.15 (1H, dd, <i>J</i> = 1.3, 7.8), 7.30 (1H, s), 7.33 (1H, t, <i>J</i> = 7.8), 7.60 (1H, d, <i>J</i> = 8.7), 8.97 (1H, brs), 9.22 (1H, brs), 9.88 (1H, s). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.4, 12.5, 16.7, 45.9, 52.2, 53.6, 63.4, 67.9, 92.1, 111.6, 116.6, 117.1, 118.6, 120.9, 121.0, 129.3, 138.5, 140.7, 141.7, 143.0, 157.2. HRMS calculated for C<sub>21</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>S + H<sup>+</sup>, 433.1904; found ESI [M + H]<sup>+</sup>, 443.1897. LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 433. HPLC: purity 100%, <i>R</i><sub>T</sub> 2.0 min.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (<i>R</i>)-<i>N</i>-(3-(1-Hydroxy-2-((2-((3-methyl-1<i>H</i>-indazol-6-yl)oxy)ethyl)amino)ethyl)phenyl)propane-2-sulfonamide (<b>13</b>)</h4><div class="NLM_p">Step 1: To a solution of <b>24</b> (96 mg, 0.15 mmol) and pyridine (18 μL, 0.23 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added propane-2-sulfonyl chloride (26 mg, 0.18 mmol) at room temperature, and the solution was stirred overnight. To the mixture was added DBU (134 μL, 0.9 mmol) and propane-2-sulfonyl chloride (20 μL, 0.18 mmol) at room temperature. The mixture was stirred overnight, and DBU (33.5 μL, 0.23 mmol) and propane-2-sulfonyl chloride (20 μL, 0.18 mmol) were added at room temperature. The mixture was stirred for 4 days, and DBU (33.5 μL, 0.23 mmol) and propane-2-sulfonyl chloride (30 μL, 0.26 mmol) were added at room temperature. The mixture was stirred overnight and purified by flash column chromatography (81:19 to 60:40 <i>n</i>-hexane/ethyl acetate) to give a mixture of <b>24</b> and sulfonamide product (41.5 mg). The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) and 1.7 mmol/g MP-isocyanate (118 mg, 0.2 mmol) was added at room temperature. The mixture was stirred overnight, filtered, and concentrated to give <i>tert</i>-butyl (<i>R</i>)-6-(2-((tert-butoxycarbonyl)(2-(3-((1-methylethyl)sulfonamido)phenyl)-2-((triethylsilyl)oxy)ethyl)amino)ethoxy)-3-methyl-1<i>H</i>-indazole-1-carboxylate (40 mg). LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 747.</div><div class="NLM_p last">Step 2: To <i>tert</i>-butyl (<i>R</i>)-6-(2-((<i>tert</i>-butoxycarbonyl)(2-(3-((1-methylethyl)sulfonamido)phenyl)-2-((triethylsilyl)oxy)ethyl)amino)ethoxy)-3-methyl-1<i>H</i>-indazole-1-carboxylate (40 mg) was added 4 M HCl in 1,4-dioxane (1.5 mL, 6.0 mmol) at room temperature. The mixture was shaken (600 min<sup>–1</sup>) overnight, and nitrogen gas was blown into the reaction solution to evaporate the solvent. The residue was dried to give compound <b>13</b> (28 mg, 0.055 mmol, 36% yield) as dihydrochloride salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.24 (6H, d, <i>J</i> = 6.8), 2.44 (3H, s), 3.02–3.09 (1H, m), 3.23 (1H, septet, <i>J</i> = 6.8), 3.24–3.26 (1H, m), 3.44–3.47 (2H, m), 4.31–4.40 (2H, m), 4.98 (1H, dd, <i>J</i> = 2.2, 10.3), 6.22 (1H, brs), 6.77 (1H, dd, <i>J</i> = 2.1, 8.7), 6.90 (1H, d, <i>J</i> = 2.1), 7.09 (1H, d, <i>J</i> = 7.7), 7.17 (1H, dd, <i>J</i> = 1.3, 8.1), 7.30–7.34 (2H, m), 7.60 (1H, d, <i>J</i> = 8.7), 8.95 (1H, brs), 9.20 (1H, brs), 9.85 (1H, s). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.4, 16.0, 45.9, 51.2, 53.6, 63.4, 68.0, 92.1, 111.6, 116.5, 117.1, 118.5, 120.8, 120.9, 129.3, 138.8, 140.8, 141.6, 143.0, 157.0. HRMS calculated for C<sub>21</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>S + H<sup>+</sup>, 433.1904; found ESI [M + H]<sup>+</sup>, 433.1895. LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 433. HPLC: purity 100%, <i>R</i><sub>T</sub> 1.9 min.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (<i>R</i>)-<i>N</i>-(3-(1-Hydroxy-2-((2-((3-methyl-1<i>H</i>-indazol-6-yl)oxy)ethyl)amino)ethyl)phenyl)cyclopropanesulfonamide (<b>14</b>)</h4><div class="NLM_p last">To a solution of <b>24</b> (96 mg, 0.15 mmol) and pyridine (18 μL, 0.23 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added cyclopropanesulfonyl chloride (25 mg, 0.18 mmol) at room temperature, and the solution was stirred overnight. To the mixture was added pyridine (24 μL, 0.3 mmol) and cyclopropanesulfonyl chloride (42 mg, 0.3 mmol) at room temperature. The mixture was stirred overnight and purified by flash column chromatography (4/3 <i>n</i>-hexane/ethyl acetate). The sulfonamide product was diluted with 1,4-dioxane (0.2 mL), to which was added 4 M HCl in 1,4-dioxane (1.6 mL, 6.4 mmol) at room temperature. The mixture was shaken (600 min<sup>–1</sup>) overnight, and nitrogen gas was blown into the reaction solution to evaporate the solvent. The residue was dried to give compound <b>14</b> (63 mg, 0.12 mmol, 83% yield) as dihydrochloride salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.90–0.97 (4H, m), 2.44 (3H, s), 2.58–2.64 (1H, m), 3.03–3.10 (1H, m), 3.23–3.28 (1H, m), 3.46 (2H, t, <i>J</i> = 5.0), 4.32–4.44 (2H, m), 5.01 (1H, dd, <i>J</i> = 2.2, 10.3), 6.25 (1H, brs), 6.77 (1H, dd, <i>J</i> = 2.1, 8.8), 6.91 (1H, d, <i>J</i> = 2.1), 7.12 (1H, d, <i>J</i> = 7.8), 7.18 (1H, dd, <i>J</i> = 1.3, 7.8), 7.32–7.36 (2H, m), 7.60 (1H, d, <i>J</i> = 8.8), 8.99 (1H, brs), 9.26 (1H, brs), 9.82 (1H, s). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.9, 11.5, 29.5, 45.9, 53.6, 63.4, 67.9, 92.1, 111.5, 117.2, 117.4, 119.4, 120.8, 121.1, 129.1, 138.5, 140.8, 141.7, 142.9, 157.1. HRMS calculated for C<sub>21</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>S + H<sup>+</sup>, 431.1748; found ESI [M + H]<sup>+</sup>, 431.1754. LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 431. HPLC: purity 100%, <i>R</i><sub>T</sub> 1.9 min.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>R</i>)-<i>N</i>-(3-(1-Hydroxy-2-((2-((3-methyl-1<i>H</i>-indazol-6-yl)oxy)ethyl)amino)ethyl)phenyl)cyclobutanesulfonamide (<b>15</b>)</h4><div class="NLM_p">Step 1: To a solution of <b>24</b> (14.95 g, 23.4 mmol) and pyridine (13.2 mL, 164 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added cyclobutanesulfonyl chloride (12.73 g, 81.9 mmol) at room temperature, and the solution was stirred overnight. The mixture was diluted with ethyl acetate, washed twice with 0.5 M HCl, washed with brine, dried over Mg<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue (28.72 g) was purified by flash column chromatography (73:27 to 52:48 <i>n</i>-hexane/ethyl acetate) to afford the sulfonamide product (11.14 g, 14.7 mmol, 63% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, 1:1 rotamers) δ 0.54 (6H, q, <i>J</i> = 7.8), 0.88 (9H, t, <i>J</i> = 7.8), 1.23–1.31 (2H, m), 1.47 (9H, s), 1.71 (9H, s), 1.88–2.02 (2H, m), 2.19–2.23 (2H, m), 2.47–2.60 (5H, m), 3.21–4.16 (5H, m), 4.88–4.93 and 5.02–5.06 (1H, each m), 6.03 and 6.44 (1H, each s), 6.86 (1H, d, <i>J</i> = 8.7), 7.09–7.12 (1H, m), 7.15–7.30 (2H, m), 7.47 (1H, dd, <i>J</i> = 1.6, 8.7), 7.54 (1H, s). LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 759.</div><div class="NLM_p">Step 2: To a solution of sulfonamide (11.14 g, 14.7 mmol) in anhydrous THF (100 mL) was added 1 M TBAF in THF (30 mL, 30 mmol) at room temperature, and the mixture was stirred for 2 h. The mixture was diluted with ethyl acetate, and the organic layer was washed with brine, water, and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by flash column chromatography (39:61 to 18:82 <i>n</i>-hexane/ethyl acetate) to give the alcohol product (8.99 g, 13.9 mmol, 95% yield). LC/MS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup>, 645.</div><div class="NLM_p last">Step 3: To a solution of the alcohol (8.99 g, 13.9 mmol) in anhydrous 1,4-dioxane (13.9 mL) was added 4 M HCl in 1,4-dioxane (139 mL, 556 mmol) at room temperature, and the mixture was stirred for 2 h. The sticky precipitate was allowed to settle to the bottom of the flask, and the supernatant solution was decanted. The residue was diluted with ethanol (150 mL) and water (15 mL). The solution was concentrated under reduced pressure. To the residue was added ethanol, and the precipitate was collected by suction filtration to give compound <b>15</b> (5.15 g, 10 mmol, 72% yield) as dihydrochloride salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.81–1.93 (2H, m), 2.11–2.19 (2H, m), 2.27–2.36 (2H, m), 2.48 (3H, s), 3.02–3.09 (1H, m), 3.22–3.25 (1H, m), 3.46 (2H, t, <i>J</i> = 5.0), 3.86–3.94 (1H, quintet, <i>J</i> = 8.2), 4.34–4.43 (2H, m), 5.81 (1H, brs), 5.02 (1H, dd, <i>J</i> = 1.9, 10.2), 6.82 (1H, dd, <i>J</i> = 2.0, 8.8), 6.93 (1H, dd, <i>J</i> = 2.0), 7.11 (1H, d, <i>J</i> = 7.8), 7.14 (1H, d, <i>J</i> = 7.8), 7.29 (1H, s), 7.31 (1H, t, <i>J</i> = 7.8), 7.65 (1H, d, <i>J</i> = 8.8), 9.09 (1H, brs), 9.47 (1H, brs), 9.80 (1H, s). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.2, 16.2, 23.2, 45.8, 53.1, 53.7, 63.4, 67.9, 92.1, 112.2, 116.8, 117.2, 119.1, 121.1, 121.2, 129.1, 138.5, 140.7, 141.5, 142.9, 157.6. HRMS calculated for C<sub>22</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>S + H<sup>+</sup>, 445.1904; found ESI [M + H]<sup>+</sup>, 445.1895. LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 445. HPLC: purity 100%, <i>R</i><sub>T</sub> 2.0 min.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>R</i>)-<i>N</i>-(3-(1-Hydroxy-2-((2-((3-methyl-1<i>H</i>-indazol-6-yl)oxy)ethyl)amino)ethyl)phenyl)cyclopentanesulfonamide (<b>16</b>)</h4><div class="NLM_p">Step 1: To a solution of <b>24</b> (95 mg, 0.15 mmol) and DBU (134 μL, 0.9 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added cyclopentanesulfonyl chloride (111 mg, 0.6 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) at room temperature, and the mixture was stirred for 2 days. Nitrogen gas was blown into the reaction solution to evaporate the solvent. The residue was diluted with methanol (2 mL), and 5 M NaOH (200 μL, 1 mmol) was added at room temperature. The mixture was stirred for 3 days and poured into saturated aq NH<sub>4</sub>Cl. The aqueous layer was extracted twice with ethyl acetate. The organic layers were washed twice with 2 M HCl, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by flash column chromatography (47:53 to 20:80 <i>n</i>-hexane/ethyl acetate) and preparative TLC (10:1 CH<sub>3</sub>Cl/MeOH) to give <i>tert</i>-butyl (<i>R</i>)-(2-(3-(cyclopentanesulfonamido)phenyl)-2-hydroxyethyl)(2-((3-methyl-1<i>H</i>-indazol-6-yl)oxy)ethyl)carbamate (35 mg, 0.063 mmol, 42% yield). LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 559.</div><div class="NLM_p last">Step 2: To the <i>tert</i>-butyl (<i>R</i>)-(2-(3-(cyclopentanesulfonamido)phenyl)-2-hydroxyethyl)(2-((3-methyl-1<i>H</i>-indazol-6-yl)oxy)ethyl)carbamate (35 mg, 0.063 mmol) was added 4 M HCl in 1,4-dioxane (1.5 mL) at room temperature. The mixture was shaken (600 min<sup>–1</sup>) overnight, and nitrogen gas was blown into the reaction solution to evaporate the solvent. The residue was dried to provide the product (34 mg, 0.064 mmol, quant) as dihydrochloride salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.48–1.57 (2H, m), 1.61–1.70 (2H, m), 1.79–1.95 (4H, m), 2.43 (3H, s), 3.02–3.09 (1H, m), 3.22–3.28 (1H, m), 3.46 (2H, t, <i>J</i> = 4.7), 3.50–3.56 (1H, m), 4.32–4.40 (2H, m), 4.98 (1H, dd, <i>J</i> = 2.0, 10.1), 6.23 (1H, brs), 6.76 (1H, dd, <i>J</i> = 2.1, 8.7), 6.90 (1H, d, <i>J</i> = 2.1), 7.10 (1H, d, <i>J</i> = 7.8), 7.17 (1H, dd, <i>J</i> = 1.4, 7.8), 7.31 (1H, s), 7.33 (1H, t, <i>J</i> = 7.8), 7.59 (1H, d, <i>J</i> = 8.7), 8.94 (1H, brs), 9.16 (1H, brs), 9.82 (1H, s). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.5, 25.3, 27.2, 45.9, 53.6, 59.6, 63.4, 67.9, 92.1, 111.5, 116.9, 117.2, 118.9, 120.9, 121.0, 129.2, 138.7, 140.1, 141.6, 143.0, 157.1. HRMS calculated for C<sub>23</sub>H<sub>30</sub>N<sub>4</sub>O<sub>4</sub>S + H<sup>+</sup>, 459.2061; found ESI [M + H]<sup>+</sup>, 459.2068. LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 459. HPLC: purity 100%, <i>R</i><sub>T</sub> 2.0 min.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>R</i>)-<i>N</i>-(3-(1-Hydroxy-2-((2-((3-methyl-1<i>H</i>-indazol-6-yl)oxy)ethyl)amino)ethyl)phenyl)benzenesulfonamide (<b>17</b>)</h4><div class="NLM_p last">To a solution of <b>24</b> (96 mg, 0.15 mmol) and pyridine (18 μL, 0.23 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added benzenesulfonyl chloride (32 mg, 0.18 mmol) at room temperature, and the solution was stirred overnight. The mixture was purified by flash column chromatography (4:3 <i>n</i>-hexane/ethyl acetate). The sulfonamide product was diluted with 1,4-dioxane (0.2 mL), and 4 M HCl in 1,4-dioxane (1.6 mL, 6.4 mmol) was added at room temperature. The mixture was shaken (600 min<sup>–1</sup>) overnight, and nitrogen gas was blown into the reaction solution to evaporate the solvent. The residue was dried to provide the product (67 mg, 0.12 mmol, 83% yield) as dihydrochloride salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.44 (3H, s), 2.88–2.99 (1H, m), 3.14–3.17 (1H, m), 3.43 (2H, t, <i>J</i> = 4.9), 4.29–4.38 (2H, m), 4.92 (1H, dd, <i>J</i> = 2.0, 10.4), 6.20 (1H, brs), 6.76 (1H, dd, <i>J</i> = 2.1, 8.8), 6.90 (1H, d, <i>J</i> = 2.1), 7.02 (1H, d, <i>J</i> = 8.0), 7.05 (1H, d, <i>J</i> = 8.0), 7.22 (1H, s), 7.23 (1H, t, <i>J</i> = 8.0), 7.52–7.56 (2H, m), 7.58–7.62 (2H, m), 7.77–7.79 (2H, m), 8.93 (1H, brs), 9.17 (1H, brs), 10.41 (1H, s). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.4, 45.9, 53.5, 63.4, 67.8, 92.1, 111.6, 117.1, 117.2, 119.0, 120.9, 121.4, 126.6, 129.1, 132.8, 137.8, 139.4, 140.8, 141.6, 142.9, 157.2. HRMS calculated for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>S + H<sup>+</sup>, 467.1748; found ESI [M + H]<sup>+</sup>, 467.1735. LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 467. HPLC: purity 95% <i>R</i><sub>T</sub> 2.0 min.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>R</i>)-2-(Benzyl(2-(benzyloxy)ethyl)amino)-1-(3-nitrophenyl)ethan-1-ol (<b>20</b>)</h4><div class="NLM_p">Step 1: A mixture of 2-(benzyloxy)ethan-1-amine (12.31 g, 81 mmol), benzaldehyde (8.72 g, 82 mmol), and Na<sub>2</sub>SO<sub>4</sub> (67.79 g, 477 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) was stirred overnight at ambient temperature. The mixture was filtered and concentrated under reduced pressure. The residue was diluted with methanol (150 mL), and sodium borohydride (3.41 g, 90 mmol) was added at 0 °C. The mixture was allowed to warm to ambient temperature and was stirred for 2 h. The mixture was concentrated under reduced pressure, quenched with water, and diluted with ethyl acetate. The layers were separated, and the aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed twice with water, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude <i>N</i>-benzyl-2-(benzyloxy)ethan-1-amine <b>19</b> (20.19 g, >100% yield) was carried forward without further purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.72 (1H, brs), 2.84 (2H, t, <i>J</i> = 5.2), 3.62 (2H, t, <i>J</i> = 5.2), 3.80 (2H, s), 4.52 (2H, s), 7.20–7.37 (10H, m).</div><div class="NLM_p last">Step 2: A mixture of (<i>R</i>)-2-(3-nitrophenyl)oxirane<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a><b>18</b> (13.65 g, 83 mmol) and <b>19</b> (20.21 g, 84 mmol) in 2-propanol (205 mL) was stirred for 36 h at reflux. The mixture was concentrated under reduced pressure. The residue was diluted with toluene (100 mL) and concentrated under reduced pressure. The residue was purified by flash column chromatography (85:15 to 80:20 <i>n</i>-hexane/ethyl acetate) to give compound <b>20</b> (30.76 g, 76 mmol, 92% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.62 (1H, dd, <i>J</i> = 10.2, 13.1), 2.75–2.87 (2H, m), 2.92–3.01 (1H, m), 3.51–3.64 (2H, m), 3.78 (2H, dd, <i>J</i> = 13.6, 69.1), 4.54 (2H, s), 4.70 (1H, dd, <i>J</i> = 3.3, 10.2), 7.27–7.39 (10H, m), 7.45 (1H, t, <i>J</i> = 7.9), 7.59 (1H, d, <i>J</i> = 7.9), 8.09 (1H, dd, <i>J</i> = 1.1, 2.3, 7.9), 8.16 (1H, d, <i>J</i> = 2.3). LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 407.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>R</i>)-<i>N</i>-Benzyl-<i>N</i>-(2-(benzyloxy)ethyl)-2-(3-nitrophenyl)-2-((triethylsilyl)oxy)ethan-1-amine (<b>21</b>)</h4><div class="NLM_p last">To a solution of <b>20</b> (30.37 g, 75 mmol) and imidazole (6.13 g, 90 mmol) in anhydrous DMF (150 mL) was added chlorotriethylsilane (15.1 mL, 90 mmol) at room temperature, and the solution was stirred overnight. The mixture was quenched with water and extracted twice with ethyl acetate. The combined organic layers were washed twice with water, washed with brine, dried over anhydrous MgSO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by flash column chromatography (100:0 to 87:13 <i>n</i>-hexane/ethyl acetate) to give compound <b>21</b> (36.66 g, 70 mmol, 93% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.42–0.56 (6H, m), 0.85 (9H, t, <i>J</i> = 7.9), 2.65–2.85 (4H, m), 3.37–3.47 (2H, m), 3.62 (2H, dd, <i>J</i> = 13.6, 42.9), 4.43 (2H, s), 4.68 (1H, dd, <i>J</i> = 5.4, 7.4), 7.06–7.11 (2H, m), 7.16–7.20 (3H, m), 7.26–7.37 (6H, m), 7.56 (1H, d, <i>J</i> = 7.7), 8.05 (1H, dd, <i>J</i> = 1.1, 2.3, 7.7), 8.12 (1H, dd, <i>J</i> = 2.3, 2.3). LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 521.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>tert</i>-Butyl (<i>R</i>)-(2-(3-Aminophenyl)-2-((triethylsilyl)oxy)ethyl)(2-hydroxyethyl)carbamate (<b>22</b>)</h4><div class="NLM_p">Step 1: A mixture of <b>21</b> (36.46 g, 70 mmol) and 10% palladium on activated charcoal (15.12 g, PE-type, NE Chemcat) in ethanol (175 mL) was evacuated, placed under a hydrogen atmosphere, and stirred for 9 h at 50 °C. The mixture was evacuated, placed under a hydrogen atmosphere, and stirred for 4 h at 50 °C. The reaction mixture was cooled to room temperature and passed through a membrane filter, and the solvent was concentrated under reduced pressure to give (<i>R</i>)-3-(2-(2-benzyloxyethylamino)-1-triethylsilyloxy-ethyl)aniline (25.08 g). LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 401.</div><div class="NLM_p last">Step 2: To a solution of (<i>R</i>)-3-(2-(2-benzyloxyethylamino)-1-triethylsilyloxy-ethyl)aniline (25.08 g, 70 mmol) in THF (175 mL) was added Boc<sub>2</sub>O (14.60 g, 67 mmol) at room temperature, and the solution was stirred for 1.5 h. The mixture was concentrated under reduced pressure. The residue was added to Pd(OH)<sub>2</sub> on activated charcoal (15.02 g, NE Chemcat), THF (80 mL), and MeOH (80 mL). The mixture was evacuated, placed under a hydrogen atmosphere, and stirred for 8 h at 50 °C. The reaction mixture was cooled to room temperature and passed through a membrane filter, and the solvent was concentrated under reduced pressure. The residue was purified by flash column chromatography (75:25 to 54:46 <i>n</i>-hexane/ethyl acetate) to give compound <b>22</b> (17.94 g, 44 mmol, 62% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, 3:2 rotamers) δ 0.44–0.63 (6H, m), 0.88 (9H, t, <i>J</i> = 7.9), 1.49 and 1.51 (9H, each s), 2.95–3.87 (8H, m), 4.90–4.95 and 5.17–5.21 (1H, each m), 6.57–6.78 (3H, m), 7.09 (1H, t, <i>J</i> = 7.7). LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 411.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>tert</i>-Butyl (<i>R</i>)-6-(2-((2-(3-Aminophenyl)-2-((triethylsilyl)oxy)ethyl)(<i>tert</i>-butoxycarbonyl)amino)ethoxy)-3-methyl-1<i>H</i>-indazole-1-carboxylate (<b>24</b>)</h4><div class="NLM_p last">To a solution of <b>22</b> (2.51 g, 6.1 mmol), <b>23</b><a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">(10c)</a> (1.99 g, 8.0 mmol), and triphenylphosphine (1.61 g, 6.1 mmol) in anhydrous toluene (25 mL) was added DMEAD<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (1.43 g, 6.1 mmol) at room temperature, and the solution was stirred overnight at 50 °C under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and washed three times with water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash column chromatography (74:26 to 53:47 <i>n</i>-hexane/ethyl acetate) to give a mixture of <b>24</b> and <b>23</b> (2.29 g). The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (25 mL), to which 2.91 mmol/g MP-carbonate (3.4 g, 9.9 mmol) was added at room temperature. The mixture was stirred overnight, and 2.91 mmol/g MP-carbonate (2.0 g, 5.8 mmol) was added at room temperature. The mixture was stirred for 5 h and filtered to give compound <b>24</b> (1.52 g, 2.4 mmol, 47% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, 3:2 rotamers) δ 0.53 (6H, t, <i>J</i> = 7.9), 0.89 (9H, q, <i>J</i> = 7.9), 1.48 (9H, s), 1.70 (9H, s), 2.53 (3H, s), 3.16–3.78 (6H, m), 4.02–4.14 (2H, m), 4.80–4.84 and 4.96–5.00 (1H, each m), 6.57–6.60 (1H, m), 6.66 (1H, d, <i>J</i> = 2.3), 6.70 and 6.78 (1H, each d, <i>J</i> = 8.7 and 7.6), 6.87 (1H, dt, <i>J</i> = 2.3, 8.7), 7.09 (1H, t, <i>J</i> = 7.6), 7.46 (1H, dd, <i>J</i> = 1.8, 8.7), 7.55 (1H, s). LC/MS-ESI (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup>, 641.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Human and Rat Unbound Microsomal Intrinsic Clearance Determination</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Human Microsomal Stability Assay</h4><div class="NLM_p last">The incubation mixtures were prepared in 96-well cluster tubes (1.4 mL PP; Micronic, Aston, PA, USA). The metabolic stability of the test compounds was determined with pooled, mixed-gender human microsomes (pool of <i>n</i> = 50; XenoTech, Kansas City, KS, USA). Each reaction mixture consisted of 100 mM potassium phosphate buffer (pH 7.4), liver microsomes (final concentration, 0.5 mg/mL), NADPH regenerating mix (final concentration, 1.0 mM NADP+, 4.0 mM glucose-6-phosphate, 3.0 mM MgCl<sub>2</sub>, 0.4 U/mL of glucose-6-phosphate dehydrogenase, 5.0 mM UDP-GA, and 0.165 mM β-NAD), and the test compound (1 μM) in a total volume of 100 μL. The incubation mixture was prewarmed for 5 min. Liver microsomes were added to the mixture and kept in a shaking water bath for 15 min at 37 °C. To the mixture was added chilled acetonitrile (200 μL) containing an internal standard to stop the reaction. The samples were centrifuged at 3500 rpm for 15 min at 4 °C. The supernatants were analyzed by LC-MS/MS. Controls were prepared by omitting NADPH regenerating mix from the reaction mixture, and adding microsomes after the reaction was terminated.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Human Liver Microsomal Binding Assay</h4><div class="NLM_p last">Microsomal binding of the test compounds was determined by equilibrium dialysis. Dialysis mixtures contained the test compound (1 μM) and microsomal solution (final concentration of microsomes, 0.5 mg/mL; ratio of components = 1:1:8 [microsomes at 5 mg/mL:PBS, pH 7.4:125 mM phosphate buffer, pH 7.4]) in a final volume of 150 μL. Duplicate mixtures were subjected to equilibrium dialysis against 150 μL of 100 mM potassium phosphate buffer (pH 7.4) using 96-well Micro-Equilibrium Dialysis Devices (HT Dialysis LLC, Gales Ferry, CT, USA). The dialyzing unit consisted of two chambers separated by an ultrathin membrane with a molecular weight cutoff of 12–14 kDa. The plate was rotated at 300 rpm for 6 h at 37 °C in the plate shaker (Taitec Inc., Japan). Upon completion of the dialysis, 50 μL samples were obtained from the microsome and buffer sides. For a matrix composition match, 50 μL of 100 mM phosphate buffer (pH 7.4) was added to the microsome side sample and the microsome mixture was added to the buffer side sample. To the mixture was added chilled acetonitrile (300 μL) containing an internal standard to stop the reaction; the samples were then analyzed by LC-MS/MS. Results are expressed as the area ratio of each sample versus control: human microsome <i>f</i><sub>u</sub> = peak area<sub>sample</sub>/peak area<sub>control</sub>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Rat Microsomal Stability Assay</h4><div class="NLM_p last">The incubation mixtures were prepared in Corning 96-well cluster plates. The metabolic stability of the test compounds was determined in pooled liver microsomes from male Sprague–Dawley rats (XenoTech). The reaction mixture consisted of 100 mM Tris-HCl buffer (pH 7.4), liver microsomes (5 mg/mL), NADPH regenerating mix (final concentrations of 0.165 mM NADP+, 4 mM glucose-6-phosphate, 3.0 mM MgCl<sub>2</sub>, 0.1 U/mL of glucose-6-phosphate dehydrogenase, 5.0 mM UDP-GA, and 0.165 mM β-NAD), and the test compound (0.5 μM) in a total volume of 100 μL. Reactions were initiated by the addition of liver microsomes (final concentration, 0.5 mg/mL) and incubated in a shaking water bath for 20 min at 37 °C. To the mixture was added chilled acetonitrile (200 μL) containing an internal standard to stop the reaction. A control sample was prepared by adding acetonitrile to a reaction mixture lacking microsomes and then adding microsomes after the reaction was terminated. The samples were centrifuged at 3500 rpm for 15 min at 4 °C. The supernatants were analyzed by LC-MS/MS.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Rat Liver Microsomal Binding Assay</h4><div class="NLM_p last">Microsomal binding of the test compounds was determined by ultracentrifugation. Each ultracentrifugation mixture contained the test compound (0.5 μM), microsomal solution (final concentration, 0.5 mg/mL; ratio of components = 1:9 [microsomes at 5 mg/mL:100 mM Tris-HCl buffer, pH 7.4]) in a final volume of 100 μL. Aliquots of 100 μL were placed in polyallomer ultracentrifuge tubes (8 mm × 34 mm; Beckman Coulter, Fullerton, CA, USA) and centrifuged at 160000<i>g</i> for 16 h at 37 °C in an Optima TL ultracentrifuge (Beckman Coulter). Upon completion of the ultracentrifugation, 50 μL of the supernatant was obtained. To the supernatant was added chilled acetonitrile (50 μL) containing an internal standard to stop the reaction; the samples were then analyzed by LC-MS/MS. Controls were prepared by adding the test compound to the ultracentrifugal supernatant of the microsomal solution. Results are expressed as the area ratio of sample versus control: rat microsome <i>f</i><sub>u</sub> = peak area<sub>sample</sub>/peak area<sub>control</sub>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> LC-MS/MS Analysis</h4><div class="NLM_p last">The LC-MS/MS system consisted of an Agilent 1100 series gradient HPLC pump (Agilent Technologies, Palo Alto, CA, USA), a CTC HTS PAL autosampler (AMR, Inc., Tokyo, Japan), and a Sciex API 3200 triple quadrupole mass spectrometer (Sciex, Foster City, CA, USA) equipped with a turbo ionspray interface. The samples were separated by reverse phase HPLC using an Inert Sustain RP C18 50 mm × 2.1 mm column (GL Science Inc., Tokyo, Japan) or Capcell Pak RP C18 50 mm × 2.1 mm column (Shiseido Inc., Tokyo, Japan). The compounds were eluted with an optimized gradient, which fell within the following method conditions: flow rate of 0.4 mL/min (range: 0–0.7 min); injection volume of 20 μL; solvent A consisting of 0.1% formic acid in water; solvent B consisting of acetonitrile or 0.1% formic acid in acetonitrile; the percentage of B was linearly increased from 5% to 90%, 90% B (1.3 min), returned to initial conditions, and equilibrated (1.5 or 1.6 min). The area ratio of each test compound was calculated by comparing the peak area of the compound to the peak area of an internal standard.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Calculation of Human and Rat Unbound Microsomal Intrinsic Clearance (hCL<sub>int,u</sub> and rCL<sub>int,u</sub>)</h4><div class="NLM_p last">Metabolic stability was determined by plotting the natural logarithm of the concentration of unchanged test compound as a function of time. The first-order rate constant was calculated using the equation <i>k</i> = [Ln(<i>C</i><sub>0</sub>) – Ln(<i>C</i>)]/incubation time, where <i>C</i><sub>0</sub> was the initial concentration of the test compound, <i>C</i> was the concentration of the test compound remaining after incubation (<i>C</i> = <i>C</i><sub>0</sub> × remaining ratio), and the incubation time was 15 min (human) or 20 min (rat). The half-life (<i>t</i><sub>1/2</sub>) was estimated using the equation <i>t</i><sub>1/2</sub> = 0.693/<i>k</i>. The hCL<sub>int,u</sub> was estimated using the equation hCL<sub>int,u</sub> = <i>k</i>/(microsomal protein concentration) × (microsomal protein per gram of liver) × (liver mass per kilogram of body mass)/(human microsome <i>f</i><sub>u</sub>), where <i>k</i> was the first-order rate constant, the microsomal protein concentration was 0.5 mg/mL, the microsomal protein per gram of liver was 48.8 mg, the liver mass per kilogram of body mass was 25.7 g, and the human microsome <i>f</i><sub>u</sub> was determined experimentally from the human liver microsomal binding assay.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The rCL<sub>int,u</sub> was estimated using the equation rCL<sub>int,u</sub> = <i>k</i>/(microsomal protein concentration) × (microsomal protein per gram of liver) × (liver mass per kilogram of body mass)/(rat microsome <i>f</i><sub>u</sub>), where <i>k</i> was the first-order rate constant, the microsomal protein concentration was 0.5 mg/mL, the microsomal protein per gram of liver was 44.8 mg, liver mass per kilogram of body mass was 40.0 g, and the rat microsome <i>f</i><sub>u</sub> was determined experimentally from the rat liver microsomal binding assay.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> PK Study</h3><div class="NLM_p last">Compounds <b>5</b>, <b>8</b>, and <b>15</b> were subjected to PK studies in male Sprague–Dawley rats. Test compounds were administered orally to rats (<i>n</i> = 2 or 3) at a dose of 5 mg/kg in saline or water (dose volume 5 mL/kg). Blood samples were collected via the subclavian vein at 0.5, 1, 2, 4, 6, and 8 h post dose. Plasma was separated by centrifugation and stored frozen at −20 °C until analysis. Plasma compound concentrations were determined using LC-MS/MS. PK parameters were calculated using the noncompartmental analysis tool provided with WinNonlin Enterprise software v6.4.0.768 (Certara, Princeton, NJ, USA).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> MD Simulation</h3><div class="NLM_p last">The compound <b>15</b>-bound structure of human β<sub>3</sub>-AR was subjected to 20 ns MD simulations using Desmond version 2.3<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> with OPLS3 force field.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The initial model structure was placed into a large palmitoyloleoylphosphatidylcholine (POPC) bilayer at a depth consistent with the structure of human β<sub>2</sub>-AR with BI-167107 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3P0G">3P0G</a>) from the Orientation of Proteins in Membranes (OPM) database<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and TIP3P water molecules solvated with 0.15 M NaCl. After minimization and relaxation of the model, the production MD phase was performed for 20 ns in the isothermal–isobaric (NPT) ensemble at 300 K and 1 bar using Langevin dynamics. Long-range electrostatic setups were performed using Maestro (Schrödinger, LLC).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01197">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46065" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46065" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01197" class="ext-link">10.1021/acs.jmedchem.6b01197</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Proposed model of compound <b>15</b> binding to the homology model of β<sub>3</sub>-AR after MD refinement (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Methods for the solubility assay, permeability assay, cytochrome P450 inhibition assay, human α<sub>1B</sub> or α<sub>1D</sub>-AR agonist assay, homology modeling of the β<sub>3</sub>-AR, and docking; sequence alignment of human β<sub>3</sub>-, α<sub>1A</sub>-, β<sub>1</sub>-, and β<sub>2</sub>-AR; summary of individual −pEC<sub>50</sub> and docking score values for β<sub>3</sub>-AR; RMSD analysis of the compound <b>15</b> with β<sub>3</sub>-AR within MD simulations (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_001.pdb">jm6b01197_si_001.pdb (364.43 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_002.csv">jm6b01197_si_002.csv (0.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_003.pdf">jm6b01197_si_003.pdf (479.99 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01197" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34840" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34840" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yasuhiro Wada</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5988-2912" title="Orcid link">http://orcid.org/0000-0002-5988-2912</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#70071114115e0900301f1d5e11031118195d1b110315195e131f5e1a00"><span class="__cf_email__" data-cfemail="fa8d9b9e9bd4838aba9597d49b899b9293d7919b899f93d49995d4908a">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satoshi Shuto</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span>; 
    <span class="hlFld-Affiliation affiliation">‡Faculty of Pharmaceutical Sciences and §Center for Research
and Education
on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan</span>; 
    <span class="hlFld-Affiliation affiliation">Molecular
Profiling Research Center for Drug Discovery (molprof), National Institute of Advanced Industrial Science
and Technology (AIST), 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan</span>; 
    <span class="hlFld-Affiliation affiliation">Division
of Biomedical Science, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7850-8064" title="Orcid link">http://orcid.org/0000-0001-7850-8064</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2e5d465b6e5e464f5c43004641455b4a4f47004f4d00445e"><span class="__cf_email__" data-cfemail="f1829984b1819990839cdf999e9a84959098df9092df9b81">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seiji Nakano</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akifumi Morimoto</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ken-ichi Kasahara</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takahiko Hayashi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshio Takada</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroko Suzuki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michiko Niwa-Sakai</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shigeki Ohashi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mutsuhiro Mori</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takatsugu Hirokawa</span> - <span class="hlFld-Affiliation affiliation">Molecular
Profiling Research Center for Drug Discovery (molprof), National Institute of Advanced Industrial Science
and Technology (AIST), 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan</span>; 
    <span class="hlFld-Affiliation affiliation">Division
of Biomedical Science, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d46e4177-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research was partially supported by the Platform Project for Supporting in Drug Discovery and Life Science Research (Platform for Drug Discovery, Informatics, and Structural Life Science) from the Japan Agency for Medical Research and Development. We are grateful to Toshinori Sugahara, Masayo Koge, and Eiichi Tanaka for in vitro assay support, Emiko Suzuki and Arata Saso for analysis of compounds, and Hisashi Aratake for project management. We thank Wataru Takahashi and Shiro Miyoshi for helpful discussions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i40" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i40"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i41" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i41"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMEAD</td><td class="NLM_def"><p class="first last">di-2-methoxyethyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">MBP</td><td class="NLM_def"><p class="first last">mean blood pressure</p></td></tr><tr><td class="NLM_term">MTBE</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl ether</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">2,3,4,6,7,8,9,10-octahydropyrimido[1,2-<i>a</i>]azepine</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetra-<i>n</i>-butylammonium fluoride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane</p></td></tr><tr><td class="NLM_term">ECL</td><td class="NLM_def"><p class="first last">extracellular loop</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">MD</td><td class="NLM_def"><p class="first last">molecular dynamics</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan assay interference compounds</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20525" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20525" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 39 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Bylund, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eikenberg, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieble, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minneman, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinoff, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruffolo, R. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trendelenburg, U.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology nomenclature of adrenoceptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1994&pages=121-136&author=D.+B.+Bylundauthor=D.+C.+Eikenbergauthor=J.+P.+Hiebleauthor=S.+Z.+Langerauthor=R.+J.+Lefkowitzauthor=K.+P.+Minnemanauthor=P.+B.+Molinoffauthor=R.+R.+Ruffoloauthor=U.+Trendelenburg&title=International+Union+of+Pharmacology+nomenclature+of+adrenoceptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBylund%26aufirst%3DD.%2BB.%26aulast%3DEikenberg%26aufirst%3DD.%2BC.%26aulast%3DHieble%26aufirst%3DJ.%2BP.%26aulast%3DLanger%26aufirst%3DS.%2BZ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DMinneman%26aufirst%3DK.%2BP.%26aulast%3DMolinoff%26aufirst%3DP.%2BB.%26aulast%3DRuffolo%26aufirst%3DR.%2BR.%26aulast%3DTrendelenburg%26aufirst%3DU.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology%2520nomenclature%2520of%2520adrenoceptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D1994%26volume%3D46%26spage%3D121%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lands, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliff, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luduena, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, T. G.,  Jr.</span><span> </span><span class="NLM_article-title">Differentiation of receptor systems activated by sympathomimetic amines</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">214</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span><span class="refDoi"> DOI: 10.1038/214597a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2F214597a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1967&pages=597-598&author=A.+M.+Landsauthor=A.+Arnoldauthor=J.+P.+McAuliffauthor=F.+P.+Luduenaauthor=T.+G.+Brown&title=Differentiation+of+receptor+systems+activated+by+sympathomimetic+amines&doi=10.1038%2F214597a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F214597a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F214597a0%26sid%3Dliteratum%253Aachs%26aulast%3DLands%26aufirst%3DA.%2BM.%26aulast%3DArnold%26aufirst%3DA.%26aulast%3DMcAuliff%26aufirst%3DJ.%2BP.%26aulast%3DLuduena%26aufirst%3DF.%2BP.%26aulast%3DBrown%26aufirst%3DT.%2BG.%26atitle%3DDifferentiation%2520of%2520receptor%2520systems%2520activated%2520by%2520sympathomimetic%2520amines%26jtitle%3DNature%26date%3D1967%26volume%3D214%26spage%3D597%26epage%3D598%26doi%3D10.1038%2F214597a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Emorine, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marullo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briend-Sutren, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delavier-Klutchko, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strosberg, A. D.</span><span> </span><span class="NLM_article-title">Molecular characterization of the human β<sub>3</sub>-adrenergic receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">245</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1121</span><span class="refDoi"> DOI: 10.1126/science.2570461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1126%2Fscience.2570461" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=245&publication_year=1989&pages=1118-1121&author=L.+J.+Emorineauthor=S.+Marulloauthor=M.+M.+Briend-Sutrenauthor=G.+Pateyauthor=K.+Tateauthor=C.+Delavier-Klutchkoauthor=A.+D.+Strosberg&title=Molecular+characterization+of+the+human+%CE%B23-adrenergic+receptor&doi=10.1126%2Fscience.2570461"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.2570461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2570461%26sid%3Dliteratum%253Aachs%26aulast%3DEmorine%26aufirst%3DL.%2BJ.%26aulast%3DMarullo%26aufirst%3DS.%26aulast%3DBriend-Sutren%26aufirst%3DM.%2BM.%26aulast%3DPatey%26aufirst%3DG.%26aulast%3DTate%26aufirst%3DK.%26aulast%3DDelavier-Klutchko%26aufirst%3DC.%26aulast%3DStrosberg%26aufirst%3DA.%2BD.%26atitle%3DMolecular%2520characterization%2520of%2520the%2520human%2520%25CE%25B23-adrenergic%2520receptor%26jtitle%3DScience%26date%3D1989%26volume%3D245%26spage%3D1118%26epage%3D1121%26doi%3D10.1126%2Fscience.2570461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Berkowitz, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreutter, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fremeau, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwinn, D. A.</span><span> </span><span class="NLM_article-title">Distribution of β<sub>3</sub>-adrenoceptor mRNA in human tissues</span> <span class="citation_source-journal">Eur. J. Pharmacol., Mol. Pharmacol. Sect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span><span class="refDoi"> DOI: 10.1016/0922-4106(95)90098-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2F0922-4106%2895%2990098-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=7621895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADyaK2MXlt1Wjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=1995&pages=223-228&author=D.+E.+Berkowitzauthor=N.+A.+Nardoneauthor=R.+M.+Smileyauthor=D.+T.+Priceauthor=D.+K.+Kreutterauthor=R.+T.+Fremeauauthor=D.+A.+Schwinn&title=Distribution+of+%CE%B23-adrenoceptor+mRNA+in+human+tissues&doi=10.1016%2F0922-4106%2895%2990098-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of β3-adrenoceptor mRNA in human tissues</span></div><div class="casAuthors">Berkowitz, Dan E.; Nardone, Nancy A.; Smiley, Richard M.; Price, David T.; Kreutter, David K.; Fremeau, Robert T.; Schwinn, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology, Molecular Pharmacology Section</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-8</span>CODEN:
                <span class="NLM_cas:coden">EJPPET</span>;
        ISSN:<span class="NLM_cas:issn">0922-4106</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The β3-adrenoceptor is a G protein-coupled receptor which mediates metabolic functions of the endogenous catecholamines epinephrine and norepinephrine.  Questions exist regarding distribution of the β3-adrenoceptor in human tissue.  To examine the distribution of β3-adrenoceptor mRNA in human tissues, the authors used sensitive and specific RNase protection assays without previous PCR amplification in an extensive list of human tissues.  The authors confirm the presence of β3-adrenoceptor mRNA in human white fat from several locations, gall bladder, and small intestine, as well as extend the distribution of β3-adrenoceptor mRNA to previously uncharacterized human tissues such as stomach and prostate.  The presence of β3-adrenoceptor mRNA in human white adipose tissue has important implications regarding possible use of β3-adrenoceptor selective agonists as anti-obesity agents, and the demonstration of β3-adrenoceptor mRNA in a no. of gastrointestinal tissues and prostate raises the question of the role of the β3-adrenoceptor in motility and secretory processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-ZEsNjICUkbVg90H21EOLACvtfcHk0lgG4zy3ebcy8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlt1Wjsbo%253D&md5=538c5c1bbdee3ae93d1b9158feb0f51b</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2F0922-4106%2895%2990098-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0922-4106%252895%252990098-5%26sid%3Dliteratum%253Aachs%26aulast%3DBerkowitz%26aufirst%3DD.%2BE.%26aulast%3DNardone%26aufirst%3DN.%2BA.%26aulast%3DSmiley%26aufirst%3DR.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BT.%26aulast%3DKreutter%26aufirst%3DD.%2BK.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26aulast%3DSchwinn%26aufirst%3DD.%2BA.%26atitle%3DDistribution%2520of%2520%25CE%25B23-adrenoceptor%2520mRNA%2520in%2520human%2520tissues%26jtitle%3DEur.%2520J.%2520Pharmacol.%252C%2520Mol.%2520Pharmacol.%2520Sect.%26date%3D1995%26volume%3D289%26spage%3D223%26epage%3D228%26doi%3D10.1016%2F0922-4106%2895%2990098-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koibuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, O.</span><span> </span><span class="NLM_article-title">Expression and possible functional role of the β<sub>3</sub>-adrenoceptor in human and rat detrusor muscle</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">685</span><span class="refDoi"> DOI: 10.1016/S0022-5347(01)61994-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2FS0022-5347%2801%2961994-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=9915482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADyaK1MXms1GrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=1999&pages=680-685&author=T.+Fujimuraauthor=K.+Tamuraauthor=T.+Tsutsumiauthor=T.+Yamamotoauthor=K.+Nakamuraauthor=Y.+Koibuchiauthor=M.+Kobayashiauthor=O.+Yamaguchi&title=Expression+and+possible+functional+role+of+the+%CE%B23-adrenoceptor+in+human+and+rat+detrusor+muscle&doi=10.1016%2FS0022-5347%2801%2961994-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and possible functional role of the β3-adrenoceptor in human and rat detrusor muscle</span></div><div class="casAuthors">Fujimura, Takao; Tamura, Kouichi; Tsutsumi, Takeshi; Yamamoto, Takao; Nakamura, Keiko; Koibuchi, Yasushi; Kobayashi, Masakazu; Yamaguchi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (Baltimore)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">680-685</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Studies were carried out to investigate the presence of the β3-adrenoceptor (β3-AR) in human and rat detrusor muscle and the usefulness of β3-AR agonists as drugs for the treatment of urinary frequency.  FK175, Et [(S)-8-[(R)-2-(3-chlorophenyl)-2-hydroxyethylamino]-6,7,8,9-tetrahydro-5H-benzocyclohepton-2-yloxy]acetate monohydrochloride monohydrate, was used as a β3-AR selective agonist.  The expression of β-AR subtypes (β1-, β2-, β3-AR) mRNA was investigated in rat and human detrusor muscle by RT-PCR.  β3-AR agonist induced cAMP levels were measured in rat detrusor muscle strips.  The relaxation response produced by a β3-AR agonist was measured in a KCl induced tonic contraction model in rat detrusor muscle strips.  The effect of a β3-AR agonist on urinary bladder function was investigated by cystometry using a conscious rat model of urinary frequency.  β3-AR mRNA was substantially expressed in both rat and human detrusor muscles.  The β3-AR agonist, FK175 (10-7 M), increased the cAMP level by 30% in rat detrusor muscle.  In isolated rat detrusor muscle strips contracted with KCl, the β3-AR agonist, FK175 (10-8 to 10-4 M), produced a concn.-dependent relaxation.  Moreover, although the relaxation induced with FK175 was blocked by the non-selective β-AR antagonist, bupranolol, it was unaffected by ether the β1-AR selective antagonist, CGP 20712A, or the β2-AR selective antagonist, ICI 118551, suggesting that FK175 induced the relaxation via the β3-AR.  Furthermore, in the rat model, the orally administered β3-AR agonist, FK175 (10 mg./kg.) significantly increased bladder capacity with no change of micturition pressure or threshold pressure.  These results suggest that β3-AR agonists may be effective in the treatment of urinary frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCM9oA-UhC97Vg90H21EOLACvtfcHk0lgG4zy3ebcy8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXms1GrtQ%253D%253D&md5=df120b5b527ad8aed862aeb914e879d4</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2801%2961994-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252801%252961994-3%26sid%3Dliteratum%253Aachs%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DTsutsumi%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DKoibuchi%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DO.%26atitle%3DExpression%2520and%2520possible%2520functional%2520role%2520of%2520the%2520%25CE%25B23-adrenoceptor%2520in%2520human%2520and%2520rat%2520detrusor%2520muscle%26jtitle%3DJ.%2520Urol.%26date%3D1999%26volume%3D161%26spage%3D680%26epage%3D685%26doi%3D10.1016%2FS0022-5347%2801%2961994-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Baker, J. G.</span><span> </span><span class="NLM_article-title">The selectivity of β-adrenoceptor agonists at human β<sub>1</sub>-, β<sub>2</sub>- and β<sub>3</sub>-adrenoceptors</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1111%2Fj.1476-5381.2010.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=20590599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1048-1061&author=J.+G.+Baker&title=The+selectivity+of+%CE%B2-adrenoceptor+agonists+at+human+%CE%B21-%2C+%CE%B22-+and+%CE%B23-adrenoceptors&doi=10.1111%2Fj.1476-5381.2010.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors</span></div><div class="casAuthors">Baker, Jillian G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1048-1061</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor-ligand complex to induce a response).  Ligands are classified as agonists or antagonists depending on whether or not they have efficacy.  In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both.  This study examd. the affinity and intrinsic efficacy of β-adrenoceptor agonists at the three human β-adrenoceptors to det. whether the current agonists are subtype selective because of affinity or intrinsic efficacy.  Stable clonal CHO-K1 cell lines, transfected with either the human β1, β2 or β3-adrenoceptor, were used, and whole-cell [3H]-CGP 12177 radioligand binding and [3H]-cAMP accumulation were measured.  Several agonists were highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the β2-adrenoceptor over the β1 or β3), while others (e.g. isoprenaline) had little affinity-selectivity.  However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes.  Other ligands (e.g. denopamine for β1; clenbuterol, AZ 40140d, salbutamol for β2) were found to have subtype-selective intrinsic efficacy.  Several ligands appeared to activate two agonist conformations of the β1- and β3-adrenoceptors.  There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy.  Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopuUPn04Hp7LVg90H21EOLACvtfcHk0lgdr-1WnLAjYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D&md5=daff8f97b1dfc4732135d3aa79e7de0f</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520selectivity%2520of%2520%25CE%25B2-adrenoceptor%2520agonists%2520at%2520human%2520%25CE%25B21-%252C%2520%25CE%25B22-%2520and%2520%25CE%25B23-adrenoceptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1048%26epage%3D1061%26doi%3D10.1111%2Fj.1476-5381.2010.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perrone, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scilimati, A.</span><span> </span><span class="NLM_article-title">β<sub>3</sub>-Adrenoceptor ligand development history through patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span><span class="refDoi"> DOI: 10.1517/13543776.2011.561316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1517%2F13543776.2011.561316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21410429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVGktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=505-536&author=M.+G.+Perroneauthor=A.+Scilimati&title=%CE%B23-Adrenoceptor+ligand+development+history+through+patent+review&doi=10.1517%2F13543776.2011.561316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">β3-Adrenoceptor ligand development history through patent review</span></div><div class="casAuthors">Perrone, Maria Grazia; Scilimati, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-536</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Stimulation of the β3-adrenoceptor (β3-AR) is thought to be a valuable approach for the treatment of obesity, type 2 diabetes, heart failure, frequent urination, preterm labor, anxiety and depression.  Therefore, the β3-AR is recognized as an attractive target for drug discovery.  Simultaneous activation of the β1- and β2-AR can cause undesirable side effects such as increased heart rate and muscle tremors.  Consequently, much effort has been directed towards the design and development of selective β3-AR agonists through original synthetic chem., extensive in vitro tests and detailed preclin. investigations to various phases of clin. trials.  Areas covered: SciFinder Scholar, PubMed, |S| web of KnowledgeSM, Espacenet, ClinicalTrials and Google have been used as the main sources for retrieving literature and patents filed since the discovery of β3-AR through to June 2010.  This review discusses the enormous efforts made by private and public research labs. to uncover β3-AR ligands and to prove their usefulness as drugs.  Expert opinion: Remarkable knowledge has been gained about the physio-pathol. role of the β3-AR to date.  Many highly potent and selective β3-AR ligands (agonists, antagonists and inverse agonists) have been discovered; however, further investigations are still needed to identify novel compds. acting as β3-AR ligands to adequately treat the diseases in which β3-AR is involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-AndCIxq8J7Vg90H21EOLACvtfcHk0lgdr-1WnLAjYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVGktbc%253D&md5=0069d127862caa40190ba08c03067241</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2011.561316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2011.561316%26sid%3Dliteratum%253Aachs%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DScilimati%26aufirst%3DA.%26atitle%3D%25CE%25B23-Adrenoceptor%2520ligand%2520development%2520history%2520through%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2011%26volume%3D21%26spage%3D505%26epage%3D536%26doi%3D10.1517%2F13543776.2011.561316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Ursino, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crema, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">The β<sub>3</sub>-adrenoceptor as a therapeutic target: current perspectives</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.phrs.2009.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.phrs.2009.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=19429463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2009&pages=221-234&author=M.+G.+Ursinoauthor=V.+Vasinaauthor=E.+Raschiauthor=F.+Cremaauthor=F.+De+Ponti&title=The+%CE%B23-adrenoceptor+as+a+therapeutic+target%3A+current+perspectives&doi=10.1016%2Fj.phrs.2009.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The β3-adrenoceptor as a therapeutic target: Current perspectives</span></div><div class="casAuthors">Ursino, Maria Grazia; Vasina, Valentina; Raschi, Emanuel; Crema, Francesca; De Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-234</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  β3-Adrenoceptors (β3-ARs) are located not only on the plasma membrane of both white and brown adipocytes, but also exist in human heart, gall bladder, gastrointestinal tract, prostate, urinary bladder detrusor, brain and in near-term myometrium.  They are now recognized as an attractive target for drug discovery and several efforts have been made in this field to understand their function and regulation in different human tissues.  The aim of this review is to highlight the functional role of β3-ARs as well as to discuss their potential for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFwN6K0dBHLVg90H21EOLACvtfcHk0lhAGMIFi0GtYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWls7Y%253D&md5=0638652d4bb93a1e8b275aec8eb37575</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2009.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2009.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DUrsino%26aufirst%3DM.%2BG.%26aulast%3DVasina%26aufirst%3DV.%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DCrema%26aufirst%3DF.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DThe%2520%25CE%25B23-adrenoceptor%2520as%2520a%2520therapeutic%2520target%253A%2520current%2520perspectives%26jtitle%3DPharmacol.%2520Res.%26date%3D2009%26volume%3D59%26spage%3D221%26epage%3D234%26doi%3D10.1016%2Fj.phrs.2009.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Arch, J. R.</span><span> </span><span class="NLM_article-title">The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β<sub>3</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span><span class="refDoi"> DOI: 10.1007/s00210-008-0271-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1007%2Fs00210-008-0271-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=18612674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2008&pages=225-240&author=J.+R.+Arch&title=The+discovery+of+drugs+for+obesity%2C+the+metabolic+effects+of+leptin+and+variable+receptor+pharmacology%3A+perspectives+from+%CE%B23-adrenoceptor+agonists&doi=10.1007%2Fs00210-008-0271-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β3-adrenoceptor agonists</span></div><div class="casAuthors">Arch, Jonathan R. S.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-240</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Although β3-adrenoceptor (β3AR) agonists have not become drugs for the treatment of obesity or diabetes, they offer perspectives on obesity drug discovery, the physiol. of energy expenditure and receptor pharmacol. β3AR agonists, some of which also stimulate other βARs in humans, selectively stimulate fat oxidn. in rodents and humans.  This appears to be why they improve insulin sensitivity and reduce body fat while preserving lean body mass.  Regulatory authorities ask that novel anti-obesity drugs improve insulin sensitivity and reduce mainly body fat.  Drugs that act on different targets to stimulate fat oxidn. may also offer these benefits.  Stimulation of energy expenditure may be easy to detect only when the sympathetic nervous system is activated.  Leptin resembles β3AR agonists in that it increases fat oxidn., energy expenditure and insulin sensitivity.  This is partly because it raises sympathetic activity, but it may also promote fat oxidn. by directly stimulating muscle leptin receptors.  The β1AR and β2AR can, like the β3AR, display atypical pharmacologies.  Moreover, the β3AR can display variable pharmacologies of its own, depending on the radioligand used in binding studies or the functional response measured.  Studies on the β3AR demonstrate both the difficulties of predicting the in vivo effects of agonist drugs from in vitro data and that there may be opportunities for identifying drugs that act at a single receptor but have different profiles in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcYdmnbRtQebVg90H21EOLACvtfcHk0lhAGMIFi0GtYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCrsLY%253D&md5=14955c4a0cd606aa68c4bce1b0afc2cb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs00210-008-0271-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-008-0271-1%26sid%3Dliteratum%253Aachs%26aulast%3DArch%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520discovery%2520of%2520drugs%2520for%2520obesity%252C%2520the%2520metabolic%2520effects%2520of%2520leptin%2520and%2520variable%2520receptor%2520pharmacology%253A%2520perspectives%2520from%2520%25CE%25B23-adrenoceptor%2520agonists%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2008%26volume%3D378%26spage%3D225%26epage%3D240%26doi%3D10.1007%2Fs00210-008-0271-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">de Souza, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkey, B. F.</span><span> </span><span class="NLM_article-title">Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span><span class="refDoi"> DOI: 10.2174/1381612013397339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.2174%2F1381612013397339" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1433-1449&author=C.+J.+de+Souzaauthor=B.+F.+Burkey&title=Beta+3-adrenoceptor+agonists+as+anti-diabetic+and+anti-obesity+drugs+in+humans&doi=10.2174%2F1381612013397339"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F1381612013397339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612013397339%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BSouza%26aufirst%3DC.%2BJ.%26aulast%3DBurkey%26aufirst%3DB.%2BF.%26atitle%3DBeta%25203-adrenoceptor%2520agonists%2520as%2520anti-diabetic%2520and%2520anti-obesity%2520drugs%2520in%2520humans%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2001%26volume%3D7%26spage%3D1433%26epage%3D1449%26doi%3D10.2174%2F1381612013397339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Woods, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldon, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argentieri, T. M.</span><span> </span><span class="NLM_article-title">Efficacy of the β<sub>3</sub>-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">1142</span><span class="NLM_x">–</span> <span class="NLM_lpage">1147</span><span class="refDoi"> DOI: 10.1016/S0022-5347(05)65936-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2FS0022-5347%2805%2965936-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=11490313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsF2gtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2001&pages=1142-1147&author=M.+Woodsauthor=N.+Carsonauthor=N.+W.+Nortonauthor=J.+H.+Sheldonauthor=T.+M.+Argentieri&title=Efficacy+of+the+%CE%B23-adrenergic+receptor+agonist+CL-316243+on+experimental+bladder+hyperreflexia+and+detrusor+instability+in+the+rat&doi=10.1016%2FS0022-5347%2805%2965936-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the β3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat</span></div><div class="casAuthors">Woods, Morgan; Carson, Nancyleigh; Norton, N. Wesley; Sheldon, Jeffrey H.; Argentieri, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1142-1147</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent evidence indicates that in a no. of species detrusor relaxation is mediated through activation of the β3-adrenergic receptor.  We detd. whether activation of the β3-adrenergic receptor would be a useful therapeutic approach for bladder instability.  We profiled in vitro activity of the β3-adrenergic receptor agonist CL-616243 and the efficacy of this compd. in exptl. models of detrusor instability and bladder hyperreflexia.  Isolated rat detrusor strips were contracted by depolarizing the prepns. with 20 mM. KCl.  CL-316423 was added to the tissue bath in increasing concns. and contraction inhibition was assessed.  Efficacy against bladder instability was evaluated using the obstructed hypertrophied bladder model in the rat.  The acetic acid bladder cystometry model was used to assess the efficacy of CL-316423 in bladder hyperreflexia.  Isovolumetric contractions were evoked by elec. stimulation using a silver bipolar electrode.  Data are expressed as the mean plus or minus std. error of mean.  CL-316243 inhibited spontaneously contracting, isolated rat detrusor strips in a concn. dependent manner with a mean concn. inhibiting 50% of maximal response of 2.65±0.36 nM.  Intrinsic activity relative to forskolin was 1.  In vivo CL-316243 administered i.v. or orally significantly increased the voiding interval and bladder compliance.  In addn., there was a decrease in the no. of spontaneous contractions during the filling phase in a model of neurogenic and obstruction induced bladder instability.  The amplitude of elec. evoked isovolumetric contractions was significantly smaller after CL-316243 exposure.  These data suggest that activating the β3-adrenergic receptor in rat bladder using CL-316243 may directly inhibit smooth muscle contractility, exptl. hyperreflexia and detrusor instability, and be useful for urge urinary incontinence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZlXr82ZfbtLVg90H21EOLACvtfcHk0lgply3xrcSq7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsF2gtLg%253D&md5=db51e7a7c23855df5ce096f457aa16fb</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2805%2965936-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252805%252965936-8%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DM.%26aulast%3DCarson%26aufirst%3DN.%26aulast%3DNorton%26aufirst%3DN.%2BW.%26aulast%3DSheldon%26aufirst%3DJ.%2BH.%26aulast%3DArgentieri%26aufirst%3DT.%2BM.%26atitle%3DEfficacy%2520of%2520the%2520%25CE%25B23-adrenergic%2520receptor%2520agonist%2520CL-316243%2520on%2520experimental%2520bladder%2520hyperreflexia%2520and%2520detrusor%2520instability%2520in%2520the%2520rat%26jtitle%3DJ.%2520Urol.%26date%3D2001%26volume%3D166%26spage%3D1142%26epage%3D1147%26doi%3D10.1016%2FS0022-5347%2805%2965936-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wuest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichhorn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravens, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaumann, A. J.</span><span> </span><span class="NLM_article-title">Catecholamines relax detrusor through β<sub>2</sub>-adrenoceptors in mouse and β<sub>3</sub>-adrenoceptors in man</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.1124/jpet.108.142562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1124%2Fjpet.108.142562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=18820136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFyktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2009&pages=213-222&author=M.+Wuestauthor=B.+Eichhornauthor=M.+O.+Grimmauthor=M.+P.+Wirthauthor=U.+Ravensauthor=A.+J.+Kaumann&title=Catecholamines+relax+detrusor+through+%CE%B22-adrenoceptors+in+mouse+and+%CE%B23-adrenoceptors+in+man&doi=10.1124%2Fjpet.108.142562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Catecholamines relax detrusor through β2-adrenoceptors in mouse and β3-adrenoceptors in man</span></div><div class="casAuthors">Wuest, Melinda; Eichhorn, Birgit; Grimm, Marc O.; Wirth, Manfred P.; Ravens, Ursula; Kaumann, Alberto J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">213-222</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(-)-Isoproterenol [4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-1,2-benzene diol hydrochloride] relaxes murine detrusor through β-adrenoceptors (ARs); however, the β-AR subtypes involved are unknown.  β2-ARs have been assocd. with caveolae, plasmalemmal scaffolding domains that are absent in caveolin-1 (cav-1) knockout (KO) mice.  Here, we studied detrusor responses in the absence and presence of β-AR subtype-selective antagonists in wild-type (WT) and cav-1 KO mice.  To inquire whether the murine detrusor model is relevant to man, β-AR subtypes that mediate (-)-isoproterenol-evoked human detrusor relaxation were investigated.  In WT mice, (-)-isoproterenol concn.-dependently relaxed the KCl (40 mM)-precontracted detrusor (-logEC50M = 8.04, Emax = 62%).  The effects of (-)-isoproterenol were surmountably antagonized by the β2-AR-selective antagonist ICI 118,551 [(±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol] (pKB = 9.28) but not affected by the β1-AR-selective antagonist CGP 20712 [1-[2-((3-carbamoyl-4-hydroxy)phenoxy)ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol] and β3-AR-selective L-748,337 (S)-M-4-2-3-3-[(acetamidomethylphenoxy-2-hydroxypropyl-amino)-ethyl]-phenylbenzsulfonamide, suggesting involvement of β2-AR only.  The cav-1 KO detrusor displayed significant contractile dysfunction.  (-)-Isoproterenol was less potent and efficient in relaxing detrusor from cav-1 KO (-logEC50M, 7.76; Emax = 44%), but ICI 118,551 caused similar antagonism (pKB = 9.15), suggesting that β2-AR function persisted in cav-1 KO.  The β3-AR-selective antagonist L-748,337 in the presence of ICI 118,551 and CGP 20712 caused addnl. blockade of (-)-isoproterenol effects in cav-1 KO, consistent with a β3-AR involvement during relaxation and suppression of this effect in WT.  (-)-Isoproterenol relaxed human detrusor muscle precontracted with carbachol (-logEC50M = 6.39, Emax = 52%).  However, the effects of (-)-isoproterenol in human detrusor were not blocked by CGP 20712 or ICI 118,551 but antagonized by L-748,337 (pKB = 7.65).  We conclude that murine detrusor relaxation occurs via β2-AR, and loss of caveolae does not perturb β2-AR function but unmasks an addnl. activation of β3-AR.  In contrast, detrusor relaxation in man is mediated exclusively via β3-AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRXvLssbSLm7Vg90H21EOLACvtfcHk0lgply3xrcSq7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFyktg%253D%253D&md5=ef05ce66d4961cf1617bc0046e416880</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.142562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.142562%26sid%3Dliteratum%253Aachs%26aulast%3DWuest%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DB.%26aulast%3DGrimm%26aufirst%3DM.%2BO.%26aulast%3DWirth%26aufirst%3DM.%2BP.%26aulast%3DRavens%26aufirst%3DU.%26aulast%3DKaumann%26aufirst%3DA.%2BJ.%26atitle%3DCatecholamines%2520relax%2520detrusor%2520through%2520%25CE%25B22-adrenoceptors%2520in%2520mouse%2520and%2520%25CE%25B23-adrenoceptors%2520in%2520man%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D328%26spage%3D213%26epage%3D222%26doi%3D10.1124%2Fjpet.108.142562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kar, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagabukuro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacre-Salem, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goble, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morriello, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyes, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzmaurice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenkl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gichuru, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochnowitz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levorse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ormes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanfiz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamlynny, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">Discovery of vibegron: a potent and selective β<sub>3</sub> adrenergic receptor agonist for the treatment of overactive bladder</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">623</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyrurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=609-623&author=S.+D.+Edmondsonauthor=C.+Zhuauthor=N.+F.+Karauthor=J.+Di+Salvoauthor=H.+Nagabukuroauthor=B.+Sacre-Salemauthor=K.+Dingleyauthor=R.+Bergerauthor=S.+D.+Gobleauthor=G.+Morrielloauthor=B.+Harperauthor=C.+R.+Moyesauthor=D.+M.+Shenauthor=L.+Wangauthor=R.+Ballauthor=A.+Fitzmauriceauthor=T.+Frenklauthor=L.+N.+Gichuruauthor=S.+Haauthor=A.+L.+Hurleyauthor=N.+Jochnowitzauthor=D.+Levorseauthor=S.+Mistryauthor=R.+R.+Millerauthor=J.+Ormesauthor=G.+M.+Salituroauthor=A.+Sanfizauthor=A.+S.+Stevensonauthor=K.+Villaauthor=B.+Zamlynnyauthor=S.+Greenauthor=M.+Struthersauthor=A.+E.+Weber&title=Discovery+of+vibegron%3A+a+potent+and+selective+%CE%B23+adrenergic+receptor+agonist+for+the+treatment+of+overactive+bladder&doi=10.1021%2Facs.jmedchem.5b01372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder</span></div><div class="casAuthors">Edmondson, Scott D.; Zhu, Cheng; Kar, Nam Fung; Di Salvo, Jerry; Nagabukuro, Hiroshi; Sacre-Salem, Beatrice; Dingley, Karen; Berger, Richard; Goble, Stephen D.; Morriello, Gregori; Harper, Bart; Moyes, Christopher R.; Shen, Dong-Ming; Wang, Liping; Ball, Richard; Fitzmaurice, Aileen; Frenkl, Tara; Gichuru, Loise N.; Ha, Sookhee; Hurley, Amanda L.; Jochnowitz, Nina; Levorse, Dorothy; Mistry, Shruty; Miller, Randy R.; Ormes, James; Salituro, Gino M.; Sanfiz, Anthony; Stevenson, Andra S.; Villa, Katherine; Zamlynny, Beata; Green, Stuart; Struthers, Mary; Weber, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described.  An early-generation clin. β3-AR agonist MK-0634 (3) exhibited efficacy in humans for the treatment of OAB, but development was discontinued due to unacceptable structure-based toxicity in preclin. species.  Optimization of a series of second-generation pyrrolidine-derived β3-AR agonists included reducing the risk for phospholipidosis, the risk of formation of disproportionate human metabolites, and the risk of formation of high levels of circulating metabolites in preclin. species.  These efforts resulted in the discovery of vibegron, which possesses improved druglike properties and an overall superior preclin. profile compared to MK-0634.  Structure-activity relationships leading to the discovery of vibegron and a summary of its preclin. profile are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTKGFhBOdMNbVg90H21EOLACvtfcHk0lgomx_1oQIeDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyrurjM&md5=89410d04a67540aa78e73e7312867ef3</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01372%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DKar%26aufirst%3DN.%2BF.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DSacre-Salem%26aufirst%3DB.%26aulast%3DDingley%26aufirst%3DK.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DGoble%26aufirst%3DS.%2BD.%26aulast%3DMorriello%26aufirst%3DG.%26aulast%3DHarper%26aufirst%3DB.%26aulast%3DMoyes%26aufirst%3DC.%2BR.%26aulast%3DShen%26aufirst%3DD.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBall%26aufirst%3DR.%26aulast%3DFitzmaurice%26aufirst%3DA.%26aulast%3DFrenkl%26aufirst%3DT.%26aulast%3DGichuru%26aufirst%3DL.%2BN.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DLevorse%26aufirst%3DD.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DOrmes%26aufirst%3DJ.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DVilla%26aufirst%3DK.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DDiscovery%2520of%2520vibegron%253A%2520a%2520potent%2520and%2520selective%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520overactive%2520bladder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D609%26epage%3D623%26doi%3D10.1021%2Facs.jmedchem.5b01372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kar, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingley, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span> </span><span class="NLM_article-title">Discovery of benzamides as potent human β<sub>3</sub> adrenergic receptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmcl.2015.11.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=55-59&author=C.+Zhuauthor=N.+F.+Karauthor=B.+Liauthor=M.+Costaauthor=K.+H.+Dingleyauthor=J.+Di+Salvoauthor=S.+N.+Haauthor=A.+L.+Hurleyauthor=X.+Liauthor=R.+R.+Millerauthor=G.+M.+Salituroauthor=M.+Struthersauthor=A.+E.+Weberauthor=J.+J.+Haleauthor=S.+D.+Edmondson&title=Discovery+of+benzamides+as+potent+human+%CE%B23+adrenergic+receptor+agonists&doi=10.1016%2Fj.bmcl.2015.11.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.030%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DKar%26aufirst%3DN.%2BF.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCosta%26aufirst%3DM.%26aulast%3DDingley%26aufirst%3DK.%2BH.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DHa%26aufirst%3DS.%2BN.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520benzamides%2520as%2520potent%2520human%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D55%26epage%3D59%26doi%3D10.1016%2Fj.bmcl.2015.11.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwanami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasahara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuto, S.</span><span> </span><span class="NLM_article-title">Discovery of novel indazole derivatives as highly potent and selective human β<sub>3</sub>-adrenergic receptor agonists with the possibility of having no cardiovascular side effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6048</span><span class="NLM_x">–</span> <span class="NLM_lpage">6057</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00638</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00638" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6048-6057&author=Y.+Wadaauthor=H.+Shirahashiauthor=T.+Iwanamiauthor=M.+Ogawaauthor=S.+Nakanoauthor=A.+Morimotoauthor=K.+Kasaharaauthor=E.+Tanakaauthor=Y.+Takadaauthor=S.+Ohashiauthor=M.+Moriauthor=S.+Shuto&title=Discovery+of+novel+indazole+derivatives+as+highly+potent+and+selective+human+%CE%B23-adrenergic+receptor+agonists+with+the+possibility+of+having+no+cardiovascular+side+effects&doi=10.1021%2Facs.jmedchem.5b00638"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00638%26sid%3Dliteratum%253Aachs%26aulast%3DWada%26aufirst%3DY.%26aulast%3DShirahashi%26aufirst%3DH.%26aulast%3DIwanami%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DS.%26aulast%3DMorimoto%26aufirst%3DA.%26aulast%3DKasahara%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DE.%26aulast%3DTakada%26aufirst%3DY.%26aulast%3DOhashi%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DShuto%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520indazole%2520derivatives%2520as%2520highly%2520potent%2520and%2520selective%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520with%2520the%2520possibility%2520of%2520having%2520no%2520cardiovascular%2520side%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6048%26epage%3D6057%26doi%3D10.1021%2Facs.jmedchem.5b00638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanabe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span> </span><span class="NLM_article-title">Discovery of highly potent and selective biphenylacylsulfonamide-based β<sub>3</sub>-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the β<sub>2</sub>-adrenergic receptor: part 6</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4679</span><span class="NLM_x">–</span> <span class="NLM_lpage">4683</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.06.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmcl.2009.06.083" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4679-4683&author=K.+Hattoriauthor=M.+Oritaauthor=S.+Todaauthor=M.+Imanishiauthor=S.+Itouauthor=Y.+Nakajimaauthor=D.+Tanabeauthor=K.+Washizukaauthor=T.+Arakiauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamura&title=Discovery+of+highly+potent+and+selective+biphenylacylsulfonamide-based+%CE%B23-adrenergic+receptor+agonists+and+molecular+modeling+based+on+the+solved+X-ray+structure+of+the+%CE%B22-adrenergic+receptor%3A+part+6&doi=10.1016%2Fj.bmcl.2009.06.083"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.06.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.06.083%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DOrita%26aufirst%3DM.%26aulast%3DToda%26aufirst%3DS.%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DTanabe%26aufirst%3DD.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520and%2520selective%2520biphenylacylsulfonamide-based%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520and%2520molecular%2520modeling%2520based%2520on%2520the%2520solved%2520X-ray%2520structure%2520of%2520the%2520%25CE%25B22-adrenergic%2520receptor%253A%2520part%25206%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4679%26epage%3D4683%26doi%3D10.1016%2Fj.bmcl.2009.06.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span> </span><span class="NLM_article-title">Discovery of highly potent and selective biphenylacylsulfonamide-based β<sub>3</sub>-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3063</span><span class="NLM_x">–</span> <span class="NLM_lpage">3072</span><span class="refDoi"> DOI: 10.1021/jm9000709</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9000709" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3063-3072&author=K.+Hattoriauthor=S.+Todaauthor=M.+Imanishiauthor=S.+Itouauthor=Y.+Nakajimaauthor=K.+Washizukaauthor=T.+Arakiauthor=H.+Hamashimaauthor=Y.+Tomishimaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamura&title=Discovery+of+highly+potent+and+selective+biphenylacylsulfonamide-based+%CE%B23-adrenergic+receptor+agonists+and+evaluation+of+physical+properties+as+potential+overactive+bladder+therapies%3A+part+5&doi=10.1021%2Fjm9000709"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1021%2Fjm9000709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9000709%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DToda%26aufirst%3DS.%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520and%2520selective%2520biphenylacylsulfonamide-based%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520and%2520evaluation%2520of%2520physical%2520properties%2520as%2520potential%2520overactive%2520bladder%2520therapies%253A%2520part%25205%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3063%26epage%3D3072%26doi%3D10.1021%2Fjm9000709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human β<sub>3</sub>-adrenergic receptor agonists: Part IV</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5037</span><span class="NLM_x">–</span> <span class="NLM_lpage">5040</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmcl.2008.08.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5037-5040&author=Y.+Nakajimaauthor=M.+Imanishiauthor=S.+Itouauthor=H.+Hamashimaauthor=Y.+Tomishimaauthor=K.+Washizukaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=K.+Hattori&title=Discovery+of+novel+series+of+benzoic+acid+derivatives+containing+biphenyl+ether+moiety+as+potent+and+selective+human+%CE%B23-adrenergic+receptor+agonists%3A+Part+IV&doi=10.1016%2Fj.bmcl.2008.08.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520novel%2520series%2520of%2520benzoic%2520acid%2520derivatives%2520containing%2520biphenyl%2520ether%2520moiety%2520as%2520potent%2520and%2520selective%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%253A%2520Part%2520IV%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5037%26epage%3D5040%26doi%3D10.1016%2Fj.bmcl.2008.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of a novel series of benzoic acid derivatives as potent and selective human β<sub>3</sub> adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4804</span><span class="NLM_x">–</span> <span class="NLM_lpage">4822</span><span class="refDoi"> DOI: 10.1021/jm800222k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800222k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4804-4822&author=M.+Imanishiauthor=Y.+Nakajimaauthor=Y.+Tomishimaauthor=H.+Hamashimaauthor=K.+Washizukaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamuraauthor=K.+Hattori&title=Discovery+of+a+novel+series+of+benzoic+acid+derivatives+as+potent+and+selective+human+%CE%B23+adrenergic+receptor+agonists+with+good+oral+bioavailability.+3.+Phenylethanolaminotetraline+%28PEAT%29+skeleton+containing+biphenyl+or+biphenyl+ether+moiety&doi=10.1021%2Fjm800222k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10g&amp;dbid=16384&amp;doi=10.1021%2Fjm800222k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800222k%26sid%3Dliteratum%253Aachs%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520benzoic%2520acid%2520derivatives%2520as%2520potent%2520and%2520selective%2520human%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%2520with%2520good%2520oral%2520bioavailability.%25203.%2520Phenylethanolaminotetraline%2520%2528PEAT%2529%2520skeleton%2520containing%2520biphenyl%2520or%2520biphenyl%2520ether%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4804%26epage%3D4822%26doi%3D10.1021%2Fjm800222k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human β<sub>3</sub> adrenergic receptor agonists with good oral bioavailability. Part II</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4002</span><span class="NLM_x">–</span> <span class="NLM_lpage">4020</span><span class="refDoi"> DOI: 10.1021/jm8000345</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8000345" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4002-4020&author=M.+Imanishiauthor=S.+Itouauthor=K.+Washizukaauthor=H.+Hamashimaauthor=Y.+Nakajimaauthor=T.+Arakiauthor=Y.+Tomishimaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamuraauthor=K.+Hattori&title=Discovery+of+a+novel+series+of+biphenyl+benzoic+acid+derivatives+as+highly+potent+and+selective+human+%CE%B23+adrenergic+receptor+agonists+with+good+oral+bioavailability.+Part+II&doi=10.1021%2Fjm8000345"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10h&amp;dbid=16384&amp;doi=10.1021%2Fjm8000345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8000345%26sid%3Dliteratum%253Aachs%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520biphenyl%2520benzoic%2520acid%2520derivatives%2520as%2520highly%2520potent%2520and%2520selective%2520human%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%2520with%2520good%2520oral%2520bioavailability.%2520Part%2520II%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4002%26epage%3D4020%26doi%3D10.1021%2Fjm8000345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human β<sub>3</sub>-adrenergic receptor agonists with good oral bioavailability. Part I</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1925</span><span class="NLM_x">–</span> <span class="NLM_lpage">1944</span><span class="refDoi"> DOI: 10.1021/jm701324c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701324c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1ekurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1925-1944&author=M.+Imanishiauthor=Y.+Tomishimaauthor=S.+Itouauthor=H.+Hamashimaauthor=Y.+Nakajimaauthor=K.+Washizukaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamuraauthor=K.+Hattori&title=Discovery+of+a+novel+series+of+biphenyl+benzoic+acid+derivatives+as+potent+and+selective+human+%CE%B23-adrenergic+receptor+agonists+with+good+oral+bioavailability.+Part+I&doi=10.1021%2Fjm701324c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10iR"><div class="casContent"><span class="casTitleNuber">10i</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Series of Biphenyl Benzoic Acid Derivatives as Potent and Selective Human β3-Adrenergic Receptor Agonists with Good Oral Bioavailability. Part I</span></div><div class="casAuthors">Imanishi, Masashi; Tomishima, Yasuyo; Itou, Shinji; Hamashima, Hitoshi; Nakajima, Yutaka; Washizuka, Kenichi; Sakurai, Minoru; Matsui, Shigeo; Imamura, Emiko; Ueshima, Koji; Yamamoto, Takao; Yamamoto, Nobuhiro; Ishikawa, Hirofumi; Nakano, Keiko; Unami, Naoko; Hamada, Kaori; Matsumura, Yasuhiro; Takamura, Fujiko; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1925-1944</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of biphenyl analogs contg. a benzoic acid moiety based on lead compd. I have been identified as potent and selective human β3 adrenergic receptor (β3-AR) agonists with good oral bioavailability and long plasma half-life.  After further substituent effects were investigated at the terminal Ph ring of lead compd. I, it has been discovered that more lipophilic substitution at the R position improved potency and selectivity.  As a result of these studies, II and III were identified as the leading candidates with the best balance of potency, selectivity, and pharmacokinetic profiles.  In addn., compds. II and III were evaluated to be efficacious for a carbachol-induced increase of intravesical pressure, such as an overactive bladder model in anesthetized dogs.  This represents the first demonstrated result dealing with β3-AR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1QxEQuf51bVg90H21EOLACvtfcHk0lj15FaHV7g5tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1ekurg%253D&md5=4ec8095eca0542c8566be8aee3bb1619</span></div><a href="/servlet/linkout?suffix=cit10i&amp;dbid=16384&amp;doi=10.1021%2Fjm701324c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701324c%26sid%3Dliteratum%253Aachs%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520biphenyl%2520benzoic%2520acid%2520derivatives%2520as%2520potent%2520and%2520selective%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520with%2520good%2520oral%2520bioavailability.%2520Part%2520I%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1925%26epage%3D1944%26doi%3D10.1021%2Fjm701324c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulmsten, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kerrebroeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Victor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wein, A.</span><span> </span><span class="NLM_article-title">Standardisation Sub-committee of the International Continence, S. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</span> <span class="citation_source-journal">Neurourol. Urodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1002/nau.10052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1002%2Fnau.10052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=11857671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A280%3ADC%252BD387it1CksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=167-178&author=P.+Abramsauthor=L.+Cardozoauthor=M.+Fallauthor=D.+Griffithsauthor=P.+Rosierauthor=U.+Ulmstenauthor=P.+van+Kerrebroeckauthor=A.+Victorauthor=A.+Wein&title=Standardisation+Sub-committee+of+the+International+Continence%2C+S.+The+standardisation+of+terminology+of+lower+urinary+tract+function%3A+report+from+the+Standardisation+Sub-committee+of+the+International+Continence+Society&doi=10.1002%2Fnau.10052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</span></div><div class="casAuthors">Abrams Paul; Cardozo Linda; Fall Magnus; Griffiths Derek; Rosier Peter; Ulmsten Ulf; van Kerrebroeck Philip; Victor Arne; Wein Alan</div><div class="citationInfo"><span class="NLM_cas:title">Neurourology and urodynamics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-78</span>
        ISSN:<span class="NLM_cas:issn">0733-2467</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5XK5Z-KmPwRgd2Wuil24tfW6udTcc2ebFmJucJfns-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387it1CksQ%253D%253D&md5=bea718982e738444bc86683b568828fb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fnau.10052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fnau.10052%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DCardozo%26aufirst%3DL.%26aulast%3DFall%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DD.%26aulast%3DRosier%26aufirst%3DP.%26aulast%3DUlmsten%26aufirst%3DU.%26aulast%3Dvan%2BKerrebroeck%26aufirst%3DP.%26aulast%3DVictor%26aufirst%3DA.%26aulast%3DWein%26aufirst%3DA.%26atitle%3DStandardisation%2520Sub-committee%2520of%2520the%2520International%2520Continence%252C%2520S.%2520The%2520standardisation%2520of%2520terminology%2520of%2520lower%2520urinary%2520tract%2520function%253A%2520report%2520from%2520the%2520Standardisation%2520Sub-committee%2520of%2520the%2520International%2520Continence%2520Society%26jtitle%3DNeurourol.%2520Urodyn.%26date%3D2002%26volume%3D21%26spage%3D167%26epage%3D178%26doi%3D10.1002%2Fnau.10052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Irwin, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milsom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunskaar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopp, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herschorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelleher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artibani, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, P.</span><span> </span><span class="NLM_article-title">Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1306</span><span class="NLM_x">–</span> <span class="NLM_lpage">1315</span><span class="refDoi"> DOI: 10.1016/j.eururo.2006.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.eururo.2006.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=17049716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A280%3ADC%252BD28nmt1Kmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1306-1315&author=D.+E.+Irwinauthor=I.+Milsomauthor=S.+Hunskaarauthor=K.+Reillyauthor=Z.+Koppauthor=S.+Herschornauthor=K.+Coyneauthor=C.+Kelleherauthor=C.+Hampelauthor=W.+Artibaniauthor=P.+Abrams&title=Population-based+survey+of+urinary+incontinence%2C+overactive+bladder%2C+and+other+lower+urinary+tract+symptoms+in+five+countries%3A+results+of+the+EPIC+study&doi=10.1016%2Fj.eururo.2006.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</span></div><div class="casAuthors">Irwin Debra E; Milsom Ian; Hunskaar Steinar; Reilly Kate; Kopp Zoe; Herschorn Sender; Coyne Karin; Kelleher Con; Hampel Christian; Artibani Walter; Abrams Paul</div><div class="citationInfo"><span class="NLM_cas:title">European urology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1306-14; discussion 1314-5</span>
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    </div><div class="casAbstract">OBJECTIVE:  Estimate the prevalence of urinary incontinence (UI), overactive bladder (OAB), and other lower urinary tract symptoms (LUTS) among men and women in five countries using the 2002 International Continence Society (ICS) definitions.  METHODS:  This population-based, cross-sectional survey was conducted between April and December 2005 in Canada, Germany, Italy, Sweden, and the United Kingdom using computer-assisted telephone interviews.  A random sample of men and women aged >/= 18 yr residing in the five countries and who were representative of the general populations in these countries was selected.  Using 2002 ICS definitions, the prevalence estimates of storage, voiding, and postmicturition LUTS were calculated.  Data were stratified by country, age cohort, and gender.  RESULTS:  A total of 19,165 individuals agreed to participate; 64.3% reported at least one LUTS.  Nocturia was the most prevalent LUTS (men, 48.6%; women, 54.5%).  The prevalence of storage LUTS (men, 51.3%; women, 59.2%) was greater than that for voiding (men, 25.7%; women, 19.5%) and postmicturition (men, 16.9%; women, 14.2%) symptoms combined.  The overall prevalence of OAB was 11.8%; rates were similar in men and women and increased with age.  OAB was more prevalent than all types of UI combined (9.4%).  CONCLUSIONS:  The EPIC study is the largest population-based survey to assess prevalence rates of OAB, UI, and other LUTS in five countries.  To date, this is the first study to evaluate these symptoms simultaneously using the 2002 ICS definitions.  The results indicate that these symptoms are highly prevalent in the countries surveyed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDX7KjsEQJ0vSAs_PE1QvifW6udTcc2ebFmJucJfns-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nmt1Kmsw%253D%253D&md5=8a24630cb261f6888e72b9dbd25ac55d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2006.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2006.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DIrwin%26aufirst%3DD.%2BE.%26aulast%3DMilsom%26aufirst%3DI.%26aulast%3DHunskaar%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DK.%26aulast%3DKopp%26aufirst%3DZ.%26aulast%3DHerschorn%26aufirst%3DS.%26aulast%3DCoyne%26aufirst%3DK.%26aulast%3DKelleher%26aufirst%3DC.%26aulast%3DHampel%26aufirst%3DC.%26aulast%3DArtibani%26aufirst%3DW.%26aulast%3DAbrams%26aufirst%3DP.%26atitle%3DPopulation-based%2520survey%2520of%2520urinary%2520incontinence%252C%2520overactive%2520bladder%252C%2520and%2520other%2520lower%2520urinary%2520tract%2520symptoms%2520in%2520five%2520countries%253A%2520results%2520of%2520the%2520EPIC%2520study%26jtitle%3DEur.%2520Urol.%26date%3D2006%26volume%3D50%26spage%3D1306%26epage%3D1315%26doi%3D10.1016%2Fj.eururo.2006.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Wein, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovner, E. S.</span><span> </span><span class="NLM_article-title">Definition and epidemiology of overactive bladder</span> <span class="citation_source-journal">Urology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1016/S0090-4295(02)01784-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2FS0090-4295%2802%2901784-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2002&pages=7-12&author=A.+J.+Weinauthor=E.+S.+Rovner&title=Definition+and+epidemiology+of+overactive+bladder&doi=10.1016%2FS0090-4295%2802%2901784-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0090-4295%2802%2901784-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0090-4295%252802%252901784-3%26sid%3Dliteratum%253Aachs%26aulast%3DWein%26aufirst%3DA.%2BJ.%26aulast%3DRovner%26aufirst%3DE.%2BS.%26atitle%3DDefinition%2520and%2520epidemiology%2520of%2520overactive%2520bladder%26jtitle%3DUrology%26date%3D2002%26volume%3D60%26spage%3D7%26epage%3D12%26doi%3D10.1016%2FS0090-4295%2802%2901784-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapple, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roehrborn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rosette, J.</span><span> </span><span class="NLM_article-title">International Consultation on New Developments in Prostate, C.; Prostate, D. Evaluation and treatment of lower urinary tract symptoms in older men</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">S93</span><span class="NLM_x">–</span> <span class="NLM_lpage">S101</span><span class="refDoi"> DOI: 10.1016/j.juro.2012.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.juro.2012.11.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2013&pages=S93-S101&author=P.+Abramsauthor=C.+Chappleauthor=S.+Khouryauthor=C.+Roehrbornauthor=J.+de+la+Rosette&title=International+Consultation+on+New+Developments+in+Prostate%2C+C.%3B+Prostate%2C+D.+Evaluation+and+treatment+of+lower+urinary+tract+symptoms+in+older+men&doi=10.1016%2Fj.juro.2012.11.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2012.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2012.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DChapple%26aufirst%3DC.%26aulast%3DKhoury%26aufirst%3DS.%26aulast%3DRoehrborn%26aufirst%3DC.%26aulast%3Dde%2Bla%2BRosette%26aufirst%3DJ.%26atitle%3DInternational%2520Consultation%2520on%2520New%2520Developments%2520in%2520Prostate%252C%2520C.%253B%2520Prostate%252C%2520D.%2520Evaluation%2520and%2520treatment%2520of%2520lower%2520urinary%2520tract%2520symptoms%2520in%2520older%2520men%26jtitle%3DJ.%2520Urol.%26date%3D2013%26volume%3D189%26spage%3DS93%26epage%3DS101%26doi%3D10.1016%2Fj.juro.2012.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, K. E.</span><span> </span><span class="NLM_article-title">Muscarinic receptor antagonists for overactive bladder</span> <span class="citation_source-journal">BJU Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span><span class="refDoi"> DOI: 10.1111/j.1464-410X.2007.07205.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1111%2Fj.1464-410X.2007.07205.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=17922784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGgur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=987-1006&author=P.+Abramsauthor=K.+E.+Andersson&title=Muscarinic+receptor+antagonists+for+overactive+bladder&doi=10.1111%2Fj.1464-410X.2007.07205.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic receptor antagonists for overactive bladder</span></div><div class="casAuthors">Abrams, Paul; Andersson, Karl-Erik</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">987-1006</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Overactive bladder (OAB) is a syndrome characterized by urinary urgency, with or without urgency urinary incontinence, usually with frequency and nocturia.  OAB symptoms are often assocd. with detrusor overactivity (DO).  Like OAB symptoms, the prevalence of DO increases with age and can have a neurogenic and/or myogenic etiol.  Bladder outlet obstruction can be a contributing factor in DO, possibly through cholinergic denervation of the detrusor and supersensitivity of muscarinic receptors to acetylcholine, although the prevalence of OAB is similar in men and women across age groups.  Acetylcholine is the primary contractile neurotransmitter in the human detrusor, and antimuscarinics exert their effects on OAB/DO by inhibiting the binding of acetylcholine at muscarinic receptors M2 and M3 on detrusor smooth muscle cells and other structures within the bladder wall.  Worldwide, there are six antimuscarinic drugs currently marketed for the treatment of OAB: oxybutynin, tolterodine, propiverine, trospium, darifenacin, and solifenacin.  Each has demonstrated efficacy for the treatment of OAB symptoms, but their pharmacokinetic and adverse event profiles differ somewhat due to structural differences (tertiary vs quaternary amines), muscarinic receptor subtype selectivities, and organ selectivities.  Antimuscarinics are generally well tolerated, even in special populations (e.g. men with bladder outlet obstruction, elderly patients, children).  The most frequently reported adverse events in clin. studies of antimuscarinics are dry mouth, constipation, headache, and blurred vision; few patients withdraw from clin. trials because of adverse events.  Development of an antimuscarinic with functional selectivity for the bladder would reduce the occurrence of antimuscarinic adverse events.  The therapeutic potential of several other agents, such as α3-adrenoceptor agonists, purinergic receptor antagonists, phosphodiesterase inhibitors, neurokinin-1 receptor antagonists, opioids, and Rho-kinase inhibitors, is also under investigation for the treatment of OAB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo46uZDo-vaI7Vg90H21EOLACvtfcHk0lhz_NG17hXCpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGgur7M&md5=ae74f99443663035095e793c43358bfa</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2007.07205.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2007.07205.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DAndersson%26aufirst%3DK.%2BE.%26atitle%3DMuscarinic%2520receptor%2520antagonists%2520for%2520overactive%2520bladder%26jtitle%3DBJU%2520Int.%26date%3D2007%26volume%3D100%26spage%3D987%26epage%3D1006%26doi%3D10.1111%2Fj.1464-410X.2007.07205.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Chapple, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khullar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitoun, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, D.</span><span> </span><span class="NLM_article-title">The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1016/j.eururo.2008.06.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.eururo.2008.06.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=18599186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2008&pages=543-562&author=C.+R.+Chappleauthor=V.+Khullarauthor=Z.+Gabrielauthor=D.+Mustonauthor=C.+E.+Bitounauthor=D.+Weinstein&title=The+effects+of+antimuscarinic+treatments+in+overactive+bladder%3A+an+update+of+a+systematic+review+and+meta-analysis&doi=10.1016%2Fj.eururo.2008.06.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis</span></div><div class="casAuthors">Chapple, Christopher R.; Khullar, Vik; Gabriel, Zahava; Muston, Dominic; Bitoun, Caty Ebel; Weinstein, David</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">543-562</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Context: Antimuscarinic agents are currently the first-line pharmacotherapy for overactive bladder.  Objectives: A systematic review published in 2005 was updated, including data on a newly licensed antimuscarinic (fesoterodine).  The primary aim of this study was to systematically review evidence on the efficacy of licensed administration of antimuscarinic treatments in overactive bladder from randomised controlled trials.  Secondary aims were to review evidence on tolerability and safety and health-related quality of life (HRQL).  Evidence acquisition: All relevant data sources from randomised controlled trials were searched, and two independent reviewers considered publications for inclusion and extd. relevant data.  Meta-anal. was used to pool efficacy, tolerability, safety, and HRQL outcomes by treatment.  Efficacy was measured by continent days, mean voided vol., urgency episodes, and micturition frequency.  Tolerability and safety were measured by means of adverse event and withdrawal rates.  HRQL was measured by various instruments.  Evidence synthesis: An addnl. 1118 refs. were retrieved with data on 83 studies extd.  Antimuscarinics were found to be more effective than placebo.  Tolerability was good; few of the antimuscarinics were found to have significantly higher withdrawal rates in comparison to placebo.  No serious adverse event for any product was statistically significant compared to placebo.  Dry mouth (mild, moderate, severe) was the most commonly reported adverse event (29.6% on treatment vs 7.9% on placebo), followed by pruritus (15.4% on treatment vs 5.2% on placebo).  Improvements were seen in HRQL with treatment by darifenacin, fesoterodine, oxybutynin transdermal delivery system, propiverine extended release (ER), solifenacin, tolterodine ER and immediate release, and trospium.  Limitations of the study include restrictions on the types of patients typically included in overactive bladder trials and topics that have not been adequately addressed in the current antimuscarinic literature.  Conclusions: Antimuscarinics are efficacious, safe, and well-tolerated treatments that improve HRQL.  Profiles of each drug and dosage differ and should be considered in making treatment choices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAxiEtWQKM7Vg90H21EOLACvtfcHk0lgGTPyv1ZZKUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKisb%252FK&md5=5bfba69dca14592a3212db8ef9a69630</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2008.06.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2008.06.047%26sid%3Dliteratum%253Aachs%26aulast%3DChapple%26aufirst%3DC.%2BR.%26aulast%3DKhullar%26aufirst%3DV.%26aulast%3DGabriel%26aufirst%3DZ.%26aulast%3DMuston%26aufirst%3DD.%26aulast%3DBitoun%26aufirst%3DC.%2BE.%26aulast%3DWeinstein%26aufirst%3DD.%26atitle%3DThe%2520effects%2520of%2520antimuscarinic%2520treatments%2520in%2520overactive%2520bladder%253A%2520an%2520update%2520of%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DEur.%2520Urol.%26date%3D2008%26volume%3D54%26spage%3D543%26epage%3D562%26doi%3D10.1016%2Fj.eururo.2008.06.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wagg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Compion, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, E.</span><span> </span><span class="NLM_article-title">Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience</span> <span class="citation_source-journal">BJU Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1767</span><span class="NLM_x">–</span> <span class="NLM_lpage">1774</span><span class="refDoi"> DOI: 10.1111/j.1464-410X.2012.11023.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1111%2Fj.1464-410X.2012.11023.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=22409769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSqurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2012&pages=1767-1774&author=A.+Waggauthor=G.+Compionauthor=A.+Faheyauthor=E.+Siddiqui&title=Persistence+with+prescribed+antimuscarinic+therapy+for+overactive+bladder%3A+a+UK+experience&doi=10.1111%2Fj.1464-410X.2012.11023.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience</span></div><div class="casAuthors">Wagg, Adrian; Compion, Gerhard; Fahey, Amanda; Siddiqui, Emad</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1767-1774</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-410X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Study Type: Therapy (prevalence) Level of Evidence 2b What's known on the subject and What does the study add Persistence with long-term medication in chronic diseases is typically low and that for overactive bladder medication is lower than av.  Sub-optimal persistence is a major challenge for the successful management of overactive bladder.  Using UK prescription data, persistence was generally low across the range of antimuscarinics.  Patients aged 60 years and above were more likely to persist with prescribed oral antimuscarinic drugs than younger patients (40-59 years).  Solifenacin was consistently assocd. with the highest rate of persistence compared with the other antimuscarinics included in the study.  OBJECTIVES: To describe the level of persistence for patients receiving antimuscarinics for overactive bladder (OAB) over a 12-mo period based on real prescription data from the UK.  To investigate patterns of persistence with oral antimuscarinic drugs prescribed for OAB, across different age groups.  PATIENTS AND METHODS: UK prescription data from a longitudinal patient database were analyzed retrospectively to assess persistence with darifenacin, flavoxate, oxybutynin (extended release [ER] and immediate release [IR]), propiverine, solifenacin, tolterodine (ER/IR) and trospium.  Data were extd. from the medical records of >1 200 000 registered patients via general practice software, and anonymized prescription data were collated for all eligible patients with documented OAB (n= 4833).  Data were collected on patients who started treatment between Jan. 2007 and Dec. 2007 and were collected up to Dec. 2008, to allow each patient a full 12-mo potential treatment period.  Failure of persistence was declared after a gap of at least 1.5 times the length of the period of the most recent prescription.  The anal. included only patients who were new to a course of treatment (i.e. who had not been prescribed that particular treatment or dosage for at least 6 mo before the study period).  RESULTS: The no. of patients prescribed each antimuscarinic drug varied from 23 for darifenacin to 1758 for tolterodine ER.  The longest mean persistence was reported for solifenacin (187 days vs. 77-157 days for the other treatments).  At 3 mo, the proportions of patients still on their original treatment were: solifenacin 58%, darifenacin 52%, tolterodine ER 47%, propiverine 47%, tolterodine IR 46%, oxybutynin ER 44%, trospium 42%, oxybutynin IR 40%, flavoxate 28%.  At 12 mo, the proportions of patients still on their original treatment were: solifenacin 35%, tolterodine ER 28%, propiverine 27%, oxybutynin ER 26%, trospium 26%, tolterodine IR 24%, oxybutynin IR 22%, darifenacin 17%, flavoxate 14%.  In a sub-anal. stratified by age, patients aged ≥60 years were more likely to persist with prescribed therapy over the 12-mo period than those aged <60 years.CONCLUSIONS : Twelve months after the initial prescription, persistence rates with pharmacotherapy in the context of OAB are generally low.  Solifenacin was assocd. with higher levels of persistence compared with other prescribed antimuscarinic agents.  Older people are more likely than younger patients to persist with prescribed therapy.  Further studies are required to understand this finding and why patients are more likely to persist with one drug rather than another.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNB7ZHoRZXiLVg90H21EOLACvtfcHk0lgGTPyv1ZZKUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSqurfE&md5=39edf40e3f46807d55a251b920826cc9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2012.11023.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2012.11023.x%26sid%3Dliteratum%253Aachs%26aulast%3DWagg%26aufirst%3DA.%26aulast%3DCompion%26aufirst%3DG.%26aulast%3DFahey%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DE.%26atitle%3DPersistence%2520with%2520prescribed%2520antimuscarinic%2520therapy%2520for%2520overactive%2520bladder%253A%2520a%2520UK%2520experience%26jtitle%3DBJU%2520Int.%26date%3D2012%26volume%3D110%26spage%3D1767%26epage%3D1774%26doi%3D10.1111%2Fj.1464-410X.2012.11023.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Staskin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDiarmid, S. A.</span><span> </span><span class="NLM_article-title">Using anticholinergics to treat overactive bladder: the issue of treatment tolerability</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/j.amjmed.2005.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.amjmed.2005.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=16483863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFGgsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=9-15&author=D.+R.+Staskinauthor=S.+A.+MacDiarmid&title=Using+anticholinergics+to+treat+overactive+bladder%3A+the+issue+of+treatment+tolerability&doi=10.1016%2Fj.amjmed.2005.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Using Anticholinergics to Treat Overactive Bladder: The Issue of Treatment Tolerability</span></div><div class="casAuthors">Staskin, David R.; MacDiarmid, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">3A</span>),
    <span class="NLM_cas:pages">9S-15S</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Overactive bladder (OAB) is a chronic syndrome with debilitating symptoms that neg. affect health-related quality of life.  Although anticholinergic agents have been first-line treatment for OAB for many years, the efficacious pharmacol. management of this condition has been compromised by concerns regarding tolerability.  Anticholinergic agents prevent involuntary contractions of the bladder detrusor muscle by preventing acetylcholine from binding to the M2 and M3 muscarinic receptor subtypes.  Anticholinergics are not tissue specific, and their use for treatment of OAB has been assocd. with side effects such as dry mouth, constipation, and blurred vision.  Recent studies with extended-release formulations and newly developed receptor subtype-specific anticholinergic agents demonstrate that side effects are typically mild to moderate and generally tolerable, seldom leading to patient withdrawal.  By incorporating patient-initiated dose adjustment into the protocol, the primary care physician can effectively manage adverse events assocd. with OAB without compromising efficacy.  Recent dose-adjustment data with extended-release oxybutynin suggest that, given some control in the process, patients are willing to tolerate certain side effects in exchange for symptom relief.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWpizZSQ8VeLVg90H21EOLACvtfcHk0lhGHA0Crvpbwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFGgsLs%253D&md5=14581bce0eec6e2588ba4a33c9bc8821</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2005.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2005.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DStaskin%26aufirst%3DD.%2BR.%26aulast%3DMacDiarmid%26aufirst%3DS.%2BA.%26atitle%3DUsing%2520anticholinergics%2520to%2520treat%2520overactive%2520bladder%253A%2520the%2520issue%2520of%2520treatment%2520tolerability%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2006%26volume%3D119%26spage%3D9%26epage%3D15%26doi%3D10.1016%2Fj.amjmed.2005.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Chapple, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitti, V. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. C.</span><span> </span><span class="NLM_article-title">Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability</span> <span class="citation_source-journal">Neurourol. Urodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1002/nau.22505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1002%2Fnau.22505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=24127366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=17-30&author=C.+R.+Chappleauthor=L.+Cardozoauthor=V.+W.+Nittiauthor=E.+Siddiquiauthor=M.+C.+Michel&title=Mirabegron+in+overactive+bladder%3A+a+review+of+efficacy%2C+safety%2C+and+tolerability&doi=10.1002%2Fnau.22505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability</span></div><div class="casAuthors">Chapple, Christopher R.; Cardozo, Linda; Nitti, Victor W.; Siddiqui, Emad; Michel, Martin C.</div><div class="citationInfo"><span class="NLM_cas:title">Neurourology and Urodynamics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-30</span>CODEN:
                <span class="NLM_cas:coden">NEUREM</span>;
        ISSN:<span class="NLM_cas:issn">0733-2467</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Aims : Mirabegron, the first β3-adrenoceptor agonist to enter clin. practice, has a different mechanism of action from antimuscarinic agents.  This review presents data on the efficacy, safety, and tolerability of mirabegron in studies conducted to date.  Methods : All clin. data on mirabegron that are currently in the public domain are included, including some in-press manuscripts.  Results : In Phase III clin. trials in patients with overactive bladder (OAB), mirabegron at daily doses of 25, 50, and 100 mg demonstrated significant efficacy in treating the symptoms of OAB, including micturition frequency, urgency incontinence, and urgency.  Significant improvements in micturition frequency, urgency incontinence, and mean vol. voided/micturition were seen as early as the first assessment (week 4) for mirabegron 50 and 100 mg, and were maintained throughout treatment.  Responder analyses showed a significant improvement with mirabegron 50 and 100 mg in terms of dry rates, ≥50% redn. in mean no. of incontinence episodes/24 h, and the proportion of patients with ≤8 micturitions/24 h at final visit.  The benefit of mirabegron 50 and 100 mg was also evident in patients ≥65 years of age, and in both treatment-naive patients and those who previously discontinued antimuscarinic therapy.  These data therefore demonstrate a clin. meaningful benefit with mirabegron in the objective endpoints of OAB.  Assessment of measures of health-related quality of life and treatment satisfaction showed that patients perceived treatment with mirabegron as meaningful.  In OAB clin. trials of up to 12 mo mirabegron appeared to be well tolerated.  The most common adverse events (AEs) obsd. with mirabegron in clin. trials of up to 12 mo were hypertension, nasopharyngitis, and urinary tract infection.  The incidence of dry mouth was similar to placebo, and was between three and fivefold less than for tolterodine extended release 4 mg.  Since dry mouth is the most bothersome AE assocd. with antimuscarinic drugs and often a reason for treatment discontinuation, mirabegron may be a valuable treatment option for these patients.  Conclusions : In Phase III clin. trials, mirabegron at daily doses of 25, 50, and 100 mg demonstrated significant efficacy in treating symptoms of OAB and, at doses of 50 and 100 mg, demonstrated significant improvements vs. placebo on key secondary endpoints, as early as the first assessment (week 4), and these were maintained throughout treatment.  In OAB clin. trials of up to 12 mo, mirabegron appeared to be well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNwKHocTclNrVg90H21EOLACvtfcHk0lhGHA0Crvpbwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegur%252FL&md5=07ec9413a0b5b86221468b34b2dbc7bb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fnau.22505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fnau.22505%26sid%3Dliteratum%253Aachs%26aulast%3DChapple%26aufirst%3DC.%2BR.%26aulast%3DCardozo%26aufirst%3DL.%26aulast%3DNitti%26aufirst%3DV.%2BW.%26aulast%3DSiddiqui%26aufirst%3DE.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26atitle%3DMirabegron%2520in%2520overactive%2520bladder%253A%2520a%2520review%2520of%2520efficacy%252C%2520safety%252C%2520and%2520tolerability%26jtitle%3DNeurourol.%2520Urodyn.%26date%3D2014%26volume%3D33%26spage%3D17%26epage%3D30%26doi%3D10.1002%2Fnau.22505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Takasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasamata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, O.</span><span> </span><span class="NLM_article-title">Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β<sub>3</sub>-adrenoceptor agonist, on bladder function</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span><span class="refDoi"> DOI: 10.1124/jpet.106.115840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1124%2Fjpet.106.115840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=17293563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFehur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=642-647&author=T.+Takasuauthor=M.+Ukaiauthor=S.+Satoauthor=T.+Matsuiauthor=I.+Nagaseauthor=T.+Maruyamaauthor=M.+Sasamataauthor=K.+Miyataauthor=H.+Uchidaauthor=O.+Yamaguchi&title=Effect+of+%28R%29-2-%282-aminothiazol-4-yl%29-4%E2%80%B2-%7B2-%5B%282-hydroxy-2-phenylethyl%29amino%5Dethyl%7D+acetanilide+%28YM178%29%2C+a+novel+selective+%CE%B23-adrenoceptor+agonist%2C+on+bladder+function&doi=10.1124%2Fjpet.106.115840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino] ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function</span></div><div class="casAuthors">Takasu, Toshiyuki; Ukai, Masashi; Sato, Shuichi; Matsui, Tetsuo; Nagase, Itsuro; Maruyama, Tatsuya; Sasamata, Masao; Miyata, Keiji; Uchida, Hisashi; Yamaguchi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">642-647</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the pharmacol. characteristics of YM178.  YM178 increased cAMP accumulation in Chinese hamster ovary (CHO) cells expressing human β3-adrenoceptor (AR).  The half-maximal effective concn. (EC50) value was 22.4 nM.  EC50 values of YM178 for human β1- and β2-ARs were 10,000 nM or more, resp.  The ratio of intrinsic activities of YM178 vs. maximal response induced by isoproterenol (nonselective β-AR agonist) was 0.8 for human β3-ARs, 0.1 for human β1-ARs, and 0.1 for human β2-ARs.  The relaxant effects of YM178 were evaluated in rats and humans bladder strips precontracted with carbachol (CCh) and compared with those of isoproterenol and 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one hydrochloride (CGP-12177A) (β3-AR agonist).  EC50 values of YM178 and isoproterenol in rat bladder strips precontracted with 10-6 M CCh were 5.1 and 1.4 μM, resp., whereas those in human bladder strips precontracted with 10-7 M CCh were 0.78 and 0.28 μM, resp.  In in vivo study, YM178 at a dose of 3 mg/kg i.v. decreased the frequency of rhythmic bladder contraction induced by intravesical filling with saline without suppressing its amplitude in anesthetized rats.  These findings suggest the suitability of YM178 as a therapeutic drug for the treatment of symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJoYI45QFLfbVg90H21EOLACvtfcHk0ljqsFaTvmCxNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFehur0%253D&md5=607d913d56ea8378fc9f22c767cbc599</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.115840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.115840%26sid%3Dliteratum%253Aachs%26aulast%3DTakasu%26aufirst%3DT.%26aulast%3DUkai%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DMatsui%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DI.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DSasamata%26aufirst%3DM.%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DUchida%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DO.%26atitle%3DEffect%2520of%2520%2528R%2529-2-%25282-aminothiazol-4-yl%2529-4%25E2%2580%25B2-%257B2-%255B%25282-hydroxy-2-phenylethyl%2529amino%255Dethyl%257D%2520acetanilide%2520%2528YM178%2529%252C%2520a%2520novel%2520selective%2520%25CE%25B23-adrenoceptor%2520agonist%252C%2520on%2520bladder%2520function%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D642%26epage%3D647%26doi%3D10.1124%2Fjpet.106.115840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Hicks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCafferty, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aiyar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luce, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coatney, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westfall, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieble, J. P.</span><span> </span><span class="NLM_article-title">GW427353 (solabegron), a novel, selective β<sub>3</sub>-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">209</span><span class="refDoi"> DOI: 10.1124/jpet.107.125757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1124%2Fjpet.107.125757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=17626794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=202-209&author=A.+Hicksauthor=G.+P.+McCaffertyauthor=E.+Riedelauthor=N.+Aiyarauthor=M.+Pullenauthor=C.+Evansauthor=T.+D.+Luceauthor=R.+W.+Coatneyauthor=G.+C.+Riveraauthor=T.+D.+Westfallauthor=J.+P.+Hieble&title=GW427353+%28solabegron%29%2C+a+novel%2C+selective+%CE%B23-adrenergic+receptor+agonist%2C+evokes+bladder+relaxation+and+increases+micturition+reflex+threshold+in+the+dog&doi=10.1124%2Fjpet.107.125757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">GW427353 (solabegron), a novel, selective β3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog</span></div><div class="casAuthors">Hicks, Alexandra; McCafferty, Gerald P.; Riedel, Erin; Aiyar, Nambi; Pullen, Mark; Evans, Christopher; Luce, Trudy D.; Coatney, Robert W.; Rivera, Gian C.; Westfall, Timothy D.; Hieble, J. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">202-209</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Functional studies have demonstrated that adrenoceptor agonist-evoked relaxation is mediated primarily by β3-adrenergic receptors (ARs) in human bladder.  Thus, the use of selective β3-AR agonists in the pharmacol. treatment of overactive bladder is being explored.  The present studies investigated the effects of a novel selective β3-AR agonist, (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid (GW427353; solabegron) on bladder function in the dog using in vitro and in vivo techniques.  GW427353 stimulated cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR, with an EC50 value of 22 ± 6 nM and an intrinsic activity 90% of isoproterenol.  At concns. of 10,000 nM, GW427353 produced a minimal response in cells expressing either β1-ARs or β2-ARs (max. response <10% of that to isoproterenol).  In dog isolated bladder strips, GW427353 evoked relaxation that was attenuated by the non-selective β-AR antagonist bupranolol and 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol (SR59230A) (reported to have β3-AR antagonist activity).  The relaxation was unaffected by atenolol, a selective β1-AR antagonist, or (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol (ICI 118551), a selective β2-AR antagonist.  GW427353 increased the vol. required to evoke micturition in the anesthetized dog following acetic acid-evoked bladder irritation, without affecting the ability of the bladder to void.  GW427353-evoked effects on bladder parameters in vivo were inhibited by bupranolol.  The present study demonstrates that selective activation of β3-AR with GW427353 evokes bladder relaxation and facilitates bladder storage mechanisms in the dog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgB2WHHmcNBrVg90H21EOLACvtfcHk0ljqsFaTvmCxNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsLfK&md5=360088edb870525e082f8379d1b21779</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.125757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.125757%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DMcCafferty%26aufirst%3DG.%2BP.%26aulast%3DRiedel%26aufirst%3DE.%26aulast%3DAiyar%26aufirst%3DN.%26aulast%3DPullen%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DC.%26aulast%3DLuce%26aufirst%3DT.%2BD.%26aulast%3DCoatney%26aufirst%3DR.%2BW.%26aulast%3DRivera%26aufirst%3DG.%2BC.%26aulast%3DWestfall%26aufirst%3DT.%2BD.%26aulast%3DHieble%26aufirst%3DJ.%2BP.%26atitle%3DGW427353%2520%2528solabegron%2529%252C%2520a%2520novel%252C%2520selective%2520%25CE%25B23-adrenergic%2520receptor%2520agonist%252C%2520evokes%2520bladder%2520relaxation%2520and%2520increases%2520micturition%2520reflex%2520threshold%2520in%2520the%2520dog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D202%26epage%3D209%26doi%3D10.1124%2Fjpet.107.125757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Maruyama, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatemichi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusama, H.</span><span> </span><span class="NLM_article-title">Bladder selectivity of the novel β<sub>3</sub>-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span><span class="refDoi"> DOI: 10.1007/s00210-012-0755-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1007%2Fs00210-012-0755-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=22552730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVemu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2012&pages=845-852&author=I.+Maruyamaauthor=Y.+Goiauthor=S.+Tatemichiauthor=K.+Maruyamaauthor=Y.+Hoyanoauthor=Y.+Yamazakiauthor=H.+Kusama&title=Bladder+selectivity+of+the+novel+%CE%B23-agonist+ritobegron+%28KUC-7483%29+explored+by+in+vitro+and+in+vivo+studies+in+the+rat&doi=10.1007%2Fs00210-012-0755-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Bladder selectivity of the novel β3-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat</span></div><div class="casAuthors">Maruyama, Itaru; Goi, Yoshiaki; Tatemichi, Satoshi; Maruyama, Kazuyasu; Hoyano, Yuji; Yamazaki, Yoshinobu; Kusama, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">845-852</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We performed in vitro and in vivo expts. to evaluate the pharmacol. profile of ritobegron and its effects on the bladder in rats. β3-AR selectivity was assessed using CHO cells expressing various subtypes of the human β-adrenoceptor (AR).  Effects on isolated organs were evaluated using the organ-bath method.  Effects on intravesical pressure, heart rate, and mean blood pressure were evaluated in urethane-anesthetized rats.  Ritobegron increased cAMP accumulation in a concn.-dependent manner in CHO cells expressing any one of three human β-AR, its selectivity for β3-AR being 301-fold and 32-fold higher vs. β1-AR and β2-AR, resp.  Ritobegron decreased the resting tension of the isolated bladder in a concn.-dependent manner (EC50, 7.7 × 10-8 mol/L; maximal relaxation, 97.0 %), and the β3-AR antagonist SR58894A produced a parallel rightward-shift of this concn.-response curve without altering the maximal response [pKB value, 6.43].  Ritobegron concn.-dependently increased atrial rate and decreased myometrial contractions in vitro, and its selectivity for the bladder was 2,078-fold higher vs. the atria and 14-fold higher vs. the uterus.  In vivo, ritobegron induced a dose-dependent decrease in intravesical pressure (ED50 0.4 mg/kg), without affecting heart rate and only slightly lowering mean blood pressure.  Thus, ritobegron displayed potent and selective β3-AR agonistic activity toward transfected human β-AR and exhibited a high selectivity for the bladder vs. other organs in rats.  Moreover, it decreased intravesical pressure with minimal effects on the cardiovascular system in anesthetized rats.  These results suggest that ritobegron shows promise as a potential agent for the treatment of overactive bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSQ21qPG2_oLVg90H21EOLACvtfcHk0lhXuqu1PLowXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVemu73N&md5=2347d7515857ba3d8e708662c6f9e8f2</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1007%2Fs00210-012-0755-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-012-0755-x%26sid%3Dliteratum%253Aachs%26aulast%3DMaruyama%26aufirst%3DI.%26aulast%3DGoi%26aufirst%3DY.%26aulast%3DTatemichi%26aufirst%3DS.%26aulast%3DMaruyama%26aufirst%3DK.%26aulast%3DHoyano%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DKusama%26aufirst%3DH.%26atitle%3DBladder%2520selectivity%2520of%2520the%2520novel%2520%25CE%25B23-agonist%2520ritobegron%2520%2528KUC-7483%2529%2520explored%2520by%2520in%2520vitro%2520and%2520in%2520vivo%2520studies%2520in%2520the%2520rat%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2012%26volume%3D385%26spage%3D845%26epage%3D852%26doi%3D10.1007%2Fs00210-012-0755-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Maruyama, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatemichi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusama, H.</span><span> </span><span class="NLM_article-title">Effects of ritobegron (KUC-7483), a novel selective β<sub>3</sub>-adrenoceptor agonist, on bladder function in cynomolgus monkey</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span><span class="refDoi"> DOI: 10.1124/jpet.112.191783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1124%2Fjpet.112.191783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=22511202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOktbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2012&pages=163-168&author=I.+Maruyamaauthor=S.+Tatemichiauthor=Y.+Goiauthor=K.+Maruyamaauthor=Y.+Hoyanoauthor=Y.+Yamazakiauthor=H.+Kusama&title=Effects+of+ritobegron+%28KUC-7483%29%2C+a+novel+selective+%CE%B23-adrenoceptor+agonist%2C+on+bladder+function+in+cynomolgus+monkey&doi=10.1124%2Fjpet.112.191783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, on bladder function in cynomolgus monkey</span></div><div class="casAuthors">Maruyama, Itaru; Tatemichi, Satoshi; Goi, Yoshiaki; Maruyama, Kazuyasu; Hoyano, Yuji; Yamazaki, Yoshinobu; Kusama, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">163-168</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the pharmacol. profile of ritobegron [KUC-7483; (-)-Et 2-[4-(2-{[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)-2,5-dimethylphenyloxy]acetate monohydrochloride] and its effects on the bladder in cynomolgus monkeys by in vitro and in vivo expts.  In vitro, ritobegron decreased the resting tension of the isolated bladder in a concn.-dependent manner (EC50 8.2 ± 2.3 × 10-7 M; maximal relaxation 88.7 ± 3.7%).  The β3-adrenoceptor (AR) antagonist 3-(2-allylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol hydrochloride (SR58894A) produced a rightward shift of this concn.-response curve without altering the maximal response (pKB value 6.56 ± 0.35).  In isolated atria, ritobegron increased the atrial rate only at high concns. (EC50 6.5 ± 1.2 × 10-5 M).  Ritobegron had no effect on tracheal contraction at concns. from 10-9 to 10-4 M, and even at the highest concn. tested, 10-3 M, the maximal relaxation it induced was only 26.7 ± 8.1%.  Tests of the selectivity of ritobegron for the bladder gave values of 79.3- and 1200-fold higher vs. atria and trachea, resp.  In the in vivo study ritobegron significantly decreased intravesical pressure (ED50 1.44 mg/kg) without affecting either mean blood pressure or heart rate.  In conclusion, ritobegron displayed potent and selective β3-AR agonistic activity and relaxed the monkey isolated bladder, and in vivo it decreased intravesical pressure without affecting cardiovascular parameters.  These results suggest that ritobegron may be a promising potential agent for the treatment of overactive bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5uUKfB5bK0LVg90H21EOLACvtfcHk0lhXuqu1PLowXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOktbjI&md5=e728f90c60c847251a0da437a2abea55</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.191783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.191783%26sid%3Dliteratum%253Aachs%26aulast%3DMaruyama%26aufirst%3DI.%26aulast%3DTatemichi%26aufirst%3DS.%26aulast%3DGoi%26aufirst%3DY.%26aulast%3DMaruyama%26aufirst%3DK.%26aulast%3DHoyano%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DKusama%26aufirst%3DH.%26atitle%3DEffects%2520of%2520ritobegron%2520%2528KUC-7483%2529%252C%2520a%2520novel%2520selective%2520%25CE%25B23-adrenoceptor%2520agonist%252C%2520on%2520bladder%2520function%2520in%2520cynomolgus%2520monkey%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D342%26spage%3D163%26epage%3D168%26doi%3D10.1124%2Fjpet.112.191783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Sacco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bientinesi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tienforti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racioppi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Agostino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, P.</span><span> </span><span class="NLM_article-title">Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span><span class="refDoi"> DOI: 10.1517/17460441.2014.892923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1517%2F17460441.2014.892923" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=433-448&author=E.+Saccoauthor=R.+Bientinesiauthor=D.+Tienfortiauthor=M.+Racioppiauthor=G.+Gulinoauthor=D.+D%E2%80%99Agostinoauthor=M.+Vittoriauthor=P.+Bassi&title=Discovery+history+and+clinical+development+of+mirabegron+for+the+treatment+of+overactive+bladder+and+urinary+incontinence&doi=10.1517%2F17460441.2014.892923"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.892923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.892923%26sid%3Dliteratum%253Aachs%26aulast%3DSacco%26aufirst%3DE.%26aulast%3DBientinesi%26aufirst%3DR.%26aulast%3DTienforti%26aufirst%3DD.%26aulast%3DRacioppi%26aufirst%3DM.%26aulast%3DGulino%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Agostino%26aufirst%3DD.%26aulast%3DVittori%26aufirst%3DM.%26aulast%3DBassi%26aufirst%3DP.%26atitle%3DDiscovery%2520history%2520and%2520clinical%2520development%2520of%2520mirabegron%2520for%2520the%2520treatment%2520of%2520overactive%2520bladder%2520and%2520urinary%2520incontinence%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D433%26epage%3D448%26doi%3D10.1517%2F17460441.2014.892923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Malik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gelderen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mujais, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaddelee, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Koning, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaibara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keirns, J. J.</span><span> </span><span class="NLM_article-title">Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">696</span><span class="NLM_x">–</span> <span class="NLM_lpage">706</span><span class="refDoi"> DOI: 10.1038/clpt.2012.181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2Fclpt.2012.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=23149929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12is7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=696-706&author=M.+Malikauthor=E.+M.+van+Gelderenauthor=J.+H.+Leeauthor=D.+L.+Kowalskiauthor=M.+Yenauthor=R.+Goldwaterauthor=S.+K.+Mujaisauthor=M.+P.+Schaddeleeauthor=P.+de+Koningauthor=A.+Kaibaraauthor=S.+S.+Moyauthor=J.+J.+Keirns&title=Proarrhythmic+safety+of+repeat+doses+of+mirabegron+in+healthy+subjects%3A+a+randomized%2C+double-blind%2C+placebo-%2C+and+active-controlled+thorough+QT+study&doi=10.1038%2Fclpt.2012.181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study</span></div><div class="casAuthors">Malik, M.; van Gelderen, E. M.; Lee, J. H.; Kowalski, D. L.; Yen, M.; Goldwater, R.; Mujais, S. K.; Schaddelee, M. P.; de Koning, P.; Kaibara, A.; Moy, S. S.; Keirns, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">696-706</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Potential effects of the selective β3-adrenoceptor agonist mirabegron on cardiac repolarization were studied in healthy subjects.  The four-arm, parallel, two-way crossover study was double-blind and placebo- and active (moxifloxacin)-controlled.  After 2 baseline ECG days, subjects were randomized to one of eight treatment sequences (22 females and 22 males per sequence) of placebo crossed over with once-daily (10 days) 50, 100, or 200 mg mirabegron or a single 400-mg moxifloxacin dose on day 10.  In each period, continuous ECGs were recorded at two baselines and on the last drug administration day.  The lower one-sided 95% confidence interval for moxifloxacin effect on QTcI was >5 ms, demonstrating assay sensitivity.  According to ICH E14 criteria, mirabegron did not cause QTcI prolongation at the 50-mg therapeutic and 100-mg supratherapeutic doses in either sex.  Mirabegron prolonged QTcI interval at the 200-mg supratherapeutic dose (upper one-sided 95% CI >10 ms) in females, but not in males.  Clin. Pharmacol. & Therapeutics (2012); 92 6, 696-706. doi:10.1038/clpt.2012.181.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozi2PKhmgjELVg90H21EOLACvtfcHk0lirjLzdEtqnfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12is7fJ&md5=4d663a83c00f179de8fa2028c22b799f</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.181%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DM.%26aulast%3Dvan%2BGelderen%26aufirst%3DE.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKowalski%26aufirst%3DD.%2BL.%26aulast%3DYen%26aufirst%3DM.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DMujais%26aufirst%3DS.%2BK.%26aulast%3DSchaddelee%26aufirst%3DM.%2BP.%26aulast%3Dde%2BKoning%26aufirst%3DP.%26aulast%3DKaibara%26aufirst%3DA.%26aulast%3DMoy%26aufirst%3DS.%2BS.%26aulast%3DKeirns%26aufirst%3DJ.%2BJ.%26atitle%3DProarrhythmic%2520safety%2520of%2520repeat%2520doses%2520of%2520mirabegron%2520in%2520healthy%2520subjects%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-%252C%2520and%2520active-controlled%2520thorough%2520QT%2520study%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D696%26epage%3D706%26doi%3D10.1038%2Fclpt.2012.181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tyagi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyagi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chancellor, M.</span><span> </span><span class="NLM_article-title">Mirabegron: a safety review</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1517/14740338.2011.542146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1517%2F14740338.2011.542146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21142693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlaqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=287-294&author=P.+Tyagiauthor=V.+Tyagiauthor=M.+Chancellor&title=Mirabegron%3A+a+safety+review&doi=10.1517%2F14740338.2011.542146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Mirabegron: a safety review</span></div><div class="casAuthors">Tyagi, Pradeep; Tyagi, Vikas; Chancellor, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Mirabegron is being developed as a new treatment for the management of overactive bladder (OAB).  It is an orally active drug that works by activating the ββ3-adrenoceptor with a better safety profile than antimuscarinic drugs.  However, long-term adverse effects are not yet completely investigated.  The following article reviews the pharmacol. and efficacy of mirabegron by analyzing the tolerability findings in the data available from several Phase II placebo-controlled clin. trials conducted with an active comparator.  We aim to provide familiarity with the metabolic pathway responsible for disposition of mirabegron which makes it likely to produce pharmacokinetic interactions with other drugs, as although mirabegron is generally well tolerated, its potential to cause drug interactions may limit its use in some patients.  Mirabegron is a ββ3-adrenoceptor agonist developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile for OAB patients with advanced age and cognitive deficit.  It has been well tolerated with significant efficacy in reducing the no. of incontinence episodes and mean micturition frequency.  The most commonly reported toxic effects of mirabegron are gastrointestinal adverse events and headache.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxUX5hgO_DILVg90H21EOLACvtfcHk0lirjLzdEtqnfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlaqsr4%253D&md5=845f4b7fee7b1e10689a68abcdd6804c</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1517%2F14740338.2011.542146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2011.542146%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DP.%26aulast%3DTyagi%26aufirst%3DV.%26aulast%3DChancellor%26aufirst%3DM.%26atitle%3DMirabegron%253A%2520a%2520safety%2520review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2011%26volume%3D10%26spage%3D287%26epage%3D294%26doi%3D10.1517%2F14740338.2011.542146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hayashi, R.; Kikuchi, T.; Arai, M.; Kurosawa, S.; Hasebe, K.; Kanie, S.; Ozono, S.; Otsuka, A.</span><span> </span><span class="NLM_article-title">Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes</span>. WO2008093767,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+Hayashi&author=T.+Kikuchi&author=M.+Arai&author=S.+Kurosawa&author=K.+Hasebe&author=S.+Kanie&author=S.+Ozono&author=A.+Otsuka&title=Benzylamine+derivative+or+pharmaceutically+acceptable+acid+addition+salt+thereof%2C+and+use+thereof+for+medical+purposes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DR.%26atitle%3DBenzylamine%2520derivative%2520or%2520pharmaceutically%2520acceptable%2520acid%2520addition%2520salt%2520thereof%252C%2520and%2520use%2520thereof%2520for%2520medical%2520purposes%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tyagi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyagi, V.</span><span> </span><span class="NLM_article-title">Mirabegron, a β<sub>3</sub>-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=713-722&author=P.+Tyagiauthor=V.+Tyagi&title=Mirabegron%2C+a+%CE%B23-adrenoceptor+agonist+for+the+potential+treatment+of+urinary+frequency%2C+urinary+incontinence+or+urgency+associated+with+overactive+bladder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DP.%26aulast%3DTyagi%26aufirst%3DV.%26atitle%3DMirabegron%252C%2520a%2520%25CE%25B23-adrenoceptor%2520agonist%2520for%2520the%2520potential%2520treatment%2520of%2520urinary%2520frequency%252C%2520urinary%2520incontinence%2520or%2520urgency%2520associated%2520with%2520overactive%2520bladder%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D713%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bragg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vouri, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitlick, J. M.</span><span> </span><span class="NLM_article-title">Mirabegron: a Beta-3 agonist for overactive bladder</span> <span class="citation_source-journal">Consult Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">823</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span><span class="refDoi"> DOI: 10.4140/TCP.n.2014.823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.4140%2FTCP.n.2014.823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=25521658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgvFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=823-837&author=R.+Braggauthor=D.+Hebelauthor=S.+M.+Vouriauthor=J.+M.+Pitlick&title=Mirabegron%3A+a+Beta-3+agonist+for+overactive+bladder&doi=10.4140%2FTCP.n.2014.823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Mirabegron: a Beta-3 agonist for overactive bladder</span></div><div class="casAuthors">Bragg Rebecca; Hebel Danielle; Vouri Scott Martin; Pitlick Jamie M</div><div class="citationInfo"><span class="NLM_cas:title">The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">823-37</span>
        ISSN:<span class="NLM_cas:issn">0888-5109</span>.
    </div><div class="casAbstract">OBJECTIVE:  To review the literature regarding the efficacy and safety of mirabegron for the treatment of overactive bladder (OAB).  DATA SOURCES:  A literature search was performed using MEDLINE (PubMed) prior to December 31, 2013, using the terms "mirabegron" and "randomized-controlled trial."  STUDY SELECTION/DATA EXTRACTION:  All published, double-blind, randomized-controlled trials assessing mirabegron were included.  Articles were reviewed and included if mirabegron was used as monotherapy and if the primary outcome analyzed drug efficacy.  DATA SYNTHESIS:  The efficacy of mirabegron for the treatment of OAB has been demonstrated in the selected five randomized, placebo-controlled trials.  The majority of these trials lasted 12 weeks and compared various doses of mirabegron with placebo and/or tolterodine extended-release (ER).  Primary efficacy outcomes for the trials included mean number of micturitions per 24 hours and mean number of incontinence episodes per 24 hours.  Included trials showed statistically significant reductions in both efficacy outcomes for various doses of mirabegron when compared with placebo.  CONCLUSION:  Based on the trials reviewed, mirabegron has been efficacious in reducing mean number of micturitions and incontinence episodes per 24 hours, as well as in improving other secondary outcomes such as OAB symptoms and quality-of-life measures.  Common adverse drug events seen with mirabegron include: hypertension, nasopharyngitis, urinary tract infections, headache, constipation, upper respiratory tract infection, arthralgia, diarrhea, tachycardia, abdominal pain, and fatigue.  Given the efficacy and safety data currently available, mirabegron represents a reasonable alternative to antimuscarinics for patients with OAB.  Future studies are needed to determine the utility of mirabegron for OAB in a variety of demographics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8R_CrClfSRxWfpMXQLRstfW6udTcc2eZSM-Vrzdurmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgvFajtg%253D%253D&md5=77c9f399bbcc48ffc99b3a39fc075116</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.4140%2FTCP.n.2014.823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4140%252FTCP.n.2014.823%26sid%3Dliteratum%253Aachs%26aulast%3DBragg%26aufirst%3DR.%26aulast%3DHebel%26aufirst%3DD.%26aulast%3DVouri%26aufirst%3DS.%2BM.%26aulast%3DPitlick%26aufirst%3DJ.%2BM.%26atitle%3DMirabegron%253A%2520a%2520Beta-3%2520agonist%2520for%2520overactive%2520bladder%26jtitle%3DConsult%2520Pharm.%26date%3D2014%26volume%3D29%26spage%3D823%26epage%3D837%26doi%3D10.4140%2FTCP.n.2014.823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Altenbach, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khilevich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolasa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohde, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searle, X. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnelle, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tietje, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayburt, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daza, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milicic, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ireland, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakane, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brune, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauvin, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katwala, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holladay, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. P.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing α<sub>1A</sub>-adrenoceptor agonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3220</span><span class="NLM_x">–</span> <span class="NLM_lpage">3235</span><span class="refDoi"> DOI: 10.1021/jm030551a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030551a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3220-3235&author=R.+J.+Altenbachauthor=A.+Khilevichauthor=T.+Kolasaauthor=J.+J.+Rohdeauthor=P.+A.+Bhatiaauthor=M.+V.+Patelauthor=X.+B.+Searleauthor=F.+Yangauthor=W.+H.+Bunnelleauthor=K.+Tietjeauthor=E.+K.+Bayburtauthor=W.+A.+Carrollauthor=M.+D.+Meyerauthor=R.+Henryauthor=S.+A.+Bucknerauthor=J.+Kukauthor=A.+V.+Dazaauthor=I.+V.+Milicicauthor=J.+C.+Cainauthor=C.+H.+Kangauthor=L.+M.+Irelandauthor=T.+L.+Carrauthor=T.+R.+Millerauthor=A.+A.+Hancockauthor=M.+Nakaneauthor=T.+A.+Esbenshadeauthor=M.+E.+Bruneauthor=A.+B.+O%E2%80%99Neillauthor=D.+M.+Gauvinauthor=S.+P.+Katwalaauthor=M.+W.+Holladayauthor=J.+D.+Brioniauthor=J.+P.+Sullivan&title=Synthesis+and+structure-activity+studies+on+N-%5B5-%281H-imidazol-4-yl%29-5%2C6%2C7%2C8-tetrahydro-1-naphthalenyl%5Dmethanesulfonamide%2C+an+imidazole-containing+%CE%B11A-adrenoceptor+agonist&doi=10.1021%2Fjm030551a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fjm030551a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030551a%26sid%3Dliteratum%253Aachs%26aulast%3DAltenbach%26aufirst%3DR.%2BJ.%26aulast%3DKhilevich%26aufirst%3DA.%26aulast%3DKolasa%26aufirst%3DT.%26aulast%3DRohde%26aufirst%3DJ.%2BJ.%26aulast%3DBhatia%26aufirst%3DP.%2BA.%26aulast%3DPatel%26aufirst%3DM.%2BV.%26aulast%3DSearle%26aufirst%3DX.%2BB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DBunnelle%26aufirst%3DW.%2BH.%26aulast%3DTietje%26aufirst%3DK.%26aulast%3DBayburt%26aufirst%3DE.%2BK.%26aulast%3DCarroll%26aufirst%3DW.%2BA.%26aulast%3DMeyer%26aufirst%3DM.%2BD.%26aulast%3DHenry%26aufirst%3DR.%26aulast%3DBuckner%26aufirst%3DS.%2BA.%26aulast%3DKuk%26aufirst%3DJ.%26aulast%3DDaza%26aufirst%3DA.%2BV.%26aulast%3DMilicic%26aufirst%3DI.%2BV.%26aulast%3DCain%26aufirst%3DJ.%2BC.%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DIreland%26aufirst%3DL.%2BM.%26aulast%3DCarr%26aufirst%3DT.%2BL.%26aulast%3DMiller%26aufirst%3DT.%2BR.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26aulast%3DNakane%26aufirst%3DM.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DBrune%26aufirst%3DM.%2BE.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DA.%2BB.%26aulast%3DGauvin%26aufirst%3DD.%2BM.%26aulast%3DKatwala%26aufirst%3DS.%2BP.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26atitle%3DSynthesis%2520and%2520structure-activity%2520studies%2520on%2520N-%255B5-%25281H-imidazol-4-yl%2529-5%252C6%252C7%252C8-tetrahydro-1-naphthalenyl%255Dmethanesulfonamide%252C%2520an%2520imidazole-containing%2520%25CE%25B11A-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3220%26epage%3D3235%26doi%3D10.1021%2Fjm030551a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateishi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujiuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furutani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, S.</span><span> </span><span class="NLM_article-title">Tryptamine-based human β<sub>3</sub>-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5963</span><span class="NLM_x">–</span> <span class="NLM_lpage">5966</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.09.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmcl.2004.09.054" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=5963-5966&author=M.+Sawaauthor=H.+Tateishiauthor=K.+Mizunoauthor=H.+Haradaauthor=M.+Oueauthor=H.+Tsujiuchiauthor=Y.+Furutaniauthor=S.+Kato&title=Tryptamine-based+human+%CE%B23-adrenergic+receptor+agonists.+Part+2%3A+SAR+of+the+methylene+derivatives&doi=10.1016%2Fj.bmcl.2004.09.054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.09.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.09.054%26sid%3Dliteratum%253Aachs%26aulast%3DSawa%26aufirst%3DM.%26aulast%3DTateishi%26aufirst%3DH.%26aulast%3DMizuno%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DH.%26aulast%3DOue%26aufirst%3DM.%26aulast%3DTsujiuchi%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DY.%26aulast%3DKato%26aufirst%3DS.%26atitle%3DTryptamine-based%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists.%2520Part%25202%253A%2520SAR%2520of%2520the%2520methylene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D5963%26epage%3D5966%26doi%3D10.1016%2Fj.bmcl.2004.09.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="note"><p class="first last">The pharmacological effect of <b>1</b> was previously investigated at a dose of 3 mg/kg iv in rats,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and the EC<sub>50</sub> values of <b>1</b> and <b>15</b> for human β<sub>3</sub>-AR were 22.4<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and 18 nM, respectively, suggesting that the two compounds are similarly potent β<sub>3</sub>-AR agonists. Therefore, as a preliminary experiment, we compared the cardiovascular safety of <b>1</b> and <b>15</b> at the same dose of 3 mg/kg iv in rats.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Matsubara, K. I.; Naoyuki; Ogawa; Masami</span><span> </span><span class="NLM_article-title">Processes for the preparation of tricyclic amino alcohol derivatives</span>. WO2001017962,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=K.+I.+Matsubara&author=+Naoyuki&author=+Ogawa&author=+Masami&title=Processes+for+the+preparation+of+tricyclic+amino+alcohol+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsubara%26aufirst%3DK.%2BI.%26atitle%3DProcesses%2520for%2520the%2520preparation%2520of%2520tricyclic%2520amino%2520alcohol%2520derivatives%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schaus, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandes, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokunaga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furrow, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. N.</span><span> </span><span class="NLM_article-title">Highly selective hydrolytic kinetic resolution of terminal epoxides catalyzed by chiral (salen)Co-III complexes. Practical synthesis of enantioenriched terminal epoxides and 1,2-diols</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">1307</span><span class="NLM_x">–</span> <span class="NLM_lpage">1315</span><span class="refDoi"> DOI: 10.1021/ja016737l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja016737l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=1307-1315&author=S.+E.+Schausauthor=B.+D.+Brandesauthor=J.+F.+Larrowauthor=M.+Tokunagaauthor=K.+B.+Hansenauthor=A.+E.+Gouldauthor=M.+E.+Furrowauthor=E.+N.+Jacobsen&title=Highly+selective+hydrolytic+kinetic+resolution+of+terminal+epoxides+catalyzed+by+chiral+%28salen%29Co-III+complexes.+Practical+synthesis+of+enantioenriched+terminal+epoxides+and+1%2C2-diols&doi=10.1021%2Fja016737l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Fja016737l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja016737l%26sid%3Dliteratum%253Aachs%26aulast%3DSchaus%26aufirst%3DS.%2BE.%26aulast%3DBrandes%26aufirst%3DB.%2BD.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DTokunaga%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DGould%26aufirst%3DA.%2BE.%26aulast%3DFurrow%26aufirst%3DM.%2BE.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DHighly%2520selective%2520hydrolytic%2520kinetic%2520resolution%2520of%2520terminal%2520epoxides%2520catalyzed%2520by%2520chiral%2520%2528salen%2529Co-III%2520complexes.%2520Practical%2520synthesis%2520of%2520enantioenriched%2520terminal%2520epoxides%2520and%25201%252C2-diols%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D1307%26epage%3D1315%26doi%3D10.1021%2Fja016737l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sugimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiya, K.</span><span> </span><span class="NLM_article-title">Di-2-methoxyethyl azodicarboxylate (DMEAD): An inexpensive and separation-friendly alternative reagent for the Mitsunobu reaction</span> <span class="citation_source-journal">Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span><span class="refDoi"> DOI: 10.1246/cl.2007.566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1246%2Fcl.2007.566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD2sXks1Oitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2007&pages=566-567&author=T.+Sugimuraauthor=K.+Hagiya&title=Di-2-methoxyethyl+azodicarboxylate+%28DMEAD%29%3A+An+inexpensive+and+separation-friendly+alternative+reagent+for+the+Mitsunobu+reaction&doi=10.1246%2Fcl.2007.566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">Di-2-methoxyethyl azodicarboxylate (DMEAD): an inexpensive and separation-friendly alternative reagent for the Mitsunobu reaction</span></div><div class="casAuthors">Sugimura, Takashi; Hagiya, Kazutake</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">566-567</span>CODEN:
                <span class="NLM_cas:coden">CMLTAG</span>;
        ISSN:<span class="NLM_cas:issn">0366-7022</span>.
    
            (<span class="NLM_cas:orgname">Chemical Society of Japan</span>)
        </div><div class="casAbstract">Bis(2-methoxyethyl) azodicarboxylate was prepd. as an alternative of DEAD or DIAD for the Mitsunobu reaction.  Removal of the hydrazinedicarboxylate generated from DMEAD becomes much easier owing to the polar and water-sol. property.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTeeOSWsEf6LVg90H21EOLACvtfcHk0liE-ljdQ3YkaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXks1Oitrc%253D&md5=5f5509554865f983adeab05a918c85a3</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1246%2Fcl.2007.566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.2007.566%26sid%3Dliteratum%253Aachs%26aulast%3DSugimura%26aufirst%3DT.%26aulast%3DHagiya%26aufirst%3DK.%26atitle%3DDi-2-methoxyethyl%2520azodicarboxylate%2520%2528DMEAD%2529%253A%2520An%2520inexpensive%2520and%2520separation-friendly%2520alternative%2520reagent%2520for%2520the%2520Mitsunobu%2520reaction%26jtitle%3DChem.%2520Lett.%26date%3D2007%26volume%3D36%26spage%3D566%26epage%3D567%26doi%3D10.1246%2Fcl.2007.566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hagiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muramoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimura, T.</span><span> </span><span class="NLM_article-title">DMEAD: a new dialkyl azodicarboxylate for the Mitsunobu reaction</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">6109</span><span class="NLM_x">–</span> <span class="NLM_lpage">6114</span><span class="refDoi"> DOI: 10.1016/j.tet.2009.05.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.tet.2009.05.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=6109-6114&author=K.+Hagiyaauthor=N.+Muramotoauthor=T.+Misakiauthor=T.+Sugimura&title=DMEAD%3A+a+new+dialkyl+azodicarboxylate+for+the+Mitsunobu+reaction&doi=10.1016%2Fj.tet.2009.05.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">DMEAD: a new dialkyl azodicarboxylate for the Mitsunobu reaction</span></div><div class="casAuthors">Hagiya, Kazutake; Muramoto, Natsuko; Misaki, Tomonori; Sugimura, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">6109-6114</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Di-2-methoxyethyl azodicarboxylate (DMEAD) is prepd. in 65% yield in two steps as a cryst. solid.  Use of DMEAD in the Mitsunobu reaction of a variety of alcs. with pronucleophiles results in good yields of the products under sufficient stereospecificity of inversion, as conventional diisopropyl azodicarboxylate (DIAD) does.  Isolation of the product is, however, much easier with DMEAD than that with DIAD, because the hydrazine produced from DMEAD is highly hydrophilic and is completely separable by a simple extn. into neutral water.  Purifn. of the org. layer, after sepn. of the other byproduct, triphenylphosphine oxide, by filtration, easily provides high purity of the product in a good yield.  Concn. of the water layer yields the hydrazine, which can be reused for the prepn. of DMEAD.  One-step removal of the two byproducts by the aq. extn. was also possible when trimethylphosphine and DMEAD were employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8942g2yxAwbVg90H21EOLACvtfcHk0lhY7b_y-hmnXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCksbc%253D&md5=1465a85e39f7dd03b9c7f74d9f599c20</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2009.05.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2009.05.048%26sid%3Dliteratum%253Aachs%26aulast%3DHagiya%26aufirst%3DK.%26aulast%3DMuramoto%26aufirst%3DN.%26aulast%3DMisaki%26aufirst%3DT.%26aulast%3DSugimura%26aufirst%3DT.%26atitle%3DDMEAD%253A%2520a%2520new%2520dialkyl%2520azodicarboxylate%2520for%2520the%2520Mitsunobu%2520reaction%26jtitle%3DTetrahedron%26date%3D2009%26volume%3D65%26spage%3D6109%26epage%3D6114%26doi%3D10.1016%2Fj.tet.2009.05.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="note"><p class="first last">In the case of <b>15</b>, removal of the <i>O</i>-TES group with 1 M TBAF in THF before treating with 4 M HCl in dioxane effectively gave crystallized compound <b>15</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span> </span><span class="NLM_article-title">Insights into the binding modes of human β<sub>3</sub>-adrenergic receptor agonists with ligand-based and receptor-based methods</span> <span class="citation_source-journal">Mol. Diversity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">831</span><span class="refDoi"> DOI: 10.1007/s11030-011-9311-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1007%2Fs11030-011-9311-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=817-831&author=F.+Jinauthor=C.+Luauthor=X.+Sunauthor=W.+Liauthor=G.+Liuauthor=Y.+Tang&title=Insights+into+the+binding+modes+of+human+%CE%B23-adrenergic+receptor+agonists+with+ligand-based+and+receptor-based+methods&doi=10.1007%2Fs11030-011-9311-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1007%2Fs11030-011-9311-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-011-9311-8%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DY.%26atitle%3DInsights%2520into%2520the%2520binding%2520modes%2520of%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520with%2520ligand-based%2520and%2520receptor-based%2520methods%26jtitle%3DMol.%2520Diversity%26date%3D2011%26volume%3D15%26spage%3D817%26epage%3D831%26doi%3D10.1007%2Fs11030-011-9311-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Roy, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, A. K.</span><span> </span><span class="NLM_article-title">Structural basis for the β-adrenergic receptor subtype selectivity of the representative agonists and antagonists</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1405</span><span class="NLM_x">–</span> <span class="NLM_lpage">1422</span><span class="refDoi"> DOI: 10.1021/ci2000874</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci2000874" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=1405-1422&author=K.+K.+Royauthor=A.+K.+Saxena&title=Structural+basis+for+the+%CE%B2-adrenergic+receptor+subtype+selectivity+of+the+representative+agonists+and+antagonists&doi=10.1021%2Fci2000874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the β-Adrenergic Receptor Subtype Selectivity of the Representative Agonists and Antagonists</span></div><div class="casAuthors">Roy, Kuldeep K.; Saxena, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1405-1422</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The β3-adrenergic receptor (β3-AR) selectivity over β1- and β2-ARs has been the most important aspect for successful therapeutic agents for obesity and type-II diabetes, as the concomitant activation of β1- and β2-ARs would lead to undesirable side effects, such as increased heart rate.  In order to explore the structural basis for the β-AR subtype selectivity of agonists and antagonists, a three-dimensional structure of until date unresolved β3-AR has been modeled, compared with the resolved X-ray structures of β1- and β2-ARs, and used to study its stereoselective binding with until-date known diverse classes of representative agonists and antagonist.  The obtained binding structures and calcd. prime mol. mechanics-generalized Born surface area (MM-GBSA) binding free energies consistently reveal that while the subtype selectivity is strongly governed by the residues present in the extracellular ends of TM3, TM5, TM6, TM7 helixes and of the ECL2 domain, the binding affinity is governed by the conserved residues present in the deep pocket limiting the degree of conformational and rotational freedoms to the bound ligand.  The study demonstrates that the key structural requirements for the β3-selectivity are: (i) a neg. ionizable group (NIG) for direct interaction with β3-specific residue R3156.58, (ii) a linker (9-10 Å length) between the protonated amine and NIG, and (iii) a substituted aryl ring directly attached to the β-hydroxyl carbon.  The new computational insights acquired in this study are expected to be valuable in structure-based rational design of high-affinity agonists and antagonists with pronounced β3-selectivity for successful therapeutic agents for type-II diabetes and obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKByl5Kn7SurVg90H21EOLACvtfcHk0lhY7b_y-hmnXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVCmt7g%253D&md5=bbfca37eae96885f6b6a62ff40ea757c</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Fci2000874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2000874%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DK.%2BK.%26aulast%3DSaxena%26aufirst%3DA.%2BK.%26atitle%3DStructural%2520basis%2520for%2520the%2520%25CE%25B2-adrenergic%2520receptor%2520subtype%2520selectivity%2520of%2520the%2520representative%2520agonists%2520and%2520antagonists%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D1405%26epage%3D1422%26doi%3D10.1021%2Fci2000874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure of a nanobody-stabilized active state of the β<sub>2</sub> adrenoceptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1038/nature09648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2Fnature09648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21228869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=175-180&author=S.+G.+Rasmussenauthor=H.+J.+Choiauthor=J.+J.+Fungauthor=E.+Pardonauthor=P.+Casarosaauthor=P.+S.+Chaeauthor=B.+T.+Devreeauthor=D.+M.+Rosenbaumauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=A.+Schnappauthor=I.+Konetzkiauthor=R.+K.+Sunaharaauthor=S.+H.+Gellmanauthor=A.+Pautschauthor=J.+Steyaertauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Structure+of+a+nanobody-stabilized+active+state+of+the+%CE%B22+adrenoceptor&doi=10.1038%2Fnature09648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a nanobody-stabilized active state of the β2 adrenoceptor</span></div><div class="casAuthors">Rasmussen, Soren G. F.; Choi, Hee-Jung; Fung, Juan Jose; Pardon, Els; Casarosa, Paola; Chae, Pil Seok; DeVree, Brian T.; Rosenbaum, Daniel M.; Thian, Foon Sun; Kobilka, Tong Sun; Schnapp, Andreas; Konetzki, Ingo; Sunahara, Roger K.; Gellman, Samuel H.; Pautsch, Alexander; Steyaert, Jan; Weis, William I.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">175-180</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein coupled receptors (GPCRs) exhibit a spectrum of functional behaviors in response to natural and synthetic ligands.  Recent crystal structures provide insights into inactive states of several GPCRs.  Efforts to obtain an agonist-bound active-state GPCR structure have proven difficult due to the inherent instability of this state in the absence of a G protein.  We generated a camelid antibody fragment (nanobody) to the human β2 adrenergic receptor (β2AR) that exhibits G protein-like behavior, and obtained an agonist-bound, active-state crystal structure of the receptor-nanobody complex.  Comparison with the inactive β2AR structure reveals subtle changes in the binding pocket; however, these small changes are assocd. with an 11 Å outward movement of the cytoplasmic end of transmembrane segment 6, and rearrangements of transmembrane segments 5 and 7 that are remarkably similar to those obsd. in opsin, an active form of rhodopsin.  This structure provides insights into the process of agonist binding and activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqITZxHz6Vi77Vg90H21EOLACvtfcHk0lhd0Xv6U3msEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFartA%253D%253D&md5=3a1d3bac6d92c9d54cf1ddd14d56ab8c</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1038%2Fnature09648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09648%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DFung%26aufirst%3DJ.%2BJ.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DDevree%26aufirst%3DB.%2BT.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DPautsch%26aufirst%3DA.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520of%2520a%2520nanobody-stabilized%2520active%2520state%2520of%2520the%2520%25CE%25B22%2520adrenoceptor%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D175%26epage%3D180%26doi%3D10.1038%2Fnature09648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calinski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiesen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caffrey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skiniotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Crystal structure of the β<sub>2</sub> adrenergic receptor-Gs protein complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">477</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span><span class="refDoi"> DOI: 10.1038/nature10361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2Fnature10361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21772288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1equrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2011&pages=549-555&author=S.+G.+Rasmussenauthor=B.+T.+DeVreeauthor=Y.+Zouauthor=A.+C.+Kruseauthor=K.+Y.+Chungauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=P.+S.+Chaeauthor=E.+Pardonauthor=D.+Calinskiauthor=J.+M.+Mathiesenauthor=S.+T.+Shahauthor=J.+A.+Lyonsauthor=M.+Caffreyauthor=S.+H.+Gellmanauthor=J.+Steyaertauthor=G.+Skiniotisauthor=W.+I.+Weisauthor=R.+K.+Sunaharaauthor=B.+K.+Kobilka&title=Crystal+structure+of+the+%CE%B22+adrenergic+receptor-Gs+protein+complex&doi=10.1038%2Fnature10361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the β2 adrenergic receptor-Gs protein complex</span></div><div class="casAuthors">Rasmussen, Soren G. F.; DeVree, Brian T.; Zou, Yao-Zhong; Kruse, Andrew C.; Chung, Ka-Young; Kobilka, Tong-Sun; Thian, Foon-Sun; Chae, Pil-Seok; Pardon, Els; Calinski, Diane; Mathiesen, Jesper M.; Shah, Syed T. A.; Lyons, Joseph A.; Caffrey, Martin; Gellman, Samuel H.; Steyaert, Jan; Skiniotis, Georgios; Weis, William I.; Sunahara, Roger K.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">477</span>
        (<span class="NLM_cas:issue">7366</span>),
    <span class="NLM_cas:pages">549-555</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are responsible for the majority of cellular responses to hormones and neurotransmitters as well as the senses of sight, olfaction and taste.  The paradigm of GPCR signalling is the activation of a heterotrimeric GTP binding protein (G protein) by an agonist-occupied receptor.  The β2 adrenergic receptor (β2AR) activation of Gs, the stimulatory G protein for adenylyl cyclase, has long been a model system for GPCR signalling.  Here we present the crystal structure of the active state ternary complex composed of agonist-occupied monomeric β2AR and nucleotide-free Gs heterotrimer.  The principal interactions between the β2AR and Gs involve the amino- and carboxy-terminal α-helixes of Gs, with conformational changes propagating to the nucleotide-binding pocket.  The largest conformational changes in the β2AR include a 14 Å outward movement at the cytoplasmic end of transmembrane segment 6 (TM6) and an α-helical extension of the cytoplasmic end of TM5.  The most surprising observation is a major displacement of the α-helical domain of Gαs relative to the Ras-like GTPase domain.  This crystal structure represents the first high-resoln. view of transmembrane signalling by a GPCR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-PdYRDvolqrVg90H21EOLACvtfcHk0ljFSdQHTRG1Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1equrrL&md5=d22a43dd677ac255d138b1aedff357d3</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1038%2Fnature10361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10361%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DDeVree%26aufirst%3DB.%2BT.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DChung%26aufirst%3DK.%2BY.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DCalinski%26aufirst%3DD.%26aulast%3DMathiesen%26aufirst%3DJ.%2BM.%26aulast%3DShah%26aufirst%3DS.%2BT.%26aulast%3DLyons%26aufirst%3DJ.%2BA.%26aulast%3DCaffrey%26aufirst%3DM.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DSkiniotis%26aufirst%3DG.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520%25CE%25B22%2520adrenergic%2520receptor-Gs%2520protein%2520complex%26jtitle%3DNature%26date%3D2011%26volume%3D477%26spage%3D549%26epage%3D555%26doi%3D10.1038%2Fnature10361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aragao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlow, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dror, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caffrey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure and function of an irreversible agonist-β<sub>2</sub> adrenoceptor complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span><span class="refDoi"> DOI: 10.1038/nature09665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2Fnature09665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21228876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=236-240&author=D.+M.+Rosenbaumauthor=C.+Zhangauthor=J.+A.+Lyonsauthor=R.+Hollauthor=D.+Aragaoauthor=D.+H.+Arlowauthor=S.+G.+Rasmussenauthor=H.+J.+Choiauthor=B.+T.+Devreeauthor=R.+K.+Sunaharaauthor=P.+S.+Chaeauthor=S.+H.+Gellmanauthor=R.+O.+Drorauthor=D.+E.+Shawauthor=W.+I.+Weisauthor=M.+Caffreyauthor=P.+Gmeinerauthor=B.+K.+Kobilka&title=Structure+and+function+of+an+irreversible+agonist-%CE%B22+adrenoceptor+complex&doi=10.1038%2Fnature09665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of an irreversible agonist-β2 adrenoceptor complex</span></div><div class="casAuthors">Rosenbaum, Daniel M.; Zhang, Cheng; Lyons, Joseph A.; Holl, Ralph; Aragao, David; Arlow, Daniel H.; Rasmussen, Soren G. F.; Choi, Hee-Jung; DeVree, Brian T.; Sunahara, Roger K.; Chae, Pil Seok; Gellman, Samuel H.; Dror, Ron O.; Shaw, David E.; Weis, William I.; Caffrey, Martin; Gmeiner, Peter; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">236-240</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are eukaryotic integral membrane proteins that modulate biol. function by initiating cellular signaling in response to chem. diverse agonists.  Despite recent progress in the structural biol. of GPCRs, the mol. basis for agonist binding and allosteric modulation of these proteins is poorly understood.  Structural knowledge of agonist-bound states is essential for deciphering the mechanism of receptor activation, and for structure-guided design and optimization of ligands.  However, the crystn. of agonist-bound GPCRs has been hampered by modest affinities and rapid off-rates of available agonists.  Using the inactive structure of the human β2 adrenergic receptor (β2AR) as a guide, we designed a β2AR agonist that can be covalently tethered to a specific site on the receptor through a disulfide bond.  The covalent β2AR-agonist complex forms efficiently, and is capable of activating a heterotrimeric G protein.  We crystd. a covalent agonist-bound β2AR-T4L fusion protein in lipid bilayers through the use of the lipidic mesophase method, and detd. its structure at 3.5 Å resoln.  A comparison to the inactive structure and an antibody-stabilized active structure (companion paper) shows how binding events at both the extracellular and intracellular surfaces are required to stabilize an active conformation of the receptor.  The structures are in agreement with long-timescale (up to 30 μs) mol. dynamics simulations showing that an agonist-bound active conformation spontaneously relaxes to an inactive-like conformation in the absence of a G protein or stabilizing antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cxTxwHig_rVg90H21EOLACvtfcHk0ljFSdQHTRG1Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFehsQ%253D%253D&md5=8629b93e43fb692395e2aa6f8bb011a9</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.1038%2Fnature09665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09665%26sid%3Dliteratum%253Aachs%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLyons%26aufirst%3DJ.%2BA.%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DAragao%26aufirst%3DD.%26aulast%3DArlow%26aufirst%3DD.%2BH.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DDevree%26aufirst%3DB.%2BT.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DCaffrey%26aufirst%3DM.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520and%2520function%2520of%2520an%2520irreversible%2520agonist-%25CE%25B22%2520adrenoceptor%2520complex%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D236%26epage%3D240%26doi%3D10.1038%2Fnature09665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lober, S.</span><span> </span><span class="NLM_article-title">GPCR crystal structures: medicinal chemistry in the pocket</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3880</span><span class="NLM_x">–</span> <span class="NLM_lpage">3906</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmc.2014.12.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=25638496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVamtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3880-3906&author=J.+Shonbergauthor=R.+C.+Klingauthor=P.+Gmeinerauthor=S.+Lober&title=GPCR+crystal+structures%3A+medicinal+chemistry+in+the+pocket&doi=10.1016%2Fj.bmc.2014.12.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32dR"><div class="casContent"><span class="casTitleNuber">32d</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR crystal structures: Medicinal chemistry in the pocket</span></div><div class="casAuthors">Shonberg, Jeremy; Kling, Ralf C.; Gmeiner, Peter; Loeber, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3880-3906</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent breakthroughs in G protein-coupled receptor (GPCR) structural biol. have significantly increased the understanding of drug action at these therapeutically relevant receptors, and this will undoubtedly lead to the design of better therapeutics.  In recent years, crystal structures of GPCRs from classes A, B, C, and F have been solved, unveiling a precise snapshot of ligand-receptor interactions.  Furthermore, some receptors have been crystd. in different functional states in complex with antagonists, partial agonists, full agonists, biased agonists, and allosteric modulators, providing further insight into the mechanisms of ligand-induced GPCR activation.  It is now obvious that there is enormous diversity in the size, shape and position of the ligand-binding pockets in GPCRs.  Here, the authors summarize the current state of solved GPCR structures, with a particular focus on ligand-receptor interactions in the binding pocket, and how this can contribute to the design of GPCR ligands with better affinity, subtype selectivity, or efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuUGn2F8NmfrVg90H21EOLACvtfcHk0ljFSdQHTRG1Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVamtw%253D%253D&md5=28f8f0f1f3c0526efce9f7f40f9053d4</span></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.034%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DLober%26aufirst%3DS.%26atitle%3DGPCR%2520crystal%2520structures%253A%2520medicinal%2520chemistry%2520in%2520the%2520pocket%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3880%26epage%3D3906%26doi%3D10.1016%2Fj.bmc.2014.12.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuto, S.</span><span> </span><span class="NLM_article-title">Investigation of the bioactive conformation of histamine H3 receptor antagonists by the cyclopropylic strain-based conformational restriction strategy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3585</span><span class="NLM_x">–</span> <span class="NLM_lpage">3593</span><span class="refDoi"> DOI: 10.1021/jm901848b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901848b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3585-3593&author=M.+Watanabeauthor=T.+Hirokawaauthor=T.+Kobayashiauthor=A.+Yoshidaauthor=Y.+Itoauthor=S.+Yamadaauthor=N.+Orimotoauthor=Y.+Yamasakiauthor=M.+Arisawaauthor=S.+Shuto&title=Investigation+of+the+bioactive+conformation+of+histamine+H3+receptor+antagonists+by+the+cyclopropylic+strain-based+conformational+restriction+strategy&doi=10.1021%2Fjm901848b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm901848b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901848b%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DHirokawa%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DS.%26aulast%3DOrimoto%26aufirst%3DN.%26aulast%3DYamasaki%26aufirst%3DY.%26aulast%3DArisawa%26aufirst%3DM.%26aulast%3DShuto%26aufirst%3DS.%26atitle%3DInvestigation%2520of%2520the%2520bioactive%2520conformation%2520of%2520histamine%2520H3%2520receptor%2520antagonists%2520by%2520the%2520cyclopropylic%2520strain-based%2520conformational%2520restriction%2520strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3585%26epage%3D3593%26doi%3D10.1021%2Fjm901848b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Chen, Y.-C.</span><span> </span><span class="NLM_article-title">Beware of docking!</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1016/j.tips.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.tips.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=25543280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=78-95&author=Y.-C.+Chen&title=Beware+of+docking%21&doi=10.1016%2Fj.tips.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Beware of docking!</span></div><div class="casAuthors">Chen, Yu-Chian</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">78-95</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Docking is now routine in virtual screening or lead optimization for drug screening and design.  The no. of papers related to docking has dramatically increased over the past decade.  However, there are many issues to consider when undertaking a docking study.  Frequent problems or issues arise, such as the wrong binding site of the target protein, screening using an unsuitable small-mol. database, the choice of docking pose, high dock score but failed in mol. dynamics (MD) simulation, and lack of clarity over whether the compd. is an inhibitor or agonist.  These problems should be cause for caution and concern before performing docking.  Some papers show comprehensive biochem. expts. but only a simple docking figure.  This review presents some evidence to show that the docking might be questionable, despite a high score.  In some cases, the accuracy of docking can even change from 0% to 92.66%.  Thus, please beware of docking!</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwtnBYohkg_bVg90H21EOLACvtfcHk0lj12abW21KX6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyluw%253D%253D&md5=5a045e1314d6382644f50a58275d536b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-C.%26atitle%3DBeware%2520of%2520docking%2521%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D78%26epage%3D95%26doi%3D10.1016%2Fj.tips.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lj12abW21KX6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Naritomi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagayama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span> </span><span class="NLM_article-title">Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=11560875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntVGqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=1316-1324&author=Y.+Naritomiauthor=S.+Terashitaauthor=S.+Kimuraauthor=A.+Suzukiauthor=A.+Kagayamaauthor=Y.+Sugiyama&title=Prediction+of+human+hepatic+clearance+from+in+vivo+animal+experiments+and+in+vitro+metabolic+studies+with+liver+microsomes+from+animals+and+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans</span></div><div class="casAuthors">Naritomi, Yoichi; Terashita, Shigeyuki; Kimura, Sumihisa; Suzuki, Akira; Kagayama, Akira; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1316-1324</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The authors investigated the quant. prediction of human hepatic metabolic clearance from in vitro expts. focusing on cytochrome P 450 metab. with 8 model compds., FK1052, FK480, zolpidem, omeprazole, nicardipine, nilvadipine, diazepam, and diltiazem.  For the compds., in vivo human hepatic extn. ratios ranged widely from 0.03 to 0.87.  In vitro and in vivo hepatic intrinsic clearance (CLint) values for each compd. were measured and calcd. in rats and/or dogs and humans.  CLint,in vitro was detd. from a substrate disappearance rate at 1 μM in hepatic microsomes, which was a useful method.  CLint,in vivo was calcd. from in vivo pharmacokinetic data using 3 frequent math. models (the well stirred, parallel-tube, and dispersion models).  The human scaling factor values (CLint,in vivo/CLint,in vitro) showed marked difference among the model compds. (0.3-26.6-fold).  On the other hand, most of the animal scaling factors were within 2-fold of the values in humans, suggesting that scaling factor values were similar in the different animal species.  When human CLint,in vitro values were compared with the actual CLint,in vivo, correlation was not necessarily good.  By contrast, using human CLint,in vitro cor. with the rat and/or dog scaling factors yielded better predictions of CLint,in vivo that were mostly within 2-fold of the actual values.  Furthermore, successful predictions of human CLoral and hepatic extn. ratio (EH) were obtained by use of the human CLint,in vitro cor. with animal scaling factors.  The new variant method is a simple one, incorporating addnl. information from animal studies and providing a more reliable prediction of human hepatic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcc19l5ypTILVg90H21EOLACvtfcHk0lgGQMBI2LP21g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntVGqurs%253D&md5=b8eb1ad7992ce8193cf1a35862823d49</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaritomi%26aufirst%3DY.%26aulast%3DTerashita%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKagayama%26aufirst%3DA.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520human%2520hepatic%2520clearance%2520from%2520in%2520vivo%2520animal%2520experiments%2520and%2520in%2520vitro%2520metabolic%2520studies%2520with%2520liver%2520microsomes%2520from%2520animals%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2001%26volume%3D29%26spage%3D1316%26epage%3D1324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Bowers, K. J.; Chow, E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregersen, B. A.; Klepeis, J. L.; Kolossvary, I.; Moraes, M. A.; Sacerdoti, F. D.; Salmon, J. K; Shan, Y.; Shaw, D. E.</span><span> </span><span class="NLM_article-title">Scalable algorithms for molecular dynamics simulations on commodity clusters</span>. Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa, Florida, November 11–17,2016,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+J.+Bowers&author=E.+Chow&author=H.+Xu&author=R.+O.+Dror&author=M.+P.+Eastwood&author=B.+A.+Gregersen&author=J.+L.+Klepeis&author=I.+Kolossvary&author=M.+A.+Moraes&author=F.+D.+Sacerdoti&author=J.+K+Salmon&author=Y.+Shan&author=D.+E.+Shaw&title=Scalable+algorithms+for+molecular+dynamics+simulations+on+commodity+clusters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DK.%2BJ.%26atitle%3DScalable%2520algorithms%2520for%2520molecular%2520dynamics%2520simulations%2520on%2520commodity%2520clusters%26jtitle%3DProceedings%2520of%2520the%2520ACM%252FIEEE%2520Conference%2520on%2520Supercomputing%2520%2528SC06%2529%252C%2520Tampa%252C%2520Florida%252C%2520November%252011%25E2%2580%259317%252C2016%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Harder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damm, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maple, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reboul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupyan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlgren, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaus, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerutti, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krilov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">OPLS3: a force field providing broad coverage of drug-like small molecules and proteins</span> <span class="citation_source-journal">J. Chem. Theory Comput.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.1021/acs.jctc.5b00864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=281-296&author=E.+Harderauthor=W.+Dammauthor=J.+Mapleauthor=C.+Wuauthor=M.+Reboulauthor=J.+Y.+Xiangauthor=L.+Wangauthor=D.+Lupyanauthor=M.+K.+Dahlgrenauthor=J.+L.+Knightauthor=J.+W.+Kausauthor=D.+S.+Ceruttiauthor=G.+Krilovauthor=W.+L.+Jorgensenauthor=R.+Abelauthor=R.+A.+Friesner&title=OPLS3%3A+a+force+field+providing+broad+coverage+of+drug-like+small+molecules+and+proteins&doi=10.1021%2Facs.jctc.5b00864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins</span></div><div class="casAuthors">Harder, Edward; Damm, Wolfgang; Maple, Jon; Wu, Chuanjie; Reboul, Mark; Xiang, Jin Yu; Wang, Lingle; Lupyan, Dmitry; Dahlgren, Markus K.; Knight, Jennifer L.; Kaus, Joseph W.; Cerutti, David S.; Krilov, Goran; Jorgensen, William L.; Abel, Robert; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and validation of the OPLS3 force field for small mols. and proteins are reported.  Enhancements with respect to the previous version (OPLS2.1) include the addn. of off-atom charge sites to represent halogen bonding and aryl nitrogen lone pairs as well as a complete refit of peptide dihedral parameters to better model the native structure of proteins.  To adequately cover medicinal chem. space, OPLS3 employs over an order of magnitude more ref. data and assocd. parameter types relative to other commonly used small mol. force fields (e.g., MMFF and OPLS_2005).  As a consequence, OPLS3 achieves a high level of accuracy across performance benchmarks that assess small mol. conformational propensities and solvation.  The newly fitted peptide dihedrals lead to significant improvements in the representation of secondary structure elements in simulated peptides and native structure stability over a no. of proteins.  Together, the improvements made to both the small mol. and protein force field lead to a high level of accuracy in predicting protein-ligand binding measured over a wide range of targets and ligands (less than 1 kcal/mol RMS error) representing a 30% improvement over earlier variants of the OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_jrOhcBRgrVg90H21EOLACvtfcHk0lgGQMBI2LP21g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE&md5=42663f8cfa84b80a67132bbb13b9b7ce</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00864%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DMaple%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DKaus%26aufirst%3DJ.%2BW.%26aulast%3DCerutti%26aufirst%3DD.%2BS.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOPLS3%253A%2520a%2520force%2520field%2520providing%2520broad%2520coverage%2520of%2520drug-like%2520small%2520molecules%2520and%2520proteins%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D281%26epage%3D296%26doi%3D10.1021%2Facs.jctc.5b00864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Lomize, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomize, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogozheva, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosberg, H. I.</span><span> </span><span class="NLM_article-title">OPM: orientations of proteins in membranes database</span> <span class="citation_source-journal">Bioinformatics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1093/bioinformatics/btk023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1093%2Fbioinformatics%2Fbtk023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=16397007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVeksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2006&pages=623-625&author=M.+A.+Lomizeauthor=A.+L.+Lomizeauthor=I.+D.+Pogozhevaauthor=H.+I.+Mosberg&title=OPM%3A+orientations+of+proteins+in+membranes+database&doi=10.1093%2Fbioinformatics%2Fbtk023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">OPM: Orientations of Proteins in Membranes database</span></div><div class="casAuthors">Lomize, Mikhail A.; Lomize, Andrei L.; Pogozheva, Irina D.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">623-625</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Orientations of Proteins in Membranes (OPM) database provides a collection of transmembrane, monotopic, and peripheral proteins from the Protein Data Bank whose spatial arrangements in the lipid bilayer have been calcd. theor. and compared with exptl. data.  The database allows anal., sorting, and searching of membrane proteins based on their structural classification, species, destination membrane, nos. of transmembrane segments and subunits, nos. of secondary structures, and the calcd. hydrophobic thickness or tilt angle with respect to the bilayer normal.  All coordinate files with the calcd. membrane boundaries are available for downloading.  The Internet site for the database is: http://opm.phar.umich.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1WjpHiq7e8LVg90H21EOLACvtfcHk0lihR0KqNCOPow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVeksro%253D&md5=8a9590a32e912509a53ca0bfc7ede4ad</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtk023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtk023%26sid%3Dliteratum%253Aachs%26aulast%3DLomize%26aufirst%3DM.%2BA.%26aulast%3DLomize%26aufirst%3DA.%2BL.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DOPM%253A%2520orientations%2520of%2520proteins%2520in%2520membranes%2520database%26jtitle%3DBioinformatics%26date%3D2006%26volume%3D22%26spage%3D623%26epage%3D625%26doi%3D10.1093%2Fbioinformatics%2Fbtk023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b','cit10c','cit10d','cit10e','cit10f','cit10g','cit10h','cit10i'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22a','cit22b'],'ref23':['cit23'],'ref24':['cit24a','cit24b','cit24c'],'ref25':['cit25a','cit25b'],'ref26':['cit26a','cit26b'],'ref27':[],'ref28':['cit28a','cit28b'],'ref29':['cit29a','cit29b'],'ref30':[],'ref31':['cit31a','cit31b'],'ref32':['cit32a','cit32b','cit32c','cit32d'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lei Jia, Qiang Tang, Meiming Luo, <span class="NLM_string-name hlFld-ContribAuthor">Xiaoming Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">Direct ortho-Selective Amination of 2-Naphthol and Its Analogues with Hydrazines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (9)
                                     , 5082-5091. <a href="https://doi.org/10.1021/acs.joc.8b00421" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00421</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00421%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDirect%252Bortho-Selective%252BAmination%252Bof%252B2-Naphthol%252Band%252BIts%252BAnalogues%252Bwith%252BHydrazines%26aulast%3DJia%26aufirst%3DLei%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D13022018%26date%3D16042018%26date%3D12042018%26volume%3D83%26issue%3D9%26spage%3D5082%26epage%3D5091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Szymon P.  Rekowski</span>, <span class="hlFld-ContribAuthor ">Bettina K.  Kroener</span>, <span class="hlFld-ContribAuthor ">Deepika  Kathuria</span>, <span class="hlFld-ContribAuthor ">Aabid A.  Wani</span>, <span class="hlFld-ContribAuthor ">Sumit S.  Chourasiya</span>, <span class="hlFld-ContribAuthor ">Jürgen  Conrad</span>, <span class="hlFld-ContribAuthor ">Prasad V.  Bharatam</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Frey</span>, <span class="hlFld-ContribAuthor ">Uwe  Beifuss</span>. </span><span class="cited-content_cbyCitation_article-title">A novel copper-catalyzed, hydrazine-free synthesis of N-1 unsubstituted 1H-indazoles using stable guanylhydrazone salts as substrates. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>91 </em>, 132192. <a href="https://doi.org/10.1016/j.tet.2021.132192" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132192%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DA%252Bnovel%252Bcopper-catalyzed%25252C%252Bhydrazine-free%252Bsynthesis%252Bof%252BN-1%252Bunsubstituted%252B1H-indazoles%252Busing%252Bstable%252Bguanylhydrazone%252Bsalts%252Bas%252Bsubstrates%26aulast%3DRekowski%26aufirst%3DSzymon%2BP.%26date%3D2021%26volume%3D91%26spage%3D132192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoshi  Shuto</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemical Studies Based on the Theoretical Design of Bioactive Compounds. </span><span class="cited-content_cbyCitation_journal-name">YAKUGAKU ZASSHI</span><span> <strong>2020,</strong> <em>140 </em>
                                    (3)
                                     , 329-344. <a href="https://doi.org/10.1248/yakushi.19-00208" title="DOI URL">https://doi.org/10.1248/yakushi.19-00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/yakushi.19-00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fyakushi.19-00208%26sid%3Dliteratum%253Aachs%26jtitle%3DYAKUGAKU%2520ZASSHI%26atitle%3DMedicinal%252BChemical%252BStudies%252BBased%252Bon%252Bthe%252BTheoretical%252BDesign%252Bof%252BBioactive%252BCompounds%26aulast%3DShuto%26aufirst%3DSatoshi%26date%3D2020%26volume%3D140%26issue%3D3%26spage%3D329%26epage%3D344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana L.  Ocampo-Néstor</span>, <span class="hlFld-ContribAuthor ">Ruth M.  López-Mayorga</span>, <span class="hlFld-ContribAuthor ">Enrique F.  Castillo-Henkel</span>, <span class="hlFld-ContribAuthor ">Itzia I.  Padilla-Martínez</span>, <span class="hlFld-ContribAuthor ">José G.  Trujillo-Ferrara</span>, <span class="hlFld-ContribAuthor ">Marvin A.  Soriano-Ursúa</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and in vitro evaluation of a Dopa-organoboron compound that acts as a bladder relaxant through non-catecholamine receptors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2019,</strong> <em>23 </em>
                                    (2)
                                     , 361-370. <a href="https://doi.org/10.1007/s11030-018-9883-7" title="DOI URL">https://doi.org/10.1007/s11030-018-9883-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-018-9883-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-018-9883-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bin%252Bvitro%252Bevaluation%252Bof%252Ba%252BDopa-organoboron%252Bcompound%252Bthat%252Bacts%252Bas%252Ba%252Bbladder%252Brelaxant%252Bthrough%252Bnon-catecholamine%252Breceptors%26aulast%3DOcampo-N%25C3%25A9stor%26aufirst%3DAna%2BL.%26date%3D2019%26date%3D2018%26volume%3D23%26issue%3D2%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giorgia  Schena</span>, <span class="hlFld-ContribAuthor ">Michael J.  Caplan</span>. </span><span class="cited-content_cbyCitation_article-title">Everything You Always Wanted to Know about β3-AR * (* But Were Afraid to Ask). </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2019,</strong> <em>8 </em>
                                    (4)
                                     , 357. <a href="https://doi.org/10.3390/cells8040357" title="DOI URL">https://doi.org/10.3390/cells8040357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells8040357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells8040357%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DEverything%252BYou%252BAlways%252BWanted%252Bto%252BKnow%252Babout%252B%2525CE%2525B23-AR%252B%252A%252B%252528%252A%252BBut%252BWere%252BAfraid%252Bto%252BAsk%252529%26aulast%3DSchena%26aufirst%3DGiorgia%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D4%26spage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of <b>1</b>, <b>2</b>, <b>3</b>, and <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design strategy of sulfonamide moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Relaxation of marmoset urinary bladder smooth muscle by <b>15</b>. Each point represents the mean of two experiments. See ref <a onclick="showRef(event, 'cit10c'); return false;" href="javascript:void(0);" class="ref cit10c">10c</a> for further details of the experimental method.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-PrOH, reflux; (b) TESCl, imidazole, DMF, rt; (c) H<sub>2</sub>, 10% Pd/C, EtOH, 50 °C; (d) Boc<sub>2</sub>O, THF, rt; (e) H<sub>2</sub>, 20% Pd(OH)<sub>2</sub>/C, THF, MeOH, 50 °C; (f) DMEAD, PPh<sub>3</sub>, toluene, rt; (g) R<sup>1</sup>-SO<sub>2</sub>Cl (R<sup>1</sup> = <i>n</i>-Pr, cyclopropyl, cyclobutyl, or phenyl), pyridine, CH<sub>2</sub>Cl<sub>2</sub> or R<sup>1</sup>-SO<sub>2</sub>Cl (R<sup>1</sup> = <i>i</i>-Pr or cyclopentyl), DBU, CH<sub>2</sub>Cl<sub>2</sub>, rt. (h) For <b>12</b>–<b>14</b>, <b>16</b>, and <b>17</b>: 4 M HCl in dioxane, rt. for <b>15</b>:<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> 1 M TBAF in THF, THF, rt then 4 M HCl in dioxane, rt.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plot of docking score calculated by Glide extra precision (XP) based on the compound <b>17</b> β<sub>3</sub>-AR model versus experimental agonistic activity (−pEC<sub>50</sub>) for eight indazole analogues (diamonds) and four other compounds (circles). The coefficient of determination, <i>R</i><sup>2</sup>, was 0.45 for the docking scores and −pEC<sub>50</sub> values of all 12 compounds. See Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_003.pdf" class="ext-link">Table S1</a>) for individual −pEC<sub>50</sub> values and docking scores.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/medium/jm-2016-01197p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Proposed model of compound <b>15</b> binding to the homology model of β<sub>3</sub>-AR after MD refinement. Receptor residues within 4.0 Å of compound <b>15</b> are represented by lines. Compound <b>15</b> is shown as a ball and stick model. All nonpolar hydrogen atoms of the receptor residues are omitted for clarity. Hydrogen bonding and salt bridges to side chains of Asn117, Ser208, Asn312, and Asn332 are depicted by blue dots. Hydrogen bonding to the backbone of Cys196 is also depicted by blue dots. (B) Schematic representation of the interactions between compound <b>15</b> and β<sub>3</sub>-AR residues using the Maestro Ligand Interaction Diagram module (Schrödinger, LLC, Portland, OR, USA). Hydrogen bonding is indicated with dashed arrows, salt bridge with purple lines, cation−π interactions with red lines, and π–π interactions with green lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-8/acs.jmedchem.6b01197/20170421/images/large/jm-2016-01197p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01197&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 39 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Bylund, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eikenberg, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieble, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minneman, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinoff, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruffolo, R. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trendelenburg, U.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology nomenclature of adrenoceptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1994&pages=121-136&author=D.+B.+Bylundauthor=D.+C.+Eikenbergauthor=J.+P.+Hiebleauthor=S.+Z.+Langerauthor=R.+J.+Lefkowitzauthor=K.+P.+Minnemanauthor=P.+B.+Molinoffauthor=R.+R.+Ruffoloauthor=U.+Trendelenburg&title=International+Union+of+Pharmacology+nomenclature+of+adrenoceptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBylund%26aufirst%3DD.%2BB.%26aulast%3DEikenberg%26aufirst%3DD.%2BC.%26aulast%3DHieble%26aufirst%3DJ.%2BP.%26aulast%3DLanger%26aufirst%3DS.%2BZ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DMinneman%26aufirst%3DK.%2BP.%26aulast%3DMolinoff%26aufirst%3DP.%2BB.%26aulast%3DRuffolo%26aufirst%3DR.%2BR.%26aulast%3DTrendelenburg%26aufirst%3DU.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology%2520nomenclature%2520of%2520adrenoceptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D1994%26volume%3D46%26spage%3D121%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lands, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliff, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luduena, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, T. G.,  Jr.</span><span> </span><span class="NLM_article-title">Differentiation of receptor systems activated by sympathomimetic amines</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">214</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span><span class="refDoi"> DOI: 10.1038/214597a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2F214597a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1967&pages=597-598&author=A.+M.+Landsauthor=A.+Arnoldauthor=J.+P.+McAuliffauthor=F.+P.+Luduenaauthor=T.+G.+Brown&title=Differentiation+of+receptor+systems+activated+by+sympathomimetic+amines&doi=10.1038%2F214597a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F214597a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F214597a0%26sid%3Dliteratum%253Aachs%26aulast%3DLands%26aufirst%3DA.%2BM.%26aulast%3DArnold%26aufirst%3DA.%26aulast%3DMcAuliff%26aufirst%3DJ.%2BP.%26aulast%3DLuduena%26aufirst%3DF.%2BP.%26aulast%3DBrown%26aufirst%3DT.%2BG.%26atitle%3DDifferentiation%2520of%2520receptor%2520systems%2520activated%2520by%2520sympathomimetic%2520amines%26jtitle%3DNature%26date%3D1967%26volume%3D214%26spage%3D597%26epage%3D598%26doi%3D10.1038%2F214597a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Emorine, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marullo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briend-Sutren, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delavier-Klutchko, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strosberg, A. D.</span><span> </span><span class="NLM_article-title">Molecular characterization of the human β<sub>3</sub>-adrenergic receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">245</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1121</span><span class="refDoi"> DOI: 10.1126/science.2570461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1126%2Fscience.2570461" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=245&publication_year=1989&pages=1118-1121&author=L.+J.+Emorineauthor=S.+Marulloauthor=M.+M.+Briend-Sutrenauthor=G.+Pateyauthor=K.+Tateauthor=C.+Delavier-Klutchkoauthor=A.+D.+Strosberg&title=Molecular+characterization+of+the+human+%CE%B23-adrenergic+receptor&doi=10.1126%2Fscience.2570461"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.2570461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2570461%26sid%3Dliteratum%253Aachs%26aulast%3DEmorine%26aufirst%3DL.%2BJ.%26aulast%3DMarullo%26aufirst%3DS.%26aulast%3DBriend-Sutren%26aufirst%3DM.%2BM.%26aulast%3DPatey%26aufirst%3DG.%26aulast%3DTate%26aufirst%3DK.%26aulast%3DDelavier-Klutchko%26aufirst%3DC.%26aulast%3DStrosberg%26aufirst%3DA.%2BD.%26atitle%3DMolecular%2520characterization%2520of%2520the%2520human%2520%25CE%25B23-adrenergic%2520receptor%26jtitle%3DScience%26date%3D1989%26volume%3D245%26spage%3D1118%26epage%3D1121%26doi%3D10.1126%2Fscience.2570461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Berkowitz, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreutter, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fremeau, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwinn, D. A.</span><span> </span><span class="NLM_article-title">Distribution of β<sub>3</sub>-adrenoceptor mRNA in human tissues</span> <span class="citation_source-journal">Eur. J. Pharmacol., Mol. Pharmacol. Sect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span><span class="refDoi"> DOI: 10.1016/0922-4106(95)90098-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2F0922-4106%2895%2990098-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=7621895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADyaK2MXlt1Wjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=1995&pages=223-228&author=D.+E.+Berkowitzauthor=N.+A.+Nardoneauthor=R.+M.+Smileyauthor=D.+T.+Priceauthor=D.+K.+Kreutterauthor=R.+T.+Fremeauauthor=D.+A.+Schwinn&title=Distribution+of+%CE%B23-adrenoceptor+mRNA+in+human+tissues&doi=10.1016%2F0922-4106%2895%2990098-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of β3-adrenoceptor mRNA in human tissues</span></div><div class="casAuthors">Berkowitz, Dan E.; Nardone, Nancy A.; Smiley, Richard M.; Price, David T.; Kreutter, David K.; Fremeau, Robert T.; Schwinn, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology, Molecular Pharmacology Section</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-8</span>CODEN:
                <span class="NLM_cas:coden">EJPPET</span>;
        ISSN:<span class="NLM_cas:issn">0922-4106</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The β3-adrenoceptor is a G protein-coupled receptor which mediates metabolic functions of the endogenous catecholamines epinephrine and norepinephrine.  Questions exist regarding distribution of the β3-adrenoceptor in human tissue.  To examine the distribution of β3-adrenoceptor mRNA in human tissues, the authors used sensitive and specific RNase protection assays without previous PCR amplification in an extensive list of human tissues.  The authors confirm the presence of β3-adrenoceptor mRNA in human white fat from several locations, gall bladder, and small intestine, as well as extend the distribution of β3-adrenoceptor mRNA to previously uncharacterized human tissues such as stomach and prostate.  The presence of β3-adrenoceptor mRNA in human white adipose tissue has important implications regarding possible use of β3-adrenoceptor selective agonists as anti-obesity agents, and the demonstration of β3-adrenoceptor mRNA in a no. of gastrointestinal tissues and prostate raises the question of the role of the β3-adrenoceptor in motility and secretory processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-ZEsNjICUkbVg90H21EOLACvtfcHk0ljRUdgk9D6e0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlt1Wjsbo%253D&md5=538c5c1bbdee3ae93d1b9158feb0f51b</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2F0922-4106%2895%2990098-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0922-4106%252895%252990098-5%26sid%3Dliteratum%253Aachs%26aulast%3DBerkowitz%26aufirst%3DD.%2BE.%26aulast%3DNardone%26aufirst%3DN.%2BA.%26aulast%3DSmiley%26aufirst%3DR.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BT.%26aulast%3DKreutter%26aufirst%3DD.%2BK.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26aulast%3DSchwinn%26aufirst%3DD.%2BA.%26atitle%3DDistribution%2520of%2520%25CE%25B23-adrenoceptor%2520mRNA%2520in%2520human%2520tissues%26jtitle%3DEur.%2520J.%2520Pharmacol.%252C%2520Mol.%2520Pharmacol.%2520Sect.%26date%3D1995%26volume%3D289%26spage%3D223%26epage%3D228%26doi%3D10.1016%2F0922-4106%2895%2990098-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fujimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koibuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, O.</span><span> </span><span class="NLM_article-title">Expression and possible functional role of the β<sub>3</sub>-adrenoceptor in human and rat detrusor muscle</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">685</span><span class="refDoi"> DOI: 10.1016/S0022-5347(01)61994-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2FS0022-5347%2801%2961994-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=9915482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADyaK1MXms1GrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=1999&pages=680-685&author=T.+Fujimuraauthor=K.+Tamuraauthor=T.+Tsutsumiauthor=T.+Yamamotoauthor=K.+Nakamuraauthor=Y.+Koibuchiauthor=M.+Kobayashiauthor=O.+Yamaguchi&title=Expression+and+possible+functional+role+of+the+%CE%B23-adrenoceptor+in+human+and+rat+detrusor+muscle&doi=10.1016%2FS0022-5347%2801%2961994-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and possible functional role of the β3-adrenoceptor in human and rat detrusor muscle</span></div><div class="casAuthors">Fujimura, Takao; Tamura, Kouichi; Tsutsumi, Takeshi; Yamamoto, Takao; Nakamura, Keiko; Koibuchi, Yasushi; Kobayashi, Masakazu; Yamaguchi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (Baltimore)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">680-685</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Studies were carried out to investigate the presence of the β3-adrenoceptor (β3-AR) in human and rat detrusor muscle and the usefulness of β3-AR agonists as drugs for the treatment of urinary frequency.  FK175, Et [(S)-8-[(R)-2-(3-chlorophenyl)-2-hydroxyethylamino]-6,7,8,9-tetrahydro-5H-benzocyclohepton-2-yloxy]acetate monohydrochloride monohydrate, was used as a β3-AR selective agonist.  The expression of β-AR subtypes (β1-, β2-, β3-AR) mRNA was investigated in rat and human detrusor muscle by RT-PCR.  β3-AR agonist induced cAMP levels were measured in rat detrusor muscle strips.  The relaxation response produced by a β3-AR agonist was measured in a KCl induced tonic contraction model in rat detrusor muscle strips.  The effect of a β3-AR agonist on urinary bladder function was investigated by cystometry using a conscious rat model of urinary frequency.  β3-AR mRNA was substantially expressed in both rat and human detrusor muscles.  The β3-AR agonist, FK175 (10-7 M), increased the cAMP level by 30% in rat detrusor muscle.  In isolated rat detrusor muscle strips contracted with KCl, the β3-AR agonist, FK175 (10-8 to 10-4 M), produced a concn.-dependent relaxation.  Moreover, although the relaxation induced with FK175 was blocked by the non-selective β-AR antagonist, bupranolol, it was unaffected by ether the β1-AR selective antagonist, CGP 20712A, or the β2-AR selective antagonist, ICI 118551, suggesting that FK175 induced the relaxation via the β3-AR.  Furthermore, in the rat model, the orally administered β3-AR agonist, FK175 (10 mg./kg.) significantly increased bladder capacity with no change of micturition pressure or threshold pressure.  These results suggest that β3-AR agonists may be effective in the treatment of urinary frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCM9oA-UhC97Vg90H21EOLACvtfcHk0liqN6y5l9s0iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXms1GrtQ%253D%253D&md5=df120b5b527ad8aed862aeb914e879d4</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2801%2961994-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252801%252961994-3%26sid%3Dliteratum%253Aachs%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DTsutsumi%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DKoibuchi%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DO.%26atitle%3DExpression%2520and%2520possible%2520functional%2520role%2520of%2520the%2520%25CE%25B23-adrenoceptor%2520in%2520human%2520and%2520rat%2520detrusor%2520muscle%26jtitle%3DJ.%2520Urol.%26date%3D1999%26volume%3D161%26spage%3D680%26epage%3D685%26doi%3D10.1016%2FS0022-5347%2801%2961994-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Baker, J. G.</span><span> </span><span class="NLM_article-title">The selectivity of β-adrenoceptor agonists at human β<sub>1</sub>-, β<sub>2</sub>- and β<sub>3</sub>-adrenoceptors</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1111%2Fj.1476-5381.2010.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=20590599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1048-1061&author=J.+G.+Baker&title=The+selectivity+of+%CE%B2-adrenoceptor+agonists+at+human+%CE%B21-%2C+%CE%B22-+and+%CE%B23-adrenoceptors&doi=10.1111%2Fj.1476-5381.2010.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors</span></div><div class="casAuthors">Baker, Jillian G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1048-1061</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor-ligand complex to induce a response).  Ligands are classified as agonists or antagonists depending on whether or not they have efficacy.  In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both.  This study examd. the affinity and intrinsic efficacy of β-adrenoceptor agonists at the three human β-adrenoceptors to det. whether the current agonists are subtype selective because of affinity or intrinsic efficacy.  Stable clonal CHO-K1 cell lines, transfected with either the human β1, β2 or β3-adrenoceptor, were used, and whole-cell [3H]-CGP 12177 radioligand binding and [3H]-cAMP accumulation were measured.  Several agonists were highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the β2-adrenoceptor over the β1 or β3), while others (e.g. isoprenaline) had little affinity-selectivity.  However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes.  Other ligands (e.g. denopamine for β1; clenbuterol, AZ 40140d, salbutamol for β2) were found to have subtype-selective intrinsic efficacy.  Several ligands appeared to activate two agonist conformations of the β1- and β3-adrenoceptors.  There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy.  Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopuUPn04Hp7LVg90H21EOLACvtfcHk0liqN6y5l9s0iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D&md5=daff8f97b1dfc4732135d3aa79e7de0f</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520selectivity%2520of%2520%25CE%25B2-adrenoceptor%2520agonists%2520at%2520human%2520%25CE%25B21-%252C%2520%25CE%25B22-%2520and%2520%25CE%25B23-adrenoceptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1048%26epage%3D1061%26doi%3D10.1111%2Fj.1476-5381.2010.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perrone, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scilimati, A.</span><span> </span><span class="NLM_article-title">β<sub>3</sub>-Adrenoceptor ligand development history through patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span><span class="refDoi"> DOI: 10.1517/13543776.2011.561316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1517%2F13543776.2011.561316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21410429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVGktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=505-536&author=M.+G.+Perroneauthor=A.+Scilimati&title=%CE%B23-Adrenoceptor+ligand+development+history+through+patent+review&doi=10.1517%2F13543776.2011.561316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">β3-Adrenoceptor ligand development history through patent review</span></div><div class="casAuthors">Perrone, Maria Grazia; Scilimati, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-536</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Stimulation of the β3-adrenoceptor (β3-AR) is thought to be a valuable approach for the treatment of obesity, type 2 diabetes, heart failure, frequent urination, preterm labor, anxiety and depression.  Therefore, the β3-AR is recognized as an attractive target for drug discovery.  Simultaneous activation of the β1- and β2-AR can cause undesirable side effects such as increased heart rate and muscle tremors.  Consequently, much effort has been directed towards the design and development of selective β3-AR agonists through original synthetic chem., extensive in vitro tests and detailed preclin. investigations to various phases of clin. trials.  Areas covered: SciFinder Scholar, PubMed, |S| web of KnowledgeSM, Espacenet, ClinicalTrials and Google have been used as the main sources for retrieving literature and patents filed since the discovery of β3-AR through to June 2010.  This review discusses the enormous efforts made by private and public research labs. to uncover β3-AR ligands and to prove their usefulness as drugs.  Expert opinion: Remarkable knowledge has been gained about the physio-pathol. role of the β3-AR to date.  Many highly potent and selective β3-AR ligands (agonists, antagonists and inverse agonists) have been discovered; however, further investigations are still needed to identify novel compds. acting as β3-AR ligands to adequately treat the diseases in which β3-AR is involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-AndCIxq8J7Vg90H21EOLACvtfcHk0lgSkIW5ifEmiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVGktbc%253D&md5=0069d127862caa40190ba08c03067241</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2011.561316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2011.561316%26sid%3Dliteratum%253Aachs%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DScilimati%26aufirst%3DA.%26atitle%3D%25CE%25B23-Adrenoceptor%2520ligand%2520development%2520history%2520through%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2011%26volume%3D21%26spage%3D505%26epage%3D536%26doi%3D10.1517%2F13543776.2011.561316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Ursino, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crema, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">The β<sub>3</sub>-adrenoceptor as a therapeutic target: current perspectives</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.phrs.2009.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.phrs.2009.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=19429463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2009&pages=221-234&author=M.+G.+Ursinoauthor=V.+Vasinaauthor=E.+Raschiauthor=F.+Cremaauthor=F.+De+Ponti&title=The+%CE%B23-adrenoceptor+as+a+therapeutic+target%3A+current+perspectives&doi=10.1016%2Fj.phrs.2009.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The β3-adrenoceptor as a therapeutic target: Current perspectives</span></div><div class="casAuthors">Ursino, Maria Grazia; Vasina, Valentina; Raschi, Emanuel; Crema, Francesca; De Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-234</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  β3-Adrenoceptors (β3-ARs) are located not only on the plasma membrane of both white and brown adipocytes, but also exist in human heart, gall bladder, gastrointestinal tract, prostate, urinary bladder detrusor, brain and in near-term myometrium.  They are now recognized as an attractive target for drug discovery and several efforts have been made in this field to understand their function and regulation in different human tissues.  The aim of this review is to highlight the functional role of β3-ARs as well as to discuss their potential for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFwN6K0dBHLVg90H21EOLACvtfcHk0lgSkIW5ifEmiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWls7Y%253D&md5=0638652d4bb93a1e8b275aec8eb37575</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2009.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2009.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DUrsino%26aufirst%3DM.%2BG.%26aulast%3DVasina%26aufirst%3DV.%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DCrema%26aufirst%3DF.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DThe%2520%25CE%25B23-adrenoceptor%2520as%2520a%2520therapeutic%2520target%253A%2520current%2520perspectives%26jtitle%3DPharmacol.%2520Res.%26date%3D2009%26volume%3D59%26spage%3D221%26epage%3D234%26doi%3D10.1016%2Fj.phrs.2009.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Arch, J. R.</span><span> </span><span class="NLM_article-title">The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β<sub>3</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span><span class="refDoi"> DOI: 10.1007/s00210-008-0271-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1007%2Fs00210-008-0271-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=18612674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2008&pages=225-240&author=J.+R.+Arch&title=The+discovery+of+drugs+for+obesity%2C+the+metabolic+effects+of+leptin+and+variable+receptor+pharmacology%3A+perspectives+from+%CE%B23-adrenoceptor+agonists&doi=10.1007%2Fs00210-008-0271-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β3-adrenoceptor agonists</span></div><div class="casAuthors">Arch, Jonathan R. S.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-240</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Although β3-adrenoceptor (β3AR) agonists have not become drugs for the treatment of obesity or diabetes, they offer perspectives on obesity drug discovery, the physiol. of energy expenditure and receptor pharmacol. β3AR agonists, some of which also stimulate other βARs in humans, selectively stimulate fat oxidn. in rodents and humans.  This appears to be why they improve insulin sensitivity and reduce body fat while preserving lean body mass.  Regulatory authorities ask that novel anti-obesity drugs improve insulin sensitivity and reduce mainly body fat.  Drugs that act on different targets to stimulate fat oxidn. may also offer these benefits.  Stimulation of energy expenditure may be easy to detect only when the sympathetic nervous system is activated.  Leptin resembles β3AR agonists in that it increases fat oxidn., energy expenditure and insulin sensitivity.  This is partly because it raises sympathetic activity, but it may also promote fat oxidn. by directly stimulating muscle leptin receptors.  The β1AR and β2AR can, like the β3AR, display atypical pharmacologies.  Moreover, the β3AR can display variable pharmacologies of its own, depending on the radioligand used in binding studies or the functional response measured.  Studies on the β3AR demonstrate both the difficulties of predicting the in vivo effects of agonist drugs from in vitro data and that there may be opportunities for identifying drugs that act at a single receptor but have different profiles in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcYdmnbRtQebVg90H21EOLACvtfcHk0ljFnaxbYEr4-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCrsLY%253D&md5=14955c4a0cd606aa68c4bce1b0afc2cb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs00210-008-0271-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-008-0271-1%26sid%3Dliteratum%253Aachs%26aulast%3DArch%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520discovery%2520of%2520drugs%2520for%2520obesity%252C%2520the%2520metabolic%2520effects%2520of%2520leptin%2520and%2520variable%2520receptor%2520pharmacology%253A%2520perspectives%2520from%2520%25CE%25B23-adrenoceptor%2520agonists%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2008%26volume%3D378%26spage%3D225%26epage%3D240%26doi%3D10.1007%2Fs00210-008-0271-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">de Souza, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkey, B. F.</span><span> </span><span class="NLM_article-title">Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span><span class="refDoi"> DOI: 10.2174/1381612013397339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.2174%2F1381612013397339" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1433-1449&author=C.+J.+de+Souzaauthor=B.+F.+Burkey&title=Beta+3-adrenoceptor+agonists+as+anti-diabetic+and+anti-obesity+drugs+in+humans&doi=10.2174%2F1381612013397339"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F1381612013397339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612013397339%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BSouza%26aufirst%3DC.%2BJ.%26aulast%3DBurkey%26aufirst%3DB.%2BF.%26atitle%3DBeta%25203-adrenoceptor%2520agonists%2520as%2520anti-diabetic%2520and%2520anti-obesity%2520drugs%2520in%2520humans%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2001%26volume%3D7%26spage%3D1433%26epage%3D1449%26doi%3D10.2174%2F1381612013397339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Woods, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldon, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argentieri, T. M.</span><span> </span><span class="NLM_article-title">Efficacy of the β<sub>3</sub>-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">1142</span><span class="NLM_x">–</span> <span class="NLM_lpage">1147</span><span class="refDoi"> DOI: 10.1016/S0022-5347(05)65936-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2FS0022-5347%2805%2965936-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=11490313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsF2gtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2001&pages=1142-1147&author=M.+Woodsauthor=N.+Carsonauthor=N.+W.+Nortonauthor=J.+H.+Sheldonauthor=T.+M.+Argentieri&title=Efficacy+of+the+%CE%B23-adrenergic+receptor+agonist+CL-316243+on+experimental+bladder+hyperreflexia+and+detrusor+instability+in+the+rat&doi=10.1016%2FS0022-5347%2805%2965936-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the β3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat</span></div><div class="casAuthors">Woods, Morgan; Carson, Nancyleigh; Norton, N. Wesley; Sheldon, Jeffrey H.; Argentieri, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1142-1147</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent evidence indicates that in a no. of species detrusor relaxation is mediated through activation of the β3-adrenergic receptor.  We detd. whether activation of the β3-adrenergic receptor would be a useful therapeutic approach for bladder instability.  We profiled in vitro activity of the β3-adrenergic receptor agonist CL-616243 and the efficacy of this compd. in exptl. models of detrusor instability and bladder hyperreflexia.  Isolated rat detrusor strips were contracted by depolarizing the prepns. with 20 mM. KCl.  CL-316423 was added to the tissue bath in increasing concns. and contraction inhibition was assessed.  Efficacy against bladder instability was evaluated using the obstructed hypertrophied bladder model in the rat.  The acetic acid bladder cystometry model was used to assess the efficacy of CL-316423 in bladder hyperreflexia.  Isovolumetric contractions were evoked by elec. stimulation using a silver bipolar electrode.  Data are expressed as the mean plus or minus std. error of mean.  CL-316243 inhibited spontaneously contracting, isolated rat detrusor strips in a concn. dependent manner with a mean concn. inhibiting 50% of maximal response of 2.65±0.36 nM.  Intrinsic activity relative to forskolin was 1.  In vivo CL-316243 administered i.v. or orally significantly increased the voiding interval and bladder compliance.  In addn., there was a decrease in the no. of spontaneous contractions during the filling phase in a model of neurogenic and obstruction induced bladder instability.  The amplitude of elec. evoked isovolumetric contractions was significantly smaller after CL-316243 exposure.  These data suggest that activating the β3-adrenergic receptor in rat bladder using CL-316243 may directly inhibit smooth muscle contractility, exptl. hyperreflexia and detrusor instability, and be useful for urge urinary incontinence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZlXr82ZfbtLVg90H21EOLACvtfcHk0lipiPRH4un4OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsF2gtLg%253D&md5=db51e7a7c23855df5ce096f457aa16fb</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2805%2965936-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252805%252965936-8%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DM.%26aulast%3DCarson%26aufirst%3DN.%26aulast%3DNorton%26aufirst%3DN.%2BW.%26aulast%3DSheldon%26aufirst%3DJ.%2BH.%26aulast%3DArgentieri%26aufirst%3DT.%2BM.%26atitle%3DEfficacy%2520of%2520the%2520%25CE%25B23-adrenergic%2520receptor%2520agonist%2520CL-316243%2520on%2520experimental%2520bladder%2520hyperreflexia%2520and%2520detrusor%2520instability%2520in%2520the%2520rat%26jtitle%3DJ.%2520Urol.%26date%3D2001%26volume%3D166%26spage%3D1142%26epage%3D1147%26doi%3D10.1016%2FS0022-5347%2805%2965936-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wuest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichhorn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravens, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaumann, A. J.</span><span> </span><span class="NLM_article-title">Catecholamines relax detrusor through β<sub>2</sub>-adrenoceptors in mouse and β<sub>3</sub>-adrenoceptors in man</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.1124/jpet.108.142562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1124%2Fjpet.108.142562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=18820136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFyktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2009&pages=213-222&author=M.+Wuestauthor=B.+Eichhornauthor=M.+O.+Grimmauthor=M.+P.+Wirthauthor=U.+Ravensauthor=A.+J.+Kaumann&title=Catecholamines+relax+detrusor+through+%CE%B22-adrenoceptors+in+mouse+and+%CE%B23-adrenoceptors+in+man&doi=10.1124%2Fjpet.108.142562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Catecholamines relax detrusor through β2-adrenoceptors in mouse and β3-adrenoceptors in man</span></div><div class="casAuthors">Wuest, Melinda; Eichhorn, Birgit; Grimm, Marc O.; Wirth, Manfred P.; Ravens, Ursula; Kaumann, Alberto J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">213-222</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(-)-Isoproterenol [4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-1,2-benzene diol hydrochloride] relaxes murine detrusor through β-adrenoceptors (ARs); however, the β-AR subtypes involved are unknown.  β2-ARs have been assocd. with caveolae, plasmalemmal scaffolding domains that are absent in caveolin-1 (cav-1) knockout (KO) mice.  Here, we studied detrusor responses in the absence and presence of β-AR subtype-selective antagonists in wild-type (WT) and cav-1 KO mice.  To inquire whether the murine detrusor model is relevant to man, β-AR subtypes that mediate (-)-isoproterenol-evoked human detrusor relaxation were investigated.  In WT mice, (-)-isoproterenol concn.-dependently relaxed the KCl (40 mM)-precontracted detrusor (-logEC50M = 8.04, Emax = 62%).  The effects of (-)-isoproterenol were surmountably antagonized by the β2-AR-selective antagonist ICI 118,551 [(±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol] (pKB = 9.28) but not affected by the β1-AR-selective antagonist CGP 20712 [1-[2-((3-carbamoyl-4-hydroxy)phenoxy)ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol] and β3-AR-selective L-748,337 (S)-M-4-2-3-3-[(acetamidomethylphenoxy-2-hydroxypropyl-amino)-ethyl]-phenylbenzsulfonamide, suggesting involvement of β2-AR only.  The cav-1 KO detrusor displayed significant contractile dysfunction.  (-)-Isoproterenol was less potent and efficient in relaxing detrusor from cav-1 KO (-logEC50M, 7.76; Emax = 44%), but ICI 118,551 caused similar antagonism (pKB = 9.15), suggesting that β2-AR function persisted in cav-1 KO.  The β3-AR-selective antagonist L-748,337 in the presence of ICI 118,551 and CGP 20712 caused addnl. blockade of (-)-isoproterenol effects in cav-1 KO, consistent with a β3-AR involvement during relaxation and suppression of this effect in WT.  (-)-Isoproterenol relaxed human detrusor muscle precontracted with carbachol (-logEC50M = 6.39, Emax = 52%).  However, the effects of (-)-isoproterenol in human detrusor were not blocked by CGP 20712 or ICI 118,551 but antagonized by L-748,337 (pKB = 7.65).  We conclude that murine detrusor relaxation occurs via β2-AR, and loss of caveolae does not perturb β2-AR function but unmasks an addnl. activation of β3-AR.  In contrast, detrusor relaxation in man is mediated exclusively via β3-AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRXvLssbSLm7Vg90H21EOLACvtfcHk0lipiPRH4un4OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFyktg%253D%253D&md5=ef05ce66d4961cf1617bc0046e416880</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.142562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.142562%26sid%3Dliteratum%253Aachs%26aulast%3DWuest%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DB.%26aulast%3DGrimm%26aufirst%3DM.%2BO.%26aulast%3DWirth%26aufirst%3DM.%2BP.%26aulast%3DRavens%26aufirst%3DU.%26aulast%3DKaumann%26aufirst%3DA.%2BJ.%26atitle%3DCatecholamines%2520relax%2520detrusor%2520through%2520%25CE%25B22-adrenoceptors%2520in%2520mouse%2520and%2520%25CE%25B23-adrenoceptors%2520in%2520man%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D328%26spage%3D213%26epage%3D222%26doi%3D10.1124%2Fjpet.108.142562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kar, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagabukuro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacre-Salem, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goble, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morriello, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyes, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzmaurice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenkl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gichuru, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochnowitz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levorse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ormes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanfiz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamlynny, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">Discovery of vibegron: a potent and selective β<sub>3</sub> adrenergic receptor agonist for the treatment of overactive bladder</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">623</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyrurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=609-623&author=S.+D.+Edmondsonauthor=C.+Zhuauthor=N.+F.+Karauthor=J.+Di+Salvoauthor=H.+Nagabukuroauthor=B.+Sacre-Salemauthor=K.+Dingleyauthor=R.+Bergerauthor=S.+D.+Gobleauthor=G.+Morrielloauthor=B.+Harperauthor=C.+R.+Moyesauthor=D.+M.+Shenauthor=L.+Wangauthor=R.+Ballauthor=A.+Fitzmauriceauthor=T.+Frenklauthor=L.+N.+Gichuruauthor=S.+Haauthor=A.+L.+Hurleyauthor=N.+Jochnowitzauthor=D.+Levorseauthor=S.+Mistryauthor=R.+R.+Millerauthor=J.+Ormesauthor=G.+M.+Salituroauthor=A.+Sanfizauthor=A.+S.+Stevensonauthor=K.+Villaauthor=B.+Zamlynnyauthor=S.+Greenauthor=M.+Struthersauthor=A.+E.+Weber&title=Discovery+of+vibegron%3A+a+potent+and+selective+%CE%B23+adrenergic+receptor+agonist+for+the+treatment+of+overactive+bladder&doi=10.1021%2Facs.jmedchem.5b01372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder</span></div><div class="casAuthors">Edmondson, Scott D.; Zhu, Cheng; Kar, Nam Fung; Di Salvo, Jerry; Nagabukuro, Hiroshi; Sacre-Salem, Beatrice; Dingley, Karen; Berger, Richard; Goble, Stephen D.; Morriello, Gregori; Harper, Bart; Moyes, Christopher R.; Shen, Dong-Ming; Wang, Liping; Ball, Richard; Fitzmaurice, Aileen; Frenkl, Tara; Gichuru, Loise N.; Ha, Sookhee; Hurley, Amanda L.; Jochnowitz, Nina; Levorse, Dorothy; Mistry, Shruty; Miller, Randy R.; Ormes, James; Salituro, Gino M.; Sanfiz, Anthony; Stevenson, Andra S.; Villa, Katherine; Zamlynny, Beata; Green, Stuart; Struthers, Mary; Weber, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described.  An early-generation clin. β3-AR agonist MK-0634 (3) exhibited efficacy in humans for the treatment of OAB, but development was discontinued due to unacceptable structure-based toxicity in preclin. species.  Optimization of a series of second-generation pyrrolidine-derived β3-AR agonists included reducing the risk for phospholipidosis, the risk of formation of disproportionate human metabolites, and the risk of formation of high levels of circulating metabolites in preclin. species.  These efforts resulted in the discovery of vibegron, which possesses improved druglike properties and an overall superior preclin. profile compared to MK-0634.  Structure-activity relationships leading to the discovery of vibegron and a summary of its preclin. profile are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTKGFhBOdMNbVg90H21EOLACvtfcHk0lipiPRH4un4OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyrurjM&md5=89410d04a67540aa78e73e7312867ef3</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01372%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DKar%26aufirst%3DN.%2BF.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DSacre-Salem%26aufirst%3DB.%26aulast%3DDingley%26aufirst%3DK.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DGoble%26aufirst%3DS.%2BD.%26aulast%3DMorriello%26aufirst%3DG.%26aulast%3DHarper%26aufirst%3DB.%26aulast%3DMoyes%26aufirst%3DC.%2BR.%26aulast%3DShen%26aufirst%3DD.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBall%26aufirst%3DR.%26aulast%3DFitzmaurice%26aufirst%3DA.%26aulast%3DFrenkl%26aufirst%3DT.%26aulast%3DGichuru%26aufirst%3DL.%2BN.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DLevorse%26aufirst%3DD.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DOrmes%26aufirst%3DJ.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DVilla%26aufirst%3DK.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DDiscovery%2520of%2520vibegron%253A%2520a%2520potent%2520and%2520selective%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520overactive%2520bladder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D609%26epage%3D623%26doi%3D10.1021%2Facs.jmedchem.5b01372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kar, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingley, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span> </span><span class="NLM_article-title">Discovery of benzamides as potent human β<sub>3</sub> adrenergic receptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmcl.2015.11.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=55-59&author=C.+Zhuauthor=N.+F.+Karauthor=B.+Liauthor=M.+Costaauthor=K.+H.+Dingleyauthor=J.+Di+Salvoauthor=S.+N.+Haauthor=A.+L.+Hurleyauthor=X.+Liauthor=R.+R.+Millerauthor=G.+M.+Salituroauthor=M.+Struthersauthor=A.+E.+Weberauthor=J.+J.+Haleauthor=S.+D.+Edmondson&title=Discovery+of+benzamides+as+potent+human+%CE%B23+adrenergic+receptor+agonists&doi=10.1016%2Fj.bmcl.2015.11.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.030%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DKar%26aufirst%3DN.%2BF.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCosta%26aufirst%3DM.%26aulast%3DDingley%26aufirst%3DK.%2BH.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DHa%26aufirst%3DS.%2BN.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520benzamides%2520as%2520potent%2520human%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D55%26epage%3D59%26doi%3D10.1016%2Fj.bmcl.2015.11.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwanami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasahara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuto, S.</span><span> </span><span class="NLM_article-title">Discovery of novel indazole derivatives as highly potent and selective human β<sub>3</sub>-adrenergic receptor agonists with the possibility of having no cardiovascular side effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6048</span><span class="NLM_x">–</span> <span class="NLM_lpage">6057</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00638</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00638" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6048-6057&author=Y.+Wadaauthor=H.+Shirahashiauthor=T.+Iwanamiauthor=M.+Ogawaauthor=S.+Nakanoauthor=A.+Morimotoauthor=K.+Kasaharaauthor=E.+Tanakaauthor=Y.+Takadaauthor=S.+Ohashiauthor=M.+Moriauthor=S.+Shuto&title=Discovery+of+novel+indazole+derivatives+as+highly+potent+and+selective+human+%CE%B23-adrenergic+receptor+agonists+with+the+possibility+of+having+no+cardiovascular+side+effects&doi=10.1021%2Facs.jmedchem.5b00638"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00638%26sid%3Dliteratum%253Aachs%26aulast%3DWada%26aufirst%3DY.%26aulast%3DShirahashi%26aufirst%3DH.%26aulast%3DIwanami%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DS.%26aulast%3DMorimoto%26aufirst%3DA.%26aulast%3DKasahara%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DE.%26aulast%3DTakada%26aufirst%3DY.%26aulast%3DOhashi%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DShuto%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520indazole%2520derivatives%2520as%2520highly%2520potent%2520and%2520selective%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520with%2520the%2520possibility%2520of%2520having%2520no%2520cardiovascular%2520side%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6048%26epage%3D6057%26doi%3D10.1021%2Facs.jmedchem.5b00638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanabe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span> </span><span class="NLM_article-title">Discovery of highly potent and selective biphenylacylsulfonamide-based β<sub>3</sub>-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the β<sub>2</sub>-adrenergic receptor: part 6</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4679</span><span class="NLM_x">–</span> <span class="NLM_lpage">4683</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.06.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmcl.2009.06.083" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4679-4683&author=K.+Hattoriauthor=M.+Oritaauthor=S.+Todaauthor=M.+Imanishiauthor=S.+Itouauthor=Y.+Nakajimaauthor=D.+Tanabeauthor=K.+Washizukaauthor=T.+Arakiauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamura&title=Discovery+of+highly+potent+and+selective+biphenylacylsulfonamide-based+%CE%B23-adrenergic+receptor+agonists+and+molecular+modeling+based+on+the+solved+X-ray+structure+of+the+%CE%B22-adrenergic+receptor%3A+part+6&doi=10.1016%2Fj.bmcl.2009.06.083"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.06.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.06.083%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DOrita%26aufirst%3DM.%26aulast%3DToda%26aufirst%3DS.%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DTanabe%26aufirst%3DD.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520and%2520selective%2520biphenylacylsulfonamide-based%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520and%2520molecular%2520modeling%2520based%2520on%2520the%2520solved%2520X-ray%2520structure%2520of%2520the%2520%25CE%25B22-adrenergic%2520receptor%253A%2520part%25206%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4679%26epage%3D4683%26doi%3D10.1016%2Fj.bmcl.2009.06.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span> </span><span class="NLM_article-title">Discovery of highly potent and selective biphenylacylsulfonamide-based β<sub>3</sub>-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3063</span><span class="NLM_x">–</span> <span class="NLM_lpage">3072</span><span class="refDoi"> DOI: 10.1021/jm9000709</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9000709" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3063-3072&author=K.+Hattoriauthor=S.+Todaauthor=M.+Imanishiauthor=S.+Itouauthor=Y.+Nakajimaauthor=K.+Washizukaauthor=T.+Arakiauthor=H.+Hamashimaauthor=Y.+Tomishimaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamura&title=Discovery+of+highly+potent+and+selective+biphenylacylsulfonamide-based+%CE%B23-adrenergic+receptor+agonists+and+evaluation+of+physical+properties+as+potential+overactive+bladder+therapies%3A+part+5&doi=10.1021%2Fjm9000709"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1021%2Fjm9000709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9000709%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DToda%26aufirst%3DS.%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520and%2520selective%2520biphenylacylsulfonamide-based%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520and%2520evaluation%2520of%2520physical%2520properties%2520as%2520potential%2520overactive%2520bladder%2520therapies%253A%2520part%25205%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3063%26epage%3D3072%26doi%3D10.1021%2Fjm9000709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human β<sub>3</sub>-adrenergic receptor agonists: Part IV</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5037</span><span class="NLM_x">–</span> <span class="NLM_lpage">5040</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmcl.2008.08.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5037-5040&author=Y.+Nakajimaauthor=M.+Imanishiauthor=S.+Itouauthor=H.+Hamashimaauthor=Y.+Tomishimaauthor=K.+Washizukaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=K.+Hattori&title=Discovery+of+novel+series+of+benzoic+acid+derivatives+containing+biphenyl+ether+moiety+as+potent+and+selective+human+%CE%B23-adrenergic+receptor+agonists%3A+Part+IV&doi=10.1016%2Fj.bmcl.2008.08.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520novel%2520series%2520of%2520benzoic%2520acid%2520derivatives%2520containing%2520biphenyl%2520ether%2520moiety%2520as%2520potent%2520and%2520selective%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%253A%2520Part%2520IV%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5037%26epage%3D5040%26doi%3D10.1016%2Fj.bmcl.2008.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of a novel series of benzoic acid derivatives as potent and selective human β<sub>3</sub> adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4804</span><span class="NLM_x">–</span> <span class="NLM_lpage">4822</span><span class="refDoi"> DOI: 10.1021/jm800222k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800222k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4804-4822&author=M.+Imanishiauthor=Y.+Nakajimaauthor=Y.+Tomishimaauthor=H.+Hamashimaauthor=K.+Washizukaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamuraauthor=K.+Hattori&title=Discovery+of+a+novel+series+of+benzoic+acid+derivatives+as+potent+and+selective+human+%CE%B23+adrenergic+receptor+agonists+with+good+oral+bioavailability.+3.+Phenylethanolaminotetraline+%28PEAT%29+skeleton+containing+biphenyl+or+biphenyl+ether+moiety&doi=10.1021%2Fjm800222k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10g&amp;dbid=16384&amp;doi=10.1021%2Fjm800222k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800222k%26sid%3Dliteratum%253Aachs%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520benzoic%2520acid%2520derivatives%2520as%2520potent%2520and%2520selective%2520human%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%2520with%2520good%2520oral%2520bioavailability.%25203.%2520Phenylethanolaminotetraline%2520%2528PEAT%2529%2520skeleton%2520containing%2520biphenyl%2520or%2520biphenyl%2520ether%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4804%26epage%3D4822%26doi%3D10.1021%2Fjm800222k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human β<sub>3</sub> adrenergic receptor agonists with good oral bioavailability. Part II</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4002</span><span class="NLM_x">–</span> <span class="NLM_lpage">4020</span><span class="refDoi"> DOI: 10.1021/jm8000345</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8000345" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4002-4020&author=M.+Imanishiauthor=S.+Itouauthor=K.+Washizukaauthor=H.+Hamashimaauthor=Y.+Nakajimaauthor=T.+Arakiauthor=Y.+Tomishimaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamuraauthor=K.+Hattori&title=Discovery+of+a+novel+series+of+biphenyl+benzoic+acid+derivatives+as+highly+potent+and+selective+human+%CE%B23+adrenergic+receptor+agonists+with+good+oral+bioavailability.+Part+II&doi=10.1021%2Fjm8000345"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10h&amp;dbid=16384&amp;doi=10.1021%2Fjm8000345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8000345%26sid%3Dliteratum%253Aachs%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DAraki%26aufirst%3DT.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520biphenyl%2520benzoic%2520acid%2520derivatives%2520as%2520highly%2520potent%2520and%2520selective%2520human%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%2520with%2520good%2520oral%2520bioavailability.%2520Part%2520II%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4002%26epage%3D4020%26doi%3D10.1021%2Fjm8000345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Imanishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washizuka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takamura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human β<sub>3</sub>-adrenergic receptor agonists with good oral bioavailability. Part I</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1925</span><span class="NLM_x">–</span> <span class="NLM_lpage">1944</span><span class="refDoi"> DOI: 10.1021/jm701324c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701324c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1ekurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1925-1944&author=M.+Imanishiauthor=Y.+Tomishimaauthor=S.+Itouauthor=H.+Hamashimaauthor=Y.+Nakajimaauthor=K.+Washizukaauthor=M.+Sakuraiauthor=S.+Matsuiauthor=E.+Imamuraauthor=K.+Ueshimaauthor=T.+Yamamotoauthor=N.+Yamamotoauthor=H.+Ishikawaauthor=K.+Nakanoauthor=N.+Unamiauthor=K.+Hamadaauthor=Y.+Matsumuraauthor=F.+Takamuraauthor=K.+Hattori&title=Discovery+of+a+novel+series+of+biphenyl+benzoic+acid+derivatives+as+potent+and+selective+human+%CE%B23-adrenergic+receptor+agonists+with+good+oral+bioavailability.+Part+I&doi=10.1021%2Fjm701324c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10iR"><div class="casContent"><span class="casTitleNuber">10i</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Series of Biphenyl Benzoic Acid Derivatives as Potent and Selective Human β3-Adrenergic Receptor Agonists with Good Oral Bioavailability. Part I</span></div><div class="casAuthors">Imanishi, Masashi; Tomishima, Yasuyo; Itou, Shinji; Hamashima, Hitoshi; Nakajima, Yutaka; Washizuka, Kenichi; Sakurai, Minoru; Matsui, Shigeo; Imamura, Emiko; Ueshima, Koji; Yamamoto, Takao; Yamamoto, Nobuhiro; Ishikawa, Hirofumi; Nakano, Keiko; Unami, Naoko; Hamada, Kaori; Matsumura, Yasuhiro; Takamura, Fujiko; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1925-1944</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of biphenyl analogs contg. a benzoic acid moiety based on lead compd. I have been identified as potent and selective human β3 adrenergic receptor (β3-AR) agonists with good oral bioavailability and long plasma half-life.  After further substituent effects were investigated at the terminal Ph ring of lead compd. I, it has been discovered that more lipophilic substitution at the R position improved potency and selectivity.  As a result of these studies, II and III were identified as the leading candidates with the best balance of potency, selectivity, and pharmacokinetic profiles.  In addn., compds. II and III were evaluated to be efficacious for a carbachol-induced increase of intravesical pressure, such as an overactive bladder model in anesthetized dogs.  This represents the first demonstrated result dealing with β3-AR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1QxEQuf51bVg90H21EOLACvtfcHk0ljc9aDuOxCjQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1ekurg%253D&md5=4ec8095eca0542c8566be8aee3bb1619</span></div><a href="/servlet/linkout?suffix=cit10i&amp;dbid=16384&amp;doi=10.1021%2Fjm701324c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701324c%26sid%3Dliteratum%253Aachs%26aulast%3DImanishi%26aufirst%3DM.%26aulast%3DTomishima%26aufirst%3DY.%26aulast%3DItou%26aufirst%3DS.%26aulast%3DHamashima%26aufirst%3DH.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DSakurai%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DE.%26aulast%3DUeshima%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DUnami%26aufirst%3DN.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DTakamura%26aufirst%3DF.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520series%2520of%2520biphenyl%2520benzoic%2520acid%2520derivatives%2520as%2520potent%2520and%2520selective%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520with%2520good%2520oral%2520bioavailability.%2520Part%2520I%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1925%26epage%3D1944%26doi%3D10.1021%2Fjm701324c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulmsten, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kerrebroeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Victor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wein, A.</span><span> </span><span class="NLM_article-title">Standardisation Sub-committee of the International Continence, S. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</span> <span class="citation_source-journal">Neurourol. Urodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1002/nau.10052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1002%2Fnau.10052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=11857671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A280%3ADC%252BD387it1CksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=167-178&author=P.+Abramsauthor=L.+Cardozoauthor=M.+Fallauthor=D.+Griffithsauthor=P.+Rosierauthor=U.+Ulmstenauthor=P.+van+Kerrebroeckauthor=A.+Victorauthor=A.+Wein&title=Standardisation+Sub-committee+of+the+International+Continence%2C+S.+The+standardisation+of+terminology+of+lower+urinary+tract+function%3A+report+from+the+Standardisation+Sub-committee+of+the+International+Continence+Society&doi=10.1002%2Fnau.10052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</span></div><div class="casAuthors">Abrams Paul; Cardozo Linda; Fall Magnus; Griffiths Derek; Rosier Peter; Ulmsten Ulf; van Kerrebroeck Philip; Victor Arne; Wein Alan</div><div class="citationInfo"><span class="NLM_cas:title">Neurourology and urodynamics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-78</span>
        ISSN:<span class="NLM_cas:issn">0733-2467</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5XK5Z-KmPwRgd2Wuil24tfW6udTcc2eZ8l4NLBxvwarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387it1CksQ%253D%253D&md5=bea718982e738444bc86683b568828fb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fnau.10052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fnau.10052%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DCardozo%26aufirst%3DL.%26aulast%3DFall%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DD.%26aulast%3DRosier%26aufirst%3DP.%26aulast%3DUlmsten%26aufirst%3DU.%26aulast%3Dvan%2BKerrebroeck%26aufirst%3DP.%26aulast%3DVictor%26aufirst%3DA.%26aulast%3DWein%26aufirst%3DA.%26atitle%3DStandardisation%2520Sub-committee%2520of%2520the%2520International%2520Continence%252C%2520S.%2520The%2520standardisation%2520of%2520terminology%2520of%2520lower%2520urinary%2520tract%2520function%253A%2520report%2520from%2520the%2520Standardisation%2520Sub-committee%2520of%2520the%2520International%2520Continence%2520Society%26jtitle%3DNeurourol.%2520Urodyn.%26date%3D2002%26volume%3D21%26spage%3D167%26epage%3D178%26doi%3D10.1002%2Fnau.10052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Irwin, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milsom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunskaar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopp, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herschorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelleher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artibani, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, P.</span><span> </span><span class="NLM_article-title">Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1306</span><span class="NLM_x">–</span> <span class="NLM_lpage">1315</span><span class="refDoi"> DOI: 10.1016/j.eururo.2006.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.eururo.2006.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=17049716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A280%3ADC%252BD28nmt1Kmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1306-1315&author=D.+E.+Irwinauthor=I.+Milsomauthor=S.+Hunskaarauthor=K.+Reillyauthor=Z.+Koppauthor=S.+Herschornauthor=K.+Coyneauthor=C.+Kelleherauthor=C.+Hampelauthor=W.+Artibaniauthor=P.+Abrams&title=Population-based+survey+of+urinary+incontinence%2C+overactive+bladder%2C+and+other+lower+urinary+tract+symptoms+in+five+countries%3A+results+of+the+EPIC+study&doi=10.1016%2Fj.eururo.2006.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</span></div><div class="casAuthors">Irwin Debra E; Milsom Ian; Hunskaar Steinar; Reilly Kate; Kopp Zoe; Herschorn Sender; Coyne Karin; Kelleher Con; Hampel Christian; Artibani Walter; Abrams Paul</div><div class="citationInfo"><span class="NLM_cas:title">European urology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1306-14; discussion 1314-5</span>
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    </div><div class="casAbstract">OBJECTIVE:  Estimate the prevalence of urinary incontinence (UI), overactive bladder (OAB), and other lower urinary tract symptoms (LUTS) among men and women in five countries using the 2002 International Continence Society (ICS) definitions.  METHODS:  This population-based, cross-sectional survey was conducted between April and December 2005 in Canada, Germany, Italy, Sweden, and the United Kingdom using computer-assisted telephone interviews.  A random sample of men and women aged >/= 18 yr residing in the five countries and who were representative of the general populations in these countries was selected.  Using 2002 ICS definitions, the prevalence estimates of storage, voiding, and postmicturition LUTS were calculated.  Data were stratified by country, age cohort, and gender.  RESULTS:  A total of 19,165 individuals agreed to participate; 64.3% reported at least one LUTS.  Nocturia was the most prevalent LUTS (men, 48.6%; women, 54.5%).  The prevalence of storage LUTS (men, 51.3%; women, 59.2%) was greater than that for voiding (men, 25.7%; women, 19.5%) and postmicturition (men, 16.9%; women, 14.2%) symptoms combined.  The overall prevalence of OAB was 11.8%; rates were similar in men and women and increased with age.  OAB was more prevalent than all types of UI combined (9.4%).  CONCLUSIONS:  The EPIC study is the largest population-based survey to assess prevalence rates of OAB, UI, and other LUTS in five countries.  To date, this is the first study to evaluate these symptoms simultaneously using the 2002 ICS definitions.  The results indicate that these symptoms are highly prevalent in the countries surveyed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDX7KjsEQJ0vSAs_PE1QvifW6udTcc2ebmqIANauhM5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nmt1Kmsw%253D%253D&md5=8a24630cb261f6888e72b9dbd25ac55d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2006.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2006.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DIrwin%26aufirst%3DD.%2BE.%26aulast%3DMilsom%26aufirst%3DI.%26aulast%3DHunskaar%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DK.%26aulast%3DKopp%26aufirst%3DZ.%26aulast%3DHerschorn%26aufirst%3DS.%26aulast%3DCoyne%26aufirst%3DK.%26aulast%3DKelleher%26aufirst%3DC.%26aulast%3DHampel%26aufirst%3DC.%26aulast%3DArtibani%26aufirst%3DW.%26aulast%3DAbrams%26aufirst%3DP.%26atitle%3DPopulation-based%2520survey%2520of%2520urinary%2520incontinence%252C%2520overactive%2520bladder%252C%2520and%2520other%2520lower%2520urinary%2520tract%2520symptoms%2520in%2520five%2520countries%253A%2520results%2520of%2520the%2520EPIC%2520study%26jtitle%3DEur.%2520Urol.%26date%3D2006%26volume%3D50%26spage%3D1306%26epage%3D1315%26doi%3D10.1016%2Fj.eururo.2006.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Wein, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovner, E. S.</span><span> </span><span class="NLM_article-title">Definition and epidemiology of overactive bladder</span> <span class="citation_source-journal">Urology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1016/S0090-4295(02)01784-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2FS0090-4295%2802%2901784-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2002&pages=7-12&author=A.+J.+Weinauthor=E.+S.+Rovner&title=Definition+and+epidemiology+of+overactive+bladder&doi=10.1016%2FS0090-4295%2802%2901784-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0090-4295%2802%2901784-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0090-4295%252802%252901784-3%26sid%3Dliteratum%253Aachs%26aulast%3DWein%26aufirst%3DA.%2BJ.%26aulast%3DRovner%26aufirst%3DE.%2BS.%26atitle%3DDefinition%2520and%2520epidemiology%2520of%2520overactive%2520bladder%26jtitle%3DUrology%26date%3D2002%26volume%3D60%26spage%3D7%26epage%3D12%26doi%3D10.1016%2FS0090-4295%2802%2901784-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapple, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roehrborn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rosette, J.</span><span> </span><span class="NLM_article-title">International Consultation on New Developments in Prostate, C.; Prostate, D. Evaluation and treatment of lower urinary tract symptoms in older men</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">S93</span><span class="NLM_x">–</span> <span class="NLM_lpage">S101</span><span class="refDoi"> DOI: 10.1016/j.juro.2012.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.juro.2012.11.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2013&pages=S93-S101&author=P.+Abramsauthor=C.+Chappleauthor=S.+Khouryauthor=C.+Roehrbornauthor=J.+de+la+Rosette&title=International+Consultation+on+New+Developments+in+Prostate%2C+C.%3B+Prostate%2C+D.+Evaluation+and+treatment+of+lower+urinary+tract+symptoms+in+older+men&doi=10.1016%2Fj.juro.2012.11.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2012.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2012.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DChapple%26aufirst%3DC.%26aulast%3DKhoury%26aufirst%3DS.%26aulast%3DRoehrborn%26aufirst%3DC.%26aulast%3Dde%2Bla%2BRosette%26aufirst%3DJ.%26atitle%3DInternational%2520Consultation%2520on%2520New%2520Developments%2520in%2520Prostate%252C%2520C.%253B%2520Prostate%252C%2520D.%2520Evaluation%2520and%2520treatment%2520of%2520lower%2520urinary%2520tract%2520symptoms%2520in%2520older%2520men%26jtitle%3DJ.%2520Urol.%26date%3D2013%26volume%3D189%26spage%3DS93%26epage%3DS101%26doi%3D10.1016%2Fj.juro.2012.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, K. E.</span><span> </span><span class="NLM_article-title">Muscarinic receptor antagonists for overactive bladder</span> <span class="citation_source-journal">BJU Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span><span class="refDoi"> DOI: 10.1111/j.1464-410X.2007.07205.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1111%2Fj.1464-410X.2007.07205.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=17922784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGgur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=987-1006&author=P.+Abramsauthor=K.+E.+Andersson&title=Muscarinic+receptor+antagonists+for+overactive+bladder&doi=10.1111%2Fj.1464-410X.2007.07205.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic receptor antagonists for overactive bladder</span></div><div class="casAuthors">Abrams, Paul; Andersson, Karl-Erik</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">987-1006</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Overactive bladder (OAB) is a syndrome characterized by urinary urgency, with or without urgency urinary incontinence, usually with frequency and nocturia.  OAB symptoms are often assocd. with detrusor overactivity (DO).  Like OAB symptoms, the prevalence of DO increases with age and can have a neurogenic and/or myogenic etiol.  Bladder outlet obstruction can be a contributing factor in DO, possibly through cholinergic denervation of the detrusor and supersensitivity of muscarinic receptors to acetylcholine, although the prevalence of OAB is similar in men and women across age groups.  Acetylcholine is the primary contractile neurotransmitter in the human detrusor, and antimuscarinics exert their effects on OAB/DO by inhibiting the binding of acetylcholine at muscarinic receptors M2 and M3 on detrusor smooth muscle cells and other structures within the bladder wall.  Worldwide, there are six antimuscarinic drugs currently marketed for the treatment of OAB: oxybutynin, tolterodine, propiverine, trospium, darifenacin, and solifenacin.  Each has demonstrated efficacy for the treatment of OAB symptoms, but their pharmacokinetic and adverse event profiles differ somewhat due to structural differences (tertiary vs quaternary amines), muscarinic receptor subtype selectivities, and organ selectivities.  Antimuscarinics are generally well tolerated, even in special populations (e.g. men with bladder outlet obstruction, elderly patients, children).  The most frequently reported adverse events in clin. studies of antimuscarinics are dry mouth, constipation, headache, and blurred vision; few patients withdraw from clin. trials because of adverse events.  Development of an antimuscarinic with functional selectivity for the bladder would reduce the occurrence of antimuscarinic adverse events.  The therapeutic potential of several other agents, such as α3-adrenoceptor agonists, purinergic receptor antagonists, phosphodiesterase inhibitors, neurokinin-1 receptor antagonists, opioids, and Rho-kinase inhibitors, is also under investigation for the treatment of OAB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo46uZDo-vaI7Vg90H21EOLACvtfcHk0ljZLYnh81kqSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGgur7M&md5=ae74f99443663035095e793c43358bfa</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2007.07205.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2007.07205.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DAndersson%26aufirst%3DK.%2BE.%26atitle%3DMuscarinic%2520receptor%2520antagonists%2520for%2520overactive%2520bladder%26jtitle%3DBJU%2520Int.%26date%3D2007%26volume%3D100%26spage%3D987%26epage%3D1006%26doi%3D10.1111%2Fj.1464-410X.2007.07205.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Chapple, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khullar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitoun, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, D.</span><span> </span><span class="NLM_article-title">The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1016/j.eururo.2008.06.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.eururo.2008.06.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=18599186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2008&pages=543-562&author=C.+R.+Chappleauthor=V.+Khullarauthor=Z.+Gabrielauthor=D.+Mustonauthor=C.+E.+Bitounauthor=D.+Weinstein&title=The+effects+of+antimuscarinic+treatments+in+overactive+bladder%3A+an+update+of+a+systematic+review+and+meta-analysis&doi=10.1016%2Fj.eururo.2008.06.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis</span></div><div class="casAuthors">Chapple, Christopher R.; Khullar, Vik; Gabriel, Zahava; Muston, Dominic; Bitoun, Caty Ebel; Weinstein, David</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">543-562</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Context: Antimuscarinic agents are currently the first-line pharmacotherapy for overactive bladder.  Objectives: A systematic review published in 2005 was updated, including data on a newly licensed antimuscarinic (fesoterodine).  The primary aim of this study was to systematically review evidence on the efficacy of licensed administration of antimuscarinic treatments in overactive bladder from randomised controlled trials.  Secondary aims were to review evidence on tolerability and safety and health-related quality of life (HRQL).  Evidence acquisition: All relevant data sources from randomised controlled trials were searched, and two independent reviewers considered publications for inclusion and extd. relevant data.  Meta-anal. was used to pool efficacy, tolerability, safety, and HRQL outcomes by treatment.  Efficacy was measured by continent days, mean voided vol., urgency episodes, and micturition frequency.  Tolerability and safety were measured by means of adverse event and withdrawal rates.  HRQL was measured by various instruments.  Evidence synthesis: An addnl. 1118 refs. were retrieved with data on 83 studies extd.  Antimuscarinics were found to be more effective than placebo.  Tolerability was good; few of the antimuscarinics were found to have significantly higher withdrawal rates in comparison to placebo.  No serious adverse event for any product was statistically significant compared to placebo.  Dry mouth (mild, moderate, severe) was the most commonly reported adverse event (29.6% on treatment vs 7.9% on placebo), followed by pruritus (15.4% on treatment vs 5.2% on placebo).  Improvements were seen in HRQL with treatment by darifenacin, fesoterodine, oxybutynin transdermal delivery system, propiverine extended release (ER), solifenacin, tolterodine ER and immediate release, and trospium.  Limitations of the study include restrictions on the types of patients typically included in overactive bladder trials and topics that have not been adequately addressed in the current antimuscarinic literature.  Conclusions: Antimuscarinics are efficacious, safe, and well-tolerated treatments that improve HRQL.  Profiles of each drug and dosage differ and should be considered in making treatment choices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAxiEtWQKM7Vg90H21EOLACvtfcHk0ljXm4lTn1Q6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKisb%252FK&md5=5bfba69dca14592a3212db8ef9a69630</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2008.06.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2008.06.047%26sid%3Dliteratum%253Aachs%26aulast%3DChapple%26aufirst%3DC.%2BR.%26aulast%3DKhullar%26aufirst%3DV.%26aulast%3DGabriel%26aufirst%3DZ.%26aulast%3DMuston%26aufirst%3DD.%26aulast%3DBitoun%26aufirst%3DC.%2BE.%26aulast%3DWeinstein%26aufirst%3DD.%26atitle%3DThe%2520effects%2520of%2520antimuscarinic%2520treatments%2520in%2520overactive%2520bladder%253A%2520an%2520update%2520of%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DEur.%2520Urol.%26date%3D2008%26volume%3D54%26spage%3D543%26epage%3D562%26doi%3D10.1016%2Fj.eururo.2008.06.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wagg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Compion, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, E.</span><span> </span><span class="NLM_article-title">Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience</span> <span class="citation_source-journal">BJU Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1767</span><span class="NLM_x">–</span> <span class="NLM_lpage">1774</span><span class="refDoi"> DOI: 10.1111/j.1464-410X.2012.11023.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1111%2Fj.1464-410X.2012.11023.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=22409769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSqurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2012&pages=1767-1774&author=A.+Waggauthor=G.+Compionauthor=A.+Faheyauthor=E.+Siddiqui&title=Persistence+with+prescribed+antimuscarinic+therapy+for+overactive+bladder%3A+a+UK+experience&doi=10.1111%2Fj.1464-410X.2012.11023.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience</span></div><div class="casAuthors">Wagg, Adrian; Compion, Gerhard; Fahey, Amanda; Siddiqui, Emad</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1767-1774</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-410X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Study Type: Therapy (prevalence) Level of Evidence 2b What's known on the subject and What does the study add Persistence with long-term medication in chronic diseases is typically low and that for overactive bladder medication is lower than av.  Sub-optimal persistence is a major challenge for the successful management of overactive bladder.  Using UK prescription data, persistence was generally low across the range of antimuscarinics.  Patients aged 60 years and above were more likely to persist with prescribed oral antimuscarinic drugs than younger patients (40-59 years).  Solifenacin was consistently assocd. with the highest rate of persistence compared with the other antimuscarinics included in the study.  OBJECTIVES: To describe the level of persistence for patients receiving antimuscarinics for overactive bladder (OAB) over a 12-mo period based on real prescription data from the UK.  To investigate patterns of persistence with oral antimuscarinic drugs prescribed for OAB, across different age groups.  PATIENTS AND METHODS: UK prescription data from a longitudinal patient database were analyzed retrospectively to assess persistence with darifenacin, flavoxate, oxybutynin (extended release [ER] and immediate release [IR]), propiverine, solifenacin, tolterodine (ER/IR) and trospium.  Data were extd. from the medical records of >1 200 000 registered patients via general practice software, and anonymized prescription data were collated for all eligible patients with documented OAB (n= 4833).  Data were collected on patients who started treatment between Jan. 2007 and Dec. 2007 and were collected up to Dec. 2008, to allow each patient a full 12-mo potential treatment period.  Failure of persistence was declared after a gap of at least 1.5 times the length of the period of the most recent prescription.  The anal. included only patients who were new to a course of treatment (i.e. who had not been prescribed that particular treatment or dosage for at least 6 mo before the study period).  RESULTS: The no. of patients prescribed each antimuscarinic drug varied from 23 for darifenacin to 1758 for tolterodine ER.  The longest mean persistence was reported for solifenacin (187 days vs. 77-157 days for the other treatments).  At 3 mo, the proportions of patients still on their original treatment were: solifenacin 58%, darifenacin 52%, tolterodine ER 47%, propiverine 47%, tolterodine IR 46%, oxybutynin ER 44%, trospium 42%, oxybutynin IR 40%, flavoxate 28%.  At 12 mo, the proportions of patients still on their original treatment were: solifenacin 35%, tolterodine ER 28%, propiverine 27%, oxybutynin ER 26%, trospium 26%, tolterodine IR 24%, oxybutynin IR 22%, darifenacin 17%, flavoxate 14%.  In a sub-anal. stratified by age, patients aged ≥60 years were more likely to persist with prescribed therapy over the 12-mo period than those aged <60 years.CONCLUSIONS : Twelve months after the initial prescription, persistence rates with pharmacotherapy in the context of OAB are generally low.  Solifenacin was assocd. with higher levels of persistence compared with other prescribed antimuscarinic agents.  Older people are more likely than younger patients to persist with prescribed therapy.  Further studies are required to understand this finding and why patients are more likely to persist with one drug rather than another.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNB7ZHoRZXiLVg90H21EOLACvtfcHk0ljXm4lTn1Q6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSqurfE&md5=39edf40e3f46807d55a251b920826cc9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2012.11023.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2012.11023.x%26sid%3Dliteratum%253Aachs%26aulast%3DWagg%26aufirst%3DA.%26aulast%3DCompion%26aufirst%3DG.%26aulast%3DFahey%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DE.%26atitle%3DPersistence%2520with%2520prescribed%2520antimuscarinic%2520therapy%2520for%2520overactive%2520bladder%253A%2520a%2520UK%2520experience%26jtitle%3DBJU%2520Int.%26date%3D2012%26volume%3D110%26spage%3D1767%26epage%3D1774%26doi%3D10.1111%2Fj.1464-410X.2012.11023.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Staskin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDiarmid, S. A.</span><span> </span><span class="NLM_article-title">Using anticholinergics to treat overactive bladder: the issue of treatment tolerability</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/j.amjmed.2005.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.amjmed.2005.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=16483863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFGgsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=9-15&author=D.+R.+Staskinauthor=S.+A.+MacDiarmid&title=Using+anticholinergics+to+treat+overactive+bladder%3A+the+issue+of+treatment+tolerability&doi=10.1016%2Fj.amjmed.2005.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Using Anticholinergics to Treat Overactive Bladder: The Issue of Treatment Tolerability</span></div><div class="casAuthors">Staskin, David R.; MacDiarmid, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">3A</span>),
    <span class="NLM_cas:pages">9S-15S</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Overactive bladder (OAB) is a chronic syndrome with debilitating symptoms that neg. affect health-related quality of life.  Although anticholinergic agents have been first-line treatment for OAB for many years, the efficacious pharmacol. management of this condition has been compromised by concerns regarding tolerability.  Anticholinergic agents prevent involuntary contractions of the bladder detrusor muscle by preventing acetylcholine from binding to the M2 and M3 muscarinic receptor subtypes.  Anticholinergics are not tissue specific, and their use for treatment of OAB has been assocd. with side effects such as dry mouth, constipation, and blurred vision.  Recent studies with extended-release formulations and newly developed receptor subtype-specific anticholinergic agents demonstrate that side effects are typically mild to moderate and generally tolerable, seldom leading to patient withdrawal.  By incorporating patient-initiated dose adjustment into the protocol, the primary care physician can effectively manage adverse events assocd. with OAB without compromising efficacy.  Recent dose-adjustment data with extended-release oxybutynin suggest that, given some control in the process, patients are willing to tolerate certain side effects in exchange for symptom relief.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWpizZSQ8VeLVg90H21EOLACvtfcHk0ljXm4lTn1Q6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFGgsLs%253D&md5=14581bce0eec6e2588ba4a33c9bc8821</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2005.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2005.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DStaskin%26aufirst%3DD.%2BR.%26aulast%3DMacDiarmid%26aufirst%3DS.%2BA.%26atitle%3DUsing%2520anticholinergics%2520to%2520treat%2520overactive%2520bladder%253A%2520the%2520issue%2520of%2520treatment%2520tolerability%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2006%26volume%3D119%26spage%3D9%26epage%3D15%26doi%3D10.1016%2Fj.amjmed.2005.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Chapple, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitti, V. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. C.</span><span> </span><span class="NLM_article-title">Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability</span> <span class="citation_source-journal">Neurourol. Urodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1002/nau.22505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1002%2Fnau.22505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=24127366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=17-30&author=C.+R.+Chappleauthor=L.+Cardozoauthor=V.+W.+Nittiauthor=E.+Siddiquiauthor=M.+C.+Michel&title=Mirabegron+in+overactive+bladder%3A+a+review+of+efficacy%2C+safety%2C+and+tolerability&doi=10.1002%2Fnau.22505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability</span></div><div class="casAuthors">Chapple, Christopher R.; Cardozo, Linda; Nitti, Victor W.; Siddiqui, Emad; Michel, Martin C.</div><div class="citationInfo"><span class="NLM_cas:title">Neurourology and Urodynamics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-30</span>CODEN:
                <span class="NLM_cas:coden">NEUREM</span>;
        ISSN:<span class="NLM_cas:issn">0733-2467</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Aims : Mirabegron, the first β3-adrenoceptor agonist to enter clin. practice, has a different mechanism of action from antimuscarinic agents.  This review presents data on the efficacy, safety, and tolerability of mirabegron in studies conducted to date.  Methods : All clin. data on mirabegron that are currently in the public domain are included, including some in-press manuscripts.  Results : In Phase III clin. trials in patients with overactive bladder (OAB), mirabegron at daily doses of 25, 50, and 100 mg demonstrated significant efficacy in treating the symptoms of OAB, including micturition frequency, urgency incontinence, and urgency.  Significant improvements in micturition frequency, urgency incontinence, and mean vol. voided/micturition were seen as early as the first assessment (week 4) for mirabegron 50 and 100 mg, and were maintained throughout treatment.  Responder analyses showed a significant improvement with mirabegron 50 and 100 mg in terms of dry rates, ≥50% redn. in mean no. of incontinence episodes/24 h, and the proportion of patients with ≤8 micturitions/24 h at final visit.  The benefit of mirabegron 50 and 100 mg was also evident in patients ≥65 years of age, and in both treatment-naive patients and those who previously discontinued antimuscarinic therapy.  These data therefore demonstrate a clin. meaningful benefit with mirabegron in the objective endpoints of OAB.  Assessment of measures of health-related quality of life and treatment satisfaction showed that patients perceived treatment with mirabegron as meaningful.  In OAB clin. trials of up to 12 mo mirabegron appeared to be well tolerated.  The most common adverse events (AEs) obsd. with mirabegron in clin. trials of up to 12 mo were hypertension, nasopharyngitis, and urinary tract infection.  The incidence of dry mouth was similar to placebo, and was between three and fivefold less than for tolterodine extended release 4 mg.  Since dry mouth is the most bothersome AE assocd. with antimuscarinic drugs and often a reason for treatment discontinuation, mirabegron may be a valuable treatment option for these patients.  Conclusions : In Phase III clin. trials, mirabegron at daily doses of 25, 50, and 100 mg demonstrated significant efficacy in treating symptoms of OAB and, at doses of 50 and 100 mg, demonstrated significant improvements vs. placebo on key secondary endpoints, as early as the first assessment (week 4), and these were maintained throughout treatment.  In OAB clin. trials of up to 12 mo, mirabegron appeared to be well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNwKHocTclNrVg90H21EOLACvtfcHk0ljXm4lTn1Q6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegur%252FL&md5=07ec9413a0b5b86221468b34b2dbc7bb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fnau.22505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fnau.22505%26sid%3Dliteratum%253Aachs%26aulast%3DChapple%26aufirst%3DC.%2BR.%26aulast%3DCardozo%26aufirst%3DL.%26aulast%3DNitti%26aufirst%3DV.%2BW.%26aulast%3DSiddiqui%26aufirst%3DE.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26atitle%3DMirabegron%2520in%2520overactive%2520bladder%253A%2520a%2520review%2520of%2520efficacy%252C%2520safety%252C%2520and%2520tolerability%26jtitle%3DNeurourol.%2520Urodyn.%26date%3D2014%26volume%3D33%26spage%3D17%26epage%3D30%26doi%3D10.1002%2Fnau.22505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Takasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasamata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, O.</span><span> </span><span class="NLM_article-title">Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β<sub>3</sub>-adrenoceptor agonist, on bladder function</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span><span class="refDoi"> DOI: 10.1124/jpet.106.115840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1124%2Fjpet.106.115840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=17293563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFehur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=642-647&author=T.+Takasuauthor=M.+Ukaiauthor=S.+Satoauthor=T.+Matsuiauthor=I.+Nagaseauthor=T.+Maruyamaauthor=M.+Sasamataauthor=K.+Miyataauthor=H.+Uchidaauthor=O.+Yamaguchi&title=Effect+of+%28R%29-2-%282-aminothiazol-4-yl%29-4%E2%80%B2-%7B2-%5B%282-hydroxy-2-phenylethyl%29amino%5Dethyl%7D+acetanilide+%28YM178%29%2C+a+novel+selective+%CE%B23-adrenoceptor+agonist%2C+on+bladder+function&doi=10.1124%2Fjpet.106.115840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino] ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function</span></div><div class="casAuthors">Takasu, Toshiyuki; Ukai, Masashi; Sato, Shuichi; Matsui, Tetsuo; Nagase, Itsuro; Maruyama, Tatsuya; Sasamata, Masao; Miyata, Keiji; Uchida, Hisashi; Yamaguchi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">642-647</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the pharmacol. characteristics of YM178.  YM178 increased cAMP accumulation in Chinese hamster ovary (CHO) cells expressing human β3-adrenoceptor (AR).  The half-maximal effective concn. (EC50) value was 22.4 nM.  EC50 values of YM178 for human β1- and β2-ARs were 10,000 nM or more, resp.  The ratio of intrinsic activities of YM178 vs. maximal response induced by isoproterenol (nonselective β-AR agonist) was 0.8 for human β3-ARs, 0.1 for human β1-ARs, and 0.1 for human β2-ARs.  The relaxant effects of YM178 were evaluated in rats and humans bladder strips precontracted with carbachol (CCh) and compared with those of isoproterenol and 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one hydrochloride (CGP-12177A) (β3-AR agonist).  EC50 values of YM178 and isoproterenol in rat bladder strips precontracted with 10-6 M CCh were 5.1 and 1.4 μM, resp., whereas those in human bladder strips precontracted with 10-7 M CCh were 0.78 and 0.28 μM, resp.  In in vivo study, YM178 at a dose of 3 mg/kg i.v. decreased the frequency of rhythmic bladder contraction induced by intravesical filling with saline without suppressing its amplitude in anesthetized rats.  These findings suggest the suitability of YM178 as a therapeutic drug for the treatment of symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJoYI45QFLfbVg90H21EOLACvtfcHk0lj1O4_QysG5rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFehur0%253D&md5=607d913d56ea8378fc9f22c767cbc599</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.115840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.115840%26sid%3Dliteratum%253Aachs%26aulast%3DTakasu%26aufirst%3DT.%26aulast%3DUkai%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DMatsui%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DI.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DSasamata%26aufirst%3DM.%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DUchida%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DO.%26atitle%3DEffect%2520of%2520%2528R%2529-2-%25282-aminothiazol-4-yl%2529-4%25E2%2580%25B2-%257B2-%255B%25282-hydroxy-2-phenylethyl%2529amino%255Dethyl%257D%2520acetanilide%2520%2528YM178%2529%252C%2520a%2520novel%2520selective%2520%25CE%25B23-adrenoceptor%2520agonist%252C%2520on%2520bladder%2520function%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D642%26epage%3D647%26doi%3D10.1124%2Fjpet.106.115840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Hicks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCafferty, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aiyar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luce, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coatney, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westfall, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieble, J. P.</span><span> </span><span class="NLM_article-title">GW427353 (solabegron), a novel, selective β<sub>3</sub>-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">209</span><span class="refDoi"> DOI: 10.1124/jpet.107.125757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1124%2Fjpet.107.125757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=17626794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=202-209&author=A.+Hicksauthor=G.+P.+McCaffertyauthor=E.+Riedelauthor=N.+Aiyarauthor=M.+Pullenauthor=C.+Evansauthor=T.+D.+Luceauthor=R.+W.+Coatneyauthor=G.+C.+Riveraauthor=T.+D.+Westfallauthor=J.+P.+Hieble&title=GW427353+%28solabegron%29%2C+a+novel%2C+selective+%CE%B23-adrenergic+receptor+agonist%2C+evokes+bladder+relaxation+and+increases+micturition+reflex+threshold+in+the+dog&doi=10.1124%2Fjpet.107.125757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">GW427353 (solabegron), a novel, selective β3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog</span></div><div class="casAuthors">Hicks, Alexandra; McCafferty, Gerald P.; Riedel, Erin; Aiyar, Nambi; Pullen, Mark; Evans, Christopher; Luce, Trudy D.; Coatney, Robert W.; Rivera, Gian C.; Westfall, Timothy D.; Hieble, J. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">202-209</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Functional studies have demonstrated that adrenoceptor agonist-evoked relaxation is mediated primarily by β3-adrenergic receptors (ARs) in human bladder.  Thus, the use of selective β3-AR agonists in the pharmacol. treatment of overactive bladder is being explored.  The present studies investigated the effects of a novel selective β3-AR agonist, (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid (GW427353; solabegron) on bladder function in the dog using in vitro and in vivo techniques.  GW427353 stimulated cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR, with an EC50 value of 22 ± 6 nM and an intrinsic activity 90% of isoproterenol.  At concns. of 10,000 nM, GW427353 produced a minimal response in cells expressing either β1-ARs or β2-ARs (max. response <10% of that to isoproterenol).  In dog isolated bladder strips, GW427353 evoked relaxation that was attenuated by the non-selective β-AR antagonist bupranolol and 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol (SR59230A) (reported to have β3-AR antagonist activity).  The relaxation was unaffected by atenolol, a selective β1-AR antagonist, or (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol (ICI 118551), a selective β2-AR antagonist.  GW427353 increased the vol. required to evoke micturition in the anesthetized dog following acetic acid-evoked bladder irritation, without affecting the ability of the bladder to void.  GW427353-evoked effects on bladder parameters in vivo were inhibited by bupranolol.  The present study demonstrates that selective activation of β3-AR with GW427353 evokes bladder relaxation and facilitates bladder storage mechanisms in the dog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgB2WHHmcNBrVg90H21EOLACvtfcHk0lj1O4_QysG5rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsLfK&md5=360088edb870525e082f8379d1b21779</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.125757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.125757%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DMcCafferty%26aufirst%3DG.%2BP.%26aulast%3DRiedel%26aufirst%3DE.%26aulast%3DAiyar%26aufirst%3DN.%26aulast%3DPullen%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DC.%26aulast%3DLuce%26aufirst%3DT.%2BD.%26aulast%3DCoatney%26aufirst%3DR.%2BW.%26aulast%3DRivera%26aufirst%3DG.%2BC.%26aulast%3DWestfall%26aufirst%3DT.%2BD.%26aulast%3DHieble%26aufirst%3DJ.%2BP.%26atitle%3DGW427353%2520%2528solabegron%2529%252C%2520a%2520novel%252C%2520selective%2520%25CE%25B23-adrenergic%2520receptor%2520agonist%252C%2520evokes%2520bladder%2520relaxation%2520and%2520increases%2520micturition%2520reflex%2520threshold%2520in%2520the%2520dog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D202%26epage%3D209%26doi%3D10.1124%2Fjpet.107.125757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Maruyama, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatemichi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusama, H.</span><span> </span><span class="NLM_article-title">Bladder selectivity of the novel β<sub>3</sub>-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">852</span><span class="refDoi"> DOI: 10.1007/s00210-012-0755-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1007%2Fs00210-012-0755-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=22552730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVemu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2012&pages=845-852&author=I.+Maruyamaauthor=Y.+Goiauthor=S.+Tatemichiauthor=K.+Maruyamaauthor=Y.+Hoyanoauthor=Y.+Yamazakiauthor=H.+Kusama&title=Bladder+selectivity+of+the+novel+%CE%B23-agonist+ritobegron+%28KUC-7483%29+explored+by+in+vitro+and+in+vivo+studies+in+the+rat&doi=10.1007%2Fs00210-012-0755-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Bladder selectivity of the novel β3-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat</span></div><div class="casAuthors">Maruyama, Itaru; Goi, Yoshiaki; Tatemichi, Satoshi; Maruyama, Kazuyasu; Hoyano, Yuji; Yamazaki, Yoshinobu; Kusama, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">845-852</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We performed in vitro and in vivo expts. to evaluate the pharmacol. profile of ritobegron and its effects on the bladder in rats. β3-AR selectivity was assessed using CHO cells expressing various subtypes of the human β-adrenoceptor (AR).  Effects on isolated organs were evaluated using the organ-bath method.  Effects on intravesical pressure, heart rate, and mean blood pressure were evaluated in urethane-anesthetized rats.  Ritobegron increased cAMP accumulation in a concn.-dependent manner in CHO cells expressing any one of three human β-AR, its selectivity for β3-AR being 301-fold and 32-fold higher vs. β1-AR and β2-AR, resp.  Ritobegron decreased the resting tension of the isolated bladder in a concn.-dependent manner (EC50, 7.7 × 10-8 mol/L; maximal relaxation, 97.0 %), and the β3-AR antagonist SR58894A produced a parallel rightward-shift of this concn.-response curve without altering the maximal response [pKB value, 6.43].  Ritobegron concn.-dependently increased atrial rate and decreased myometrial contractions in vitro, and its selectivity for the bladder was 2,078-fold higher vs. the atria and 14-fold higher vs. the uterus.  In vivo, ritobegron induced a dose-dependent decrease in intravesical pressure (ED50 0.4 mg/kg), without affecting heart rate and only slightly lowering mean blood pressure.  Thus, ritobegron displayed potent and selective β3-AR agonistic activity toward transfected human β-AR and exhibited a high selectivity for the bladder vs. other organs in rats.  Moreover, it decreased intravesical pressure with minimal effects on the cardiovascular system in anesthetized rats.  These results suggest that ritobegron shows promise as a potential agent for the treatment of overactive bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSQ21qPG2_oLVg90H21EOLACvtfcHk0lj1O4_QysG5rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVemu73N&md5=2347d7515857ba3d8e708662c6f9e8f2</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1007%2Fs00210-012-0755-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-012-0755-x%26sid%3Dliteratum%253Aachs%26aulast%3DMaruyama%26aufirst%3DI.%26aulast%3DGoi%26aufirst%3DY.%26aulast%3DTatemichi%26aufirst%3DS.%26aulast%3DMaruyama%26aufirst%3DK.%26aulast%3DHoyano%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DKusama%26aufirst%3DH.%26atitle%3DBladder%2520selectivity%2520of%2520the%2520novel%2520%25CE%25B23-agonist%2520ritobegron%2520%2528KUC-7483%2529%2520explored%2520by%2520in%2520vitro%2520and%2520in%2520vivo%2520studies%2520in%2520the%2520rat%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2012%26volume%3D385%26spage%3D845%26epage%3D852%26doi%3D10.1007%2Fs00210-012-0755-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Maruyama, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatemichi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusama, H.</span><span> </span><span class="NLM_article-title">Effects of ritobegron (KUC-7483), a novel selective β<sub>3</sub>-adrenoceptor agonist, on bladder function in cynomolgus monkey</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span><span class="refDoi"> DOI: 10.1124/jpet.112.191783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1124%2Fjpet.112.191783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=22511202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOktbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2012&pages=163-168&author=I.+Maruyamaauthor=S.+Tatemichiauthor=Y.+Goiauthor=K.+Maruyamaauthor=Y.+Hoyanoauthor=Y.+Yamazakiauthor=H.+Kusama&title=Effects+of+ritobegron+%28KUC-7483%29%2C+a+novel+selective+%CE%B23-adrenoceptor+agonist%2C+on+bladder+function+in+cynomolgus+monkey&doi=10.1124%2Fjpet.112.191783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, on bladder function in cynomolgus monkey</span></div><div class="casAuthors">Maruyama, Itaru; Tatemichi, Satoshi; Goi, Yoshiaki; Maruyama, Kazuyasu; Hoyano, Yuji; Yamazaki, Yoshinobu; Kusama, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">163-168</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the pharmacol. profile of ritobegron [KUC-7483; (-)-Et 2-[4-(2-{[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)-2,5-dimethylphenyloxy]acetate monohydrochloride] and its effects on the bladder in cynomolgus monkeys by in vitro and in vivo expts.  In vitro, ritobegron decreased the resting tension of the isolated bladder in a concn.-dependent manner (EC50 8.2 ± 2.3 × 10-7 M; maximal relaxation 88.7 ± 3.7%).  The β3-adrenoceptor (AR) antagonist 3-(2-allylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol hydrochloride (SR58894A) produced a rightward shift of this concn.-response curve without altering the maximal response (pKB value 6.56 ± 0.35).  In isolated atria, ritobegron increased the atrial rate only at high concns. (EC50 6.5 ± 1.2 × 10-5 M).  Ritobegron had no effect on tracheal contraction at concns. from 10-9 to 10-4 M, and even at the highest concn. tested, 10-3 M, the maximal relaxation it induced was only 26.7 ± 8.1%.  Tests of the selectivity of ritobegron for the bladder gave values of 79.3- and 1200-fold higher vs. atria and trachea, resp.  In the in vivo study ritobegron significantly decreased intravesical pressure (ED50 1.44 mg/kg) without affecting either mean blood pressure or heart rate.  In conclusion, ritobegron displayed potent and selective β3-AR agonistic activity and relaxed the monkey isolated bladder, and in vivo it decreased intravesical pressure without affecting cardiovascular parameters.  These results suggest that ritobegron may be a promising potential agent for the treatment of overactive bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5uUKfB5bK0LVg90H21EOLACvtfcHk0lhRf4GFpJMtBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOktbjI&md5=e728f90c60c847251a0da437a2abea55</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.191783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.191783%26sid%3Dliteratum%253Aachs%26aulast%3DMaruyama%26aufirst%3DI.%26aulast%3DTatemichi%26aufirst%3DS.%26aulast%3DGoi%26aufirst%3DY.%26aulast%3DMaruyama%26aufirst%3DK.%26aulast%3DHoyano%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DKusama%26aufirst%3DH.%26atitle%3DEffects%2520of%2520ritobegron%2520%2528KUC-7483%2529%252C%2520a%2520novel%2520selective%2520%25CE%25B23-adrenoceptor%2520agonist%252C%2520on%2520bladder%2520function%2520in%2520cynomolgus%2520monkey%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D342%26spage%3D163%26epage%3D168%26doi%3D10.1124%2Fjpet.112.191783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Sacco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bientinesi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tienforti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racioppi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Agostino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, P.</span><span> </span><span class="NLM_article-title">Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span><span class="refDoi"> DOI: 10.1517/17460441.2014.892923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1517%2F17460441.2014.892923" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=433-448&author=E.+Saccoauthor=R.+Bientinesiauthor=D.+Tienfortiauthor=M.+Racioppiauthor=G.+Gulinoauthor=D.+D%E2%80%99Agostinoauthor=M.+Vittoriauthor=P.+Bassi&title=Discovery+history+and+clinical+development+of+mirabegron+for+the+treatment+of+overactive+bladder+and+urinary+incontinence&doi=10.1517%2F17460441.2014.892923"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.892923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.892923%26sid%3Dliteratum%253Aachs%26aulast%3DSacco%26aufirst%3DE.%26aulast%3DBientinesi%26aufirst%3DR.%26aulast%3DTienforti%26aufirst%3DD.%26aulast%3DRacioppi%26aufirst%3DM.%26aulast%3DGulino%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Agostino%26aufirst%3DD.%26aulast%3DVittori%26aufirst%3DM.%26aulast%3DBassi%26aufirst%3DP.%26atitle%3DDiscovery%2520history%2520and%2520clinical%2520development%2520of%2520mirabegron%2520for%2520the%2520treatment%2520of%2520overactive%2520bladder%2520and%2520urinary%2520incontinence%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D433%26epage%3D448%26doi%3D10.1517%2F17460441.2014.892923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Malik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gelderen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mujais, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaddelee, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Koning, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaibara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keirns, J. J.</span><span> </span><span class="NLM_article-title">Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">696</span><span class="NLM_x">–</span> <span class="NLM_lpage">706</span><span class="refDoi"> DOI: 10.1038/clpt.2012.181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2Fclpt.2012.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=23149929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12is7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=696-706&author=M.+Malikauthor=E.+M.+van+Gelderenauthor=J.+H.+Leeauthor=D.+L.+Kowalskiauthor=M.+Yenauthor=R.+Goldwaterauthor=S.+K.+Mujaisauthor=M.+P.+Schaddeleeauthor=P.+de+Koningauthor=A.+Kaibaraauthor=S.+S.+Moyauthor=J.+J.+Keirns&title=Proarrhythmic+safety+of+repeat+doses+of+mirabegron+in+healthy+subjects%3A+a+randomized%2C+double-blind%2C+placebo-%2C+and+active-controlled+thorough+QT+study&doi=10.1038%2Fclpt.2012.181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24aR"><div class="casContent"><span class="casTitleNuber">24a</span><div class="casTitle"><span class="NLM_cas:atitle">Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study</span></div><div class="casAuthors">Malik, M.; van Gelderen, E. M.; Lee, J. H.; Kowalski, D. L.; Yen, M.; Goldwater, R.; Mujais, S. K.; Schaddelee, M. P.; de Koning, P.; Kaibara, A.; Moy, S. S.; Keirns, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">696-706</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Potential effects of the selective β3-adrenoceptor agonist mirabegron on cardiac repolarization were studied in healthy subjects.  The four-arm, parallel, two-way crossover study was double-blind and placebo- and active (moxifloxacin)-controlled.  After 2 baseline ECG days, subjects were randomized to one of eight treatment sequences (22 females and 22 males per sequence) of placebo crossed over with once-daily (10 days) 50, 100, or 200 mg mirabegron or a single 400-mg moxifloxacin dose on day 10.  In each period, continuous ECGs were recorded at two baselines and on the last drug administration day.  The lower one-sided 95% confidence interval for moxifloxacin effect on QTcI was >5 ms, demonstrating assay sensitivity.  According to ICH E14 criteria, mirabegron did not cause QTcI prolongation at the 50-mg therapeutic and 100-mg supratherapeutic doses in either sex.  Mirabegron prolonged QTcI interval at the 200-mg supratherapeutic dose (upper one-sided 95% CI >10 ms) in females, but not in males.  Clin. Pharmacol. & Therapeutics (2012); 92 6, 696-706. doi:10.1038/clpt.2012.181.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozi2PKhmgjELVg90H21EOLACvtfcHk0liw9hHZnyd4qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12is7fJ&md5=4d663a83c00f179de8fa2028c22b799f</span></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.181%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DM.%26aulast%3Dvan%2BGelderen%26aufirst%3DE.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKowalski%26aufirst%3DD.%2BL.%26aulast%3DYen%26aufirst%3DM.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DMujais%26aufirst%3DS.%2BK.%26aulast%3DSchaddelee%26aufirst%3DM.%2BP.%26aulast%3Dde%2BKoning%26aufirst%3DP.%26aulast%3DKaibara%26aufirst%3DA.%26aulast%3DMoy%26aufirst%3DS.%2BS.%26aulast%3DKeirns%26aufirst%3DJ.%2BJ.%26atitle%3DProarrhythmic%2520safety%2520of%2520repeat%2520doses%2520of%2520mirabegron%2520in%2520healthy%2520subjects%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-%252C%2520and%2520active-controlled%2520thorough%2520QT%2520study%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D696%26epage%3D706%26doi%3D10.1038%2Fclpt.2012.181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tyagi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyagi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chancellor, M.</span><span> </span><span class="NLM_article-title">Mirabegron: a safety review</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1517/14740338.2011.542146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1517%2F14740338.2011.542146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21142693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlaqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=287-294&author=P.+Tyagiauthor=V.+Tyagiauthor=M.+Chancellor&title=Mirabegron%3A+a+safety+review&doi=10.1517%2F14740338.2011.542146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Mirabegron: a safety review</span></div><div class="casAuthors">Tyagi, Pradeep; Tyagi, Vikas; Chancellor, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Mirabegron is being developed as a new treatment for the management of overactive bladder (OAB).  It is an orally active drug that works by activating the ββ3-adrenoceptor with a better safety profile than antimuscarinic drugs.  However, long-term adverse effects are not yet completely investigated.  The following article reviews the pharmacol. and efficacy of mirabegron by analyzing the tolerability findings in the data available from several Phase II placebo-controlled clin. trials conducted with an active comparator.  We aim to provide familiarity with the metabolic pathway responsible for disposition of mirabegron which makes it likely to produce pharmacokinetic interactions with other drugs, as although mirabegron is generally well tolerated, its potential to cause drug interactions may limit its use in some patients.  Mirabegron is a ββ3-adrenoceptor agonist developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile for OAB patients with advanced age and cognitive deficit.  It has been well tolerated with significant efficacy in reducing the no. of incontinence episodes and mean micturition frequency.  The most commonly reported toxic effects of mirabegron are gastrointestinal adverse events and headache.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxUX5hgO_DILVg90H21EOLACvtfcHk0liZgzbLLsg65g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlaqsr4%253D&md5=845f4b7fee7b1e10689a68abcdd6804c</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1517%2F14740338.2011.542146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2011.542146%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DP.%26aulast%3DTyagi%26aufirst%3DV.%26aulast%3DChancellor%26aufirst%3DM.%26atitle%3DMirabegron%253A%2520a%2520safety%2520review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2011%26volume%3D10%26spage%3D287%26epage%3D294%26doi%3D10.1517%2F14740338.2011.542146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hayashi, R.; Kikuchi, T.; Arai, M.; Kurosawa, S.; Hasebe, K.; Kanie, S.; Ozono, S.; Otsuka, A.</span><span> </span><span class="NLM_article-title">Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes</span>. WO2008093767,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+Hayashi&author=T.+Kikuchi&author=M.+Arai&author=S.+Kurosawa&author=K.+Hasebe&author=S.+Kanie&author=S.+Ozono&author=A.+Otsuka&title=Benzylamine+derivative+or+pharmaceutically+acceptable+acid+addition+salt+thereof%2C+and+use+thereof+for+medical+purposes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DR.%26atitle%3DBenzylamine%2520derivative%2520or%2520pharmaceutically%2520acceptable%2520acid%2520addition%2520salt%2520thereof%252C%2520and%2520use%2520thereof%2520for%2520medical%2520purposes%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tyagi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyagi, V.</span><span> </span><span class="NLM_article-title">Mirabegron, a β<sub>3</sub>-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=713-722&author=P.+Tyagiauthor=V.+Tyagi&title=Mirabegron%2C+a+%CE%B23-adrenoceptor+agonist+for+the+potential+treatment+of+urinary+frequency%2C+urinary+incontinence+or+urgency+associated+with+overactive+bladder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DP.%26aulast%3DTyagi%26aufirst%3DV.%26atitle%3DMirabegron%252C%2520a%2520%25CE%25B23-adrenoceptor%2520agonist%2520for%2520the%2520potential%2520treatment%2520of%2520urinary%2520frequency%252C%2520urinary%2520incontinence%2520or%2520urgency%2520associated%2520with%2520overactive%2520bladder%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D713%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bragg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vouri, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitlick, J. M.</span><span> </span><span class="NLM_article-title">Mirabegron: a Beta-3 agonist for overactive bladder</span> <span class="citation_source-journal">Consult Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">823</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span><span class="refDoi"> DOI: 10.4140/TCP.n.2014.823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.4140%2FTCP.n.2014.823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=25521658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgvFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=823-837&author=R.+Braggauthor=D.+Hebelauthor=S.+M.+Vouriauthor=J.+M.+Pitlick&title=Mirabegron%3A+a+Beta-3+agonist+for+overactive+bladder&doi=10.4140%2FTCP.n.2014.823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Mirabegron: a Beta-3 agonist for overactive bladder</span></div><div class="casAuthors">Bragg Rebecca; Hebel Danielle; Vouri Scott Martin; Pitlick Jamie M</div><div class="citationInfo"><span class="NLM_cas:title">The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">823-37</span>
        ISSN:<span class="NLM_cas:issn">0888-5109</span>.
    </div><div class="casAbstract">OBJECTIVE:  To review the literature regarding the efficacy and safety of mirabegron for the treatment of overactive bladder (OAB).  DATA SOURCES:  A literature search was performed using MEDLINE (PubMed) prior to December 31, 2013, using the terms "mirabegron" and "randomized-controlled trial."  STUDY SELECTION/DATA EXTRACTION:  All published, double-blind, randomized-controlled trials assessing mirabegron were included.  Articles were reviewed and included if mirabegron was used as monotherapy and if the primary outcome analyzed drug efficacy.  DATA SYNTHESIS:  The efficacy of mirabegron for the treatment of OAB has been demonstrated in the selected five randomized, placebo-controlled trials.  The majority of these trials lasted 12 weeks and compared various doses of mirabegron with placebo and/or tolterodine extended-release (ER).  Primary efficacy outcomes for the trials included mean number of micturitions per 24 hours and mean number of incontinence episodes per 24 hours.  Included trials showed statistically significant reductions in both efficacy outcomes for various doses of mirabegron when compared with placebo.  CONCLUSION:  Based on the trials reviewed, mirabegron has been efficacious in reducing mean number of micturitions and incontinence episodes per 24 hours, as well as in improving other secondary outcomes such as OAB symptoms and quality-of-life measures.  Common adverse drug events seen with mirabegron include: hypertension, nasopharyngitis, urinary tract infections, headache, constipation, upper respiratory tract infection, arthralgia, diarrhea, tachycardia, abdominal pain, and fatigue.  Given the efficacy and safety data currently available, mirabegron represents a reasonable alternative to antimuscarinics for patients with OAB.  Future studies are needed to determine the utility of mirabegron for OAB in a variety of demographics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8R_CrClfSRxWfpMXQLRstfW6udTcc2eZelkP2d9HR_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgvFajtg%253D%253D&md5=77c9f399bbcc48ffc99b3a39fc075116</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.4140%2FTCP.n.2014.823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4140%252FTCP.n.2014.823%26sid%3Dliteratum%253Aachs%26aulast%3DBragg%26aufirst%3DR.%26aulast%3DHebel%26aufirst%3DD.%26aulast%3DVouri%26aufirst%3DS.%2BM.%26aulast%3DPitlick%26aufirst%3DJ.%2BM.%26atitle%3DMirabegron%253A%2520a%2520Beta-3%2520agonist%2520for%2520overactive%2520bladder%26jtitle%3DConsult%2520Pharm.%26date%3D2014%26volume%3D29%26spage%3D823%26epage%3D837%26doi%3D10.4140%2FTCP.n.2014.823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Altenbach, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khilevich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolasa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohde, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searle, X. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnelle, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tietje, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayburt, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daza, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milicic, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ireland, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakane, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brune, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauvin, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katwala, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holladay, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. P.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing α<sub>1A</sub>-adrenoceptor agonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3220</span><span class="NLM_x">–</span> <span class="NLM_lpage">3235</span><span class="refDoi"> DOI: 10.1021/jm030551a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030551a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3220-3235&author=R.+J.+Altenbachauthor=A.+Khilevichauthor=T.+Kolasaauthor=J.+J.+Rohdeauthor=P.+A.+Bhatiaauthor=M.+V.+Patelauthor=X.+B.+Searleauthor=F.+Yangauthor=W.+H.+Bunnelleauthor=K.+Tietjeauthor=E.+K.+Bayburtauthor=W.+A.+Carrollauthor=M.+D.+Meyerauthor=R.+Henryauthor=S.+A.+Bucknerauthor=J.+Kukauthor=A.+V.+Dazaauthor=I.+V.+Milicicauthor=J.+C.+Cainauthor=C.+H.+Kangauthor=L.+M.+Irelandauthor=T.+L.+Carrauthor=T.+R.+Millerauthor=A.+A.+Hancockauthor=M.+Nakaneauthor=T.+A.+Esbenshadeauthor=M.+E.+Bruneauthor=A.+B.+O%E2%80%99Neillauthor=D.+M.+Gauvinauthor=S.+P.+Katwalaauthor=M.+W.+Holladayauthor=J.+D.+Brioniauthor=J.+P.+Sullivan&title=Synthesis+and+structure-activity+studies+on+N-%5B5-%281H-imidazol-4-yl%29-5%2C6%2C7%2C8-tetrahydro-1-naphthalenyl%5Dmethanesulfonamide%2C+an+imidazole-containing+%CE%B11A-adrenoceptor+agonist&doi=10.1021%2Fjm030551a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fjm030551a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030551a%26sid%3Dliteratum%253Aachs%26aulast%3DAltenbach%26aufirst%3DR.%2BJ.%26aulast%3DKhilevich%26aufirst%3DA.%26aulast%3DKolasa%26aufirst%3DT.%26aulast%3DRohde%26aufirst%3DJ.%2BJ.%26aulast%3DBhatia%26aufirst%3DP.%2BA.%26aulast%3DPatel%26aufirst%3DM.%2BV.%26aulast%3DSearle%26aufirst%3DX.%2BB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DBunnelle%26aufirst%3DW.%2BH.%26aulast%3DTietje%26aufirst%3DK.%26aulast%3DBayburt%26aufirst%3DE.%2BK.%26aulast%3DCarroll%26aufirst%3DW.%2BA.%26aulast%3DMeyer%26aufirst%3DM.%2BD.%26aulast%3DHenry%26aufirst%3DR.%26aulast%3DBuckner%26aufirst%3DS.%2BA.%26aulast%3DKuk%26aufirst%3DJ.%26aulast%3DDaza%26aufirst%3DA.%2BV.%26aulast%3DMilicic%26aufirst%3DI.%2BV.%26aulast%3DCain%26aufirst%3DJ.%2BC.%26aulast%3DKang%26aufirst%3DC.%2BH.%26aulast%3DIreland%26aufirst%3DL.%2BM.%26aulast%3DCarr%26aufirst%3DT.%2BL.%26aulast%3DMiller%26aufirst%3DT.%2BR.%26aulast%3DHancock%26aufirst%3DA.%2BA.%26aulast%3DNakane%26aufirst%3DM.%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DBrune%26aufirst%3DM.%2BE.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DA.%2BB.%26aulast%3DGauvin%26aufirst%3DD.%2BM.%26aulast%3DKatwala%26aufirst%3DS.%2BP.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26atitle%3DSynthesis%2520and%2520structure-activity%2520studies%2520on%2520N-%255B5-%25281H-imidazol-4-yl%2529-5%252C6%252C7%252C8-tetrahydro-1-naphthalenyl%255Dmethanesulfonamide%252C%2520an%2520imidazole-containing%2520%25CE%25B11A-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3220%26epage%3D3235%26doi%3D10.1021%2Fjm030551a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateishi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujiuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furutani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, S.</span><span> </span><span class="NLM_article-title">Tryptamine-based human β<sub>3</sub>-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5963</span><span class="NLM_x">–</span> <span class="NLM_lpage">5966</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.09.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmcl.2004.09.054" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=5963-5966&author=M.+Sawaauthor=H.+Tateishiauthor=K.+Mizunoauthor=H.+Haradaauthor=M.+Oueauthor=H.+Tsujiuchiauthor=Y.+Furutaniauthor=S.+Kato&title=Tryptamine-based+human+%CE%B23-adrenergic+receptor+agonists.+Part+2%3A+SAR+of+the+methylene+derivatives&doi=10.1016%2Fj.bmcl.2004.09.054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.09.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.09.054%26sid%3Dliteratum%253Aachs%26aulast%3DSawa%26aufirst%3DM.%26aulast%3DTateishi%26aufirst%3DH.%26aulast%3DMizuno%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DH.%26aulast%3DOue%26aufirst%3DM.%26aulast%3DTsujiuchi%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DY.%26aulast%3DKato%26aufirst%3DS.%26atitle%3DTryptamine-based%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists.%2520Part%25202%253A%2520SAR%2520of%2520the%2520methylene%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D5963%26epage%3D5966%26doi%3D10.1016%2Fj.bmcl.2004.09.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="note"><p class="first last">The pharmacological effect of <b>1</b> was previously investigated at a dose of 3 mg/kg iv in rats,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and the EC<sub>50</sub> values of <b>1</b> and <b>15</b> for human β<sub>3</sub>-AR were 22.4<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and 18 nM, respectively, suggesting that the two compounds are similarly potent β<sub>3</sub>-AR agonists. Therefore, as a preliminary experiment, we compared the cardiovascular safety of <b>1</b> and <b>15</b> at the same dose of 3 mg/kg iv in rats.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Matsubara, K. I.; Naoyuki; Ogawa; Masami</span><span> </span><span class="NLM_article-title">Processes for the preparation of tricyclic amino alcohol derivatives</span>. WO2001017962,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=K.+I.+Matsubara&author=+Naoyuki&author=+Ogawa&author=+Masami&title=Processes+for+the+preparation+of+tricyclic+amino+alcohol+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsubara%26aufirst%3DK.%2BI.%26atitle%3DProcesses%2520for%2520the%2520preparation%2520of%2520tricyclic%2520amino%2520alcohol%2520derivatives%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schaus, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandes, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokunaga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furrow, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. N.</span><span> </span><span class="NLM_article-title">Highly selective hydrolytic kinetic resolution of terminal epoxides catalyzed by chiral (salen)Co-III complexes. Practical synthesis of enantioenriched terminal epoxides and 1,2-diols</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">1307</span><span class="NLM_x">–</span> <span class="NLM_lpage">1315</span><span class="refDoi"> DOI: 10.1021/ja016737l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja016737l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=1307-1315&author=S.+E.+Schausauthor=B.+D.+Brandesauthor=J.+F.+Larrowauthor=M.+Tokunagaauthor=K.+B.+Hansenauthor=A.+E.+Gouldauthor=M.+E.+Furrowauthor=E.+N.+Jacobsen&title=Highly+selective+hydrolytic+kinetic+resolution+of+terminal+epoxides+catalyzed+by+chiral+%28salen%29Co-III+complexes.+Practical+synthesis+of+enantioenriched+terminal+epoxides+and+1%2C2-diols&doi=10.1021%2Fja016737l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Fja016737l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja016737l%26sid%3Dliteratum%253Aachs%26aulast%3DSchaus%26aufirst%3DS.%2BE.%26aulast%3DBrandes%26aufirst%3DB.%2BD.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DTokunaga%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DK.%2BB.%26aulast%3DGould%26aufirst%3DA.%2BE.%26aulast%3DFurrow%26aufirst%3DM.%2BE.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DHighly%2520selective%2520hydrolytic%2520kinetic%2520resolution%2520of%2520terminal%2520epoxides%2520catalyzed%2520by%2520chiral%2520%2528salen%2529Co-III%2520complexes.%2520Practical%2520synthesis%2520of%2520enantioenriched%2520terminal%2520epoxides%2520and%25201%252C2-diols%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D1307%26epage%3D1315%26doi%3D10.1021%2Fja016737l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sugimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiya, K.</span><span> </span><span class="NLM_article-title">Di-2-methoxyethyl azodicarboxylate (DMEAD): An inexpensive and separation-friendly alternative reagent for the Mitsunobu reaction</span> <span class="citation_source-journal">Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span><span class="refDoi"> DOI: 10.1246/cl.2007.566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1246%2Fcl.2007.566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD2sXks1Oitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2007&pages=566-567&author=T.+Sugimuraauthor=K.+Hagiya&title=Di-2-methoxyethyl+azodicarboxylate+%28DMEAD%29%3A+An+inexpensive+and+separation-friendly+alternative+reagent+for+the+Mitsunobu+reaction&doi=10.1246%2Fcl.2007.566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">Di-2-methoxyethyl azodicarboxylate (DMEAD): an inexpensive and separation-friendly alternative reagent for the Mitsunobu reaction</span></div><div class="casAuthors">Sugimura, Takashi; Hagiya, Kazutake</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">566-567</span>CODEN:
                <span class="NLM_cas:coden">CMLTAG</span>;
        ISSN:<span class="NLM_cas:issn">0366-7022</span>.
    
            (<span class="NLM_cas:orgname">Chemical Society of Japan</span>)
        </div><div class="casAbstract">Bis(2-methoxyethyl) azodicarboxylate was prepd. as an alternative of DEAD or DIAD for the Mitsunobu reaction.  Removal of the hydrazinedicarboxylate generated from DMEAD becomes much easier owing to the polar and water-sol. property.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTeeOSWsEf6LVg90H21EOLACvtfcHk0lgskJZil-WSYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXks1Oitrc%253D&md5=5f5509554865f983adeab05a918c85a3</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1246%2Fcl.2007.566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.2007.566%26sid%3Dliteratum%253Aachs%26aulast%3DSugimura%26aufirst%3DT.%26aulast%3DHagiya%26aufirst%3DK.%26atitle%3DDi-2-methoxyethyl%2520azodicarboxylate%2520%2528DMEAD%2529%253A%2520An%2520inexpensive%2520and%2520separation-friendly%2520alternative%2520reagent%2520for%2520the%2520Mitsunobu%2520reaction%26jtitle%3DChem.%2520Lett.%26date%3D2007%26volume%3D36%26spage%3D566%26epage%3D567%26doi%3D10.1246%2Fcl.2007.566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hagiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muramoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimura, T.</span><span> </span><span class="NLM_article-title">DMEAD: a new dialkyl azodicarboxylate for the Mitsunobu reaction</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">6109</span><span class="NLM_x">–</span> <span class="NLM_lpage">6114</span><span class="refDoi"> DOI: 10.1016/j.tet.2009.05.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.tet.2009.05.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=6109-6114&author=K.+Hagiyaauthor=N.+Muramotoauthor=T.+Misakiauthor=T.+Sugimura&title=DMEAD%3A+a+new+dialkyl+azodicarboxylate+for+the+Mitsunobu+reaction&doi=10.1016%2Fj.tet.2009.05.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">DMEAD: a new dialkyl azodicarboxylate for the Mitsunobu reaction</span></div><div class="casAuthors">Hagiya, Kazutake; Muramoto, Natsuko; Misaki, Tomonori; Sugimura, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">6109-6114</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Di-2-methoxyethyl azodicarboxylate (DMEAD) is prepd. in 65% yield in two steps as a cryst. solid.  Use of DMEAD in the Mitsunobu reaction of a variety of alcs. with pronucleophiles results in good yields of the products under sufficient stereospecificity of inversion, as conventional diisopropyl azodicarboxylate (DIAD) does.  Isolation of the product is, however, much easier with DMEAD than that with DIAD, because the hydrazine produced from DMEAD is highly hydrophilic and is completely separable by a simple extn. into neutral water.  Purifn. of the org. layer, after sepn. of the other byproduct, triphenylphosphine oxide, by filtration, easily provides high purity of the product in a good yield.  Concn. of the water layer yields the hydrazine, which can be reused for the prepn. of DMEAD.  One-step removal of the two byproducts by the aq. extn. was also possible when trimethylphosphine and DMEAD were employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8942g2yxAwbVg90H21EOLACvtfcHk0lgskJZil-WSYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCksbc%253D&md5=1465a85e39f7dd03b9c7f74d9f599c20</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2009.05.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2009.05.048%26sid%3Dliteratum%253Aachs%26aulast%3DHagiya%26aufirst%3DK.%26aulast%3DMuramoto%26aufirst%3DN.%26aulast%3DMisaki%26aufirst%3DT.%26aulast%3DSugimura%26aufirst%3DT.%26atitle%3DDMEAD%253A%2520a%2520new%2520dialkyl%2520azodicarboxylate%2520for%2520the%2520Mitsunobu%2520reaction%26jtitle%3DTetrahedron%26date%3D2009%26volume%3D65%26spage%3D6109%26epage%3D6114%26doi%3D10.1016%2Fj.tet.2009.05.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="note"><p class="first last">In the case of <b>15</b>, removal of the <i>O</i>-TES group with 1 M TBAF in THF before treating with 4 M HCl in dioxane effectively gave crystallized compound <b>15</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span> </span><span class="NLM_article-title">Insights into the binding modes of human β<sub>3</sub>-adrenergic receptor agonists with ligand-based and receptor-based methods</span> <span class="citation_source-journal">Mol. Diversity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">831</span><span class="refDoi"> DOI: 10.1007/s11030-011-9311-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1007%2Fs11030-011-9311-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=817-831&author=F.+Jinauthor=C.+Luauthor=X.+Sunauthor=W.+Liauthor=G.+Liuauthor=Y.+Tang&title=Insights+into+the+binding+modes+of+human+%CE%B23-adrenergic+receptor+agonists+with+ligand-based+and+receptor-based+methods&doi=10.1007%2Fs11030-011-9311-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1007%2Fs11030-011-9311-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-011-9311-8%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DY.%26atitle%3DInsights%2520into%2520the%2520binding%2520modes%2520of%2520human%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520with%2520ligand-based%2520and%2520receptor-based%2520methods%26jtitle%3DMol.%2520Diversity%26date%3D2011%26volume%3D15%26spage%3D817%26epage%3D831%26doi%3D10.1007%2Fs11030-011-9311-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Roy, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, A. K.</span><span> </span><span class="NLM_article-title">Structural basis for the β-adrenergic receptor subtype selectivity of the representative agonists and antagonists</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1405</span><span class="NLM_x">–</span> <span class="NLM_lpage">1422</span><span class="refDoi"> DOI: 10.1021/ci2000874</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci2000874" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=1405-1422&author=K.+K.+Royauthor=A.+K.+Saxena&title=Structural+basis+for+the+%CE%B2-adrenergic+receptor+subtype+selectivity+of+the+representative+agonists+and+antagonists&doi=10.1021%2Fci2000874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the β-Adrenergic Receptor Subtype Selectivity of the Representative Agonists and Antagonists</span></div><div class="casAuthors">Roy, Kuldeep K.; Saxena, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1405-1422</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The β3-adrenergic receptor (β3-AR) selectivity over β1- and β2-ARs has been the most important aspect for successful therapeutic agents for obesity and type-II diabetes, as the concomitant activation of β1- and β2-ARs would lead to undesirable side effects, such as increased heart rate.  In order to explore the structural basis for the β-AR subtype selectivity of agonists and antagonists, a three-dimensional structure of until date unresolved β3-AR has been modeled, compared with the resolved X-ray structures of β1- and β2-ARs, and used to study its stereoselective binding with until-date known diverse classes of representative agonists and antagonist.  The obtained binding structures and calcd. prime mol. mechanics-generalized Born surface area (MM-GBSA) binding free energies consistently reveal that while the subtype selectivity is strongly governed by the residues present in the extracellular ends of TM3, TM5, TM6, TM7 helixes and of the ECL2 domain, the binding affinity is governed by the conserved residues present in the deep pocket limiting the degree of conformational and rotational freedoms to the bound ligand.  The study demonstrates that the key structural requirements for the β3-selectivity are: (i) a neg. ionizable group (NIG) for direct interaction with β3-specific residue R3156.58, (ii) a linker (9-10 Å length) between the protonated amine and NIG, and (iii) a substituted aryl ring directly attached to the β-hydroxyl carbon.  The new computational insights acquired in this study are expected to be valuable in structure-based rational design of high-affinity agonists and antagonists with pronounced β3-selectivity for successful therapeutic agents for type-II diabetes and obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKByl5Kn7SurVg90H21EOLACvtfcHk0lgskJZil-WSYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVCmt7g%253D&md5=bbfca37eae96885f6b6a62ff40ea757c</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Fci2000874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2000874%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DK.%2BK.%26aulast%3DSaxena%26aufirst%3DA.%2BK.%26atitle%3DStructural%2520basis%2520for%2520the%2520%25CE%25B2-adrenergic%2520receptor%2520subtype%2520selectivity%2520of%2520the%2520representative%2520agonists%2520and%2520antagonists%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D1405%26epage%3D1422%26doi%3D10.1021%2Fci2000874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure of a nanobody-stabilized active state of the β<sub>2</sub> adrenoceptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1038/nature09648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2Fnature09648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21228869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=175-180&author=S.+G.+Rasmussenauthor=H.+J.+Choiauthor=J.+J.+Fungauthor=E.+Pardonauthor=P.+Casarosaauthor=P.+S.+Chaeauthor=B.+T.+Devreeauthor=D.+M.+Rosenbaumauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=A.+Schnappauthor=I.+Konetzkiauthor=R.+K.+Sunaharaauthor=S.+H.+Gellmanauthor=A.+Pautschauthor=J.+Steyaertauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Structure+of+a+nanobody-stabilized+active+state+of+the+%CE%B22+adrenoceptor&doi=10.1038%2Fnature09648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a nanobody-stabilized active state of the β2 adrenoceptor</span></div><div class="casAuthors">Rasmussen, Soren G. F.; Choi, Hee-Jung; Fung, Juan Jose; Pardon, Els; Casarosa, Paola; Chae, Pil Seok; DeVree, Brian T.; Rosenbaum, Daniel M.; Thian, Foon Sun; Kobilka, Tong Sun; Schnapp, Andreas; Konetzki, Ingo; Sunahara, Roger K.; Gellman, Samuel H.; Pautsch, Alexander; Steyaert, Jan; Weis, William I.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">175-180</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein coupled receptors (GPCRs) exhibit a spectrum of functional behaviors in response to natural and synthetic ligands.  Recent crystal structures provide insights into inactive states of several GPCRs.  Efforts to obtain an agonist-bound active-state GPCR structure have proven difficult due to the inherent instability of this state in the absence of a G protein.  We generated a camelid antibody fragment (nanobody) to the human β2 adrenergic receptor (β2AR) that exhibits G protein-like behavior, and obtained an agonist-bound, active-state crystal structure of the receptor-nanobody complex.  Comparison with the inactive β2AR structure reveals subtle changes in the binding pocket; however, these small changes are assocd. with an 11 Å outward movement of the cytoplasmic end of transmembrane segment 6, and rearrangements of transmembrane segments 5 and 7 that are remarkably similar to those obsd. in opsin, an active form of rhodopsin.  This structure provides insights into the process of agonist binding and activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqITZxHz6Vi77Vg90H21EOLACvtfcHk0limjjVN_05dNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFartA%253D%253D&md5=3a1d3bac6d92c9d54cf1ddd14d56ab8c</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1038%2Fnature09648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09648%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DFung%26aufirst%3DJ.%2BJ.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DDevree%26aufirst%3DB.%2BT.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DPautsch%26aufirst%3DA.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520of%2520a%2520nanobody-stabilized%2520active%2520state%2520of%2520the%2520%25CE%25B22%2520adrenoceptor%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D175%26epage%3D180%26doi%3D10.1038%2Fnature09648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calinski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiesen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caffrey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyaert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skiniotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Crystal structure of the β<sub>2</sub> adrenergic receptor-Gs protein complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">477</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span><span class="refDoi"> DOI: 10.1038/nature10361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2Fnature10361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21772288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1equrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2011&pages=549-555&author=S.+G.+Rasmussenauthor=B.+T.+DeVreeauthor=Y.+Zouauthor=A.+C.+Kruseauthor=K.+Y.+Chungauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=P.+S.+Chaeauthor=E.+Pardonauthor=D.+Calinskiauthor=J.+M.+Mathiesenauthor=S.+T.+Shahauthor=J.+A.+Lyonsauthor=M.+Caffreyauthor=S.+H.+Gellmanauthor=J.+Steyaertauthor=G.+Skiniotisauthor=W.+I.+Weisauthor=R.+K.+Sunaharaauthor=B.+K.+Kobilka&title=Crystal+structure+of+the+%CE%B22+adrenergic+receptor-Gs+protein+complex&doi=10.1038%2Fnature10361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the β2 adrenergic receptor-Gs protein complex</span></div><div class="casAuthors">Rasmussen, Soren G. F.; DeVree, Brian T.; Zou, Yao-Zhong; Kruse, Andrew C.; Chung, Ka-Young; Kobilka, Tong-Sun; Thian, Foon-Sun; Chae, Pil-Seok; Pardon, Els; Calinski, Diane; Mathiesen, Jesper M.; Shah, Syed T. A.; Lyons, Joseph A.; Caffrey, Martin; Gellman, Samuel H.; Steyaert, Jan; Skiniotis, Georgios; Weis, William I.; Sunahara, Roger K.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">477</span>
        (<span class="NLM_cas:issue">7366</span>),
    <span class="NLM_cas:pages">549-555</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are responsible for the majority of cellular responses to hormones and neurotransmitters as well as the senses of sight, olfaction and taste.  The paradigm of GPCR signalling is the activation of a heterotrimeric GTP binding protein (G protein) by an agonist-occupied receptor.  The β2 adrenergic receptor (β2AR) activation of Gs, the stimulatory G protein for adenylyl cyclase, has long been a model system for GPCR signalling.  Here we present the crystal structure of the active state ternary complex composed of agonist-occupied monomeric β2AR and nucleotide-free Gs heterotrimer.  The principal interactions between the β2AR and Gs involve the amino- and carboxy-terminal α-helixes of Gs, with conformational changes propagating to the nucleotide-binding pocket.  The largest conformational changes in the β2AR include a 14 Å outward movement at the cytoplasmic end of transmembrane segment 6 (TM6) and an α-helical extension of the cytoplasmic end of TM5.  The most surprising observation is a major displacement of the α-helical domain of Gαs relative to the Ras-like GTPase domain.  This crystal structure represents the first high-resoln. view of transmembrane signalling by a GPCR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-PdYRDvolqrVg90H21EOLACvtfcHk0limjjVN_05dNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1equrrL&md5=d22a43dd677ac255d138b1aedff357d3</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1038%2Fnature10361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10361%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DDeVree%26aufirst%3DB.%2BT.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DChung%26aufirst%3DK.%2BY.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DCalinski%26aufirst%3DD.%26aulast%3DMathiesen%26aufirst%3DJ.%2BM.%26aulast%3DShah%26aufirst%3DS.%2BT.%26aulast%3DLyons%26aufirst%3DJ.%2BA.%26aulast%3DCaffrey%26aufirst%3DM.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DSkiniotis%26aufirst%3DG.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520%25CE%25B22%2520adrenergic%2520receptor-Gs%2520protein%2520complex%26jtitle%3DNature%26date%3D2011%26volume%3D477%26spage%3D549%26epage%3D555%26doi%3D10.1038%2Fnature10361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aragao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arlow, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devree, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunahara, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dror, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caffrey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Structure and function of an irreversible agonist-β<sub>2</sub> adrenoceptor complex</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">469</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span><span class="refDoi"> DOI: 10.1038/nature09665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1038%2Fnature09665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=21228876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=236-240&author=D.+M.+Rosenbaumauthor=C.+Zhangauthor=J.+A.+Lyonsauthor=R.+Hollauthor=D.+Aragaoauthor=D.+H.+Arlowauthor=S.+G.+Rasmussenauthor=H.+J.+Choiauthor=B.+T.+Devreeauthor=R.+K.+Sunaharaauthor=P.+S.+Chaeauthor=S.+H.+Gellmanauthor=R.+O.+Drorauthor=D.+E.+Shawauthor=W.+I.+Weisauthor=M.+Caffreyauthor=P.+Gmeinerauthor=B.+K.+Kobilka&title=Structure+and+function+of+an+irreversible+agonist-%CE%B22+adrenoceptor+complex&doi=10.1038%2Fnature09665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of an irreversible agonist-β2 adrenoceptor complex</span></div><div class="casAuthors">Rosenbaum, Daniel M.; Zhang, Cheng; Lyons, Joseph A.; Holl, Ralph; Aragao, David; Arlow, Daniel H.; Rasmussen, Soren G. F.; Choi, Hee-Jung; DeVree, Brian T.; Sunahara, Roger K.; Chae, Pil Seok; Gellman, Samuel H.; Dror, Ron O.; Shaw, David E.; Weis, William I.; Caffrey, Martin; Gmeiner, Peter; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">236-240</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are eukaryotic integral membrane proteins that modulate biol. function by initiating cellular signaling in response to chem. diverse agonists.  Despite recent progress in the structural biol. of GPCRs, the mol. basis for agonist binding and allosteric modulation of these proteins is poorly understood.  Structural knowledge of agonist-bound states is essential for deciphering the mechanism of receptor activation, and for structure-guided design and optimization of ligands.  However, the crystn. of agonist-bound GPCRs has been hampered by modest affinities and rapid off-rates of available agonists.  Using the inactive structure of the human β2 adrenergic receptor (β2AR) as a guide, we designed a β2AR agonist that can be covalently tethered to a specific site on the receptor through a disulfide bond.  The covalent β2AR-agonist complex forms efficiently, and is capable of activating a heterotrimeric G protein.  We crystd. a covalent agonist-bound β2AR-T4L fusion protein in lipid bilayers through the use of the lipidic mesophase method, and detd. its structure at 3.5 Å resoln.  A comparison to the inactive structure and an antibody-stabilized active structure (companion paper) shows how binding events at both the extracellular and intracellular surfaces are required to stabilize an active conformation of the receptor.  The structures are in agreement with long-timescale (up to 30 μs) mol. dynamics simulations showing that an agonist-bound active conformation spontaneously relaxes to an inactive-like conformation in the absence of a G protein or stabilizing antibody.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cxTxwHig_rVg90H21EOLACvtfcHk0ljkdjZ0UZ-9pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFehsQ%253D%253D&md5=8629b93e43fb692395e2aa6f8bb011a9</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.1038%2Fnature09665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09665%26sid%3Dliteratum%253Aachs%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLyons%26aufirst%3DJ.%2BA.%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DAragao%26aufirst%3DD.%26aulast%3DArlow%26aufirst%3DD.%2BH.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DDevree%26aufirst%3DB.%2BT.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DCaffrey%26aufirst%3DM.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520and%2520function%2520of%2520an%2520irreversible%2520agonist-%25CE%25B22%2520adrenoceptor%2520complex%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D236%26epage%3D240%26doi%3D10.1038%2Fnature09665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lober, S.</span><span> </span><span class="NLM_article-title">GPCR crystal structures: medicinal chemistry in the pocket</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3880</span><span class="NLM_x">–</span> <span class="NLM_lpage">3906</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.bmc.2014.12.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=25638496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVamtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3880-3906&author=J.+Shonbergauthor=R.+C.+Klingauthor=P.+Gmeinerauthor=S.+Lober&title=GPCR+crystal+structures%3A+medicinal+chemistry+in+the+pocket&doi=10.1016%2Fj.bmc.2014.12.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32dR"><div class="casContent"><span class="casTitleNuber">32d</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR crystal structures: Medicinal chemistry in the pocket</span></div><div class="casAuthors">Shonberg, Jeremy; Kling, Ralf C.; Gmeiner, Peter; Loeber, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3880-3906</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent breakthroughs in G protein-coupled receptor (GPCR) structural biol. have significantly increased the understanding of drug action at these therapeutically relevant receptors, and this will undoubtedly lead to the design of better therapeutics.  In recent years, crystal structures of GPCRs from classes A, B, C, and F have been solved, unveiling a precise snapshot of ligand-receptor interactions.  Furthermore, some receptors have been crystd. in different functional states in complex with antagonists, partial agonists, full agonists, biased agonists, and allosteric modulators, providing further insight into the mechanisms of ligand-induced GPCR activation.  It is now obvious that there is enormous diversity in the size, shape and position of the ligand-binding pockets in GPCRs.  Here, the authors summarize the current state of solved GPCR structures, with a particular focus on ligand-receptor interactions in the binding pocket, and how this can contribute to the design of GPCR ligands with better affinity, subtype selectivity, or efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuUGn2F8NmfrVg90H21EOLACvtfcHk0ljkdjZ0UZ-9pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVamtw%253D%253D&md5=28f8f0f1f3c0526efce9f7f40f9053d4</span></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.034%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DLober%26aufirst%3DS.%26atitle%3DGPCR%2520crystal%2520structures%253A%2520medicinal%2520chemistry%2520in%2520the%2520pocket%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3880%26epage%3D3906%26doi%3D10.1016%2Fj.bmc.2014.12.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuto, S.</span><span> </span><span class="NLM_article-title">Investigation of the bioactive conformation of histamine H3 receptor antagonists by the cyclopropylic strain-based conformational restriction strategy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3585</span><span class="NLM_x">–</span> <span class="NLM_lpage">3593</span><span class="refDoi"> DOI: 10.1021/jm901848b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901848b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3585-3593&author=M.+Watanabeauthor=T.+Hirokawaauthor=T.+Kobayashiauthor=A.+Yoshidaauthor=Y.+Itoauthor=S.+Yamadaauthor=N.+Orimotoauthor=Y.+Yamasakiauthor=M.+Arisawaauthor=S.+Shuto&title=Investigation+of+the+bioactive+conformation+of+histamine+H3+receptor+antagonists+by+the+cyclopropylic+strain-based+conformational+restriction+strategy&doi=10.1021%2Fjm901848b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm901848b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901848b%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DHirokawa%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DS.%26aulast%3DOrimoto%26aufirst%3DN.%26aulast%3DYamasaki%26aufirst%3DY.%26aulast%3DArisawa%26aufirst%3DM.%26aulast%3DShuto%26aufirst%3DS.%26atitle%3DInvestigation%2520of%2520the%2520bioactive%2520conformation%2520of%2520histamine%2520H3%2520receptor%2520antagonists%2520by%2520the%2520cyclopropylic%2520strain-based%2520conformational%2520restriction%2520strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3585%26epage%3D3593%26doi%3D10.1021%2Fjm901848b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Chen, Y.-C.</span><span> </span><span class="NLM_article-title">Beware of docking!</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1016/j.tips.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1016%2Fj.tips.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=25543280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=78-95&author=Y.-C.+Chen&title=Beware+of+docking%21&doi=10.1016%2Fj.tips.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Beware of docking!</span></div><div class="casAuthors">Chen, Yu-Chian</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">78-95</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Docking is now routine in virtual screening or lead optimization for drug screening and design.  The no. of papers related to docking has dramatically increased over the past decade.  However, there are many issues to consider when undertaking a docking study.  Frequent problems or issues arise, such as the wrong binding site of the target protein, screening using an unsuitable small-mol. database, the choice of docking pose, high dock score but failed in mol. dynamics (MD) simulation, and lack of clarity over whether the compd. is an inhibitor or agonist.  These problems should be cause for caution and concern before performing docking.  Some papers show comprehensive biochem. expts. but only a simple docking figure.  This review presents some evidence to show that the docking might be questionable, despite a high score.  In some cases, the accuracy of docking can even change from 0% to 92.66%.  Thus, please beware of docking!</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwtnBYohkg_bVg90H21EOLACvtfcHk0liVBzMt4MWpWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyluw%253D%253D&md5=5a045e1314d6382644f50a58275d536b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-C.%26atitle%3DBeware%2520of%2520docking%2521%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D78%26epage%3D95%26doi%3D10.1016%2Fj.tips.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0liVBzMt4MWpWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Naritomi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagayama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span> </span><span class="NLM_article-title">Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=11560875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntVGqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=1316-1324&author=Y.+Naritomiauthor=S.+Terashitaauthor=S.+Kimuraauthor=A.+Suzukiauthor=A.+Kagayamaauthor=Y.+Sugiyama&title=Prediction+of+human+hepatic+clearance+from+in+vivo+animal+experiments+and+in+vitro+metabolic+studies+with+liver+microsomes+from+animals+and+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans</span></div><div class="casAuthors">Naritomi, Yoichi; Terashita, Shigeyuki; Kimura, Sumihisa; Suzuki, Akira; Kagayama, Akira; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1316-1324</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The authors investigated the quant. prediction of human hepatic metabolic clearance from in vitro expts. focusing on cytochrome P 450 metab. with 8 model compds., FK1052, FK480, zolpidem, omeprazole, nicardipine, nilvadipine, diazepam, and diltiazem.  For the compds., in vivo human hepatic extn. ratios ranged widely from 0.03 to 0.87.  In vitro and in vivo hepatic intrinsic clearance (CLint) values for each compd. were measured and calcd. in rats and/or dogs and humans.  CLint,in vitro was detd. from a substrate disappearance rate at 1 μM in hepatic microsomes, which was a useful method.  CLint,in vivo was calcd. from in vivo pharmacokinetic data using 3 frequent math. models (the well stirred, parallel-tube, and dispersion models).  The human scaling factor values (CLint,in vivo/CLint,in vitro) showed marked difference among the model compds. (0.3-26.6-fold).  On the other hand, most of the animal scaling factors were within 2-fold of the values in humans, suggesting that scaling factor values were similar in the different animal species.  When human CLint,in vitro values were compared with the actual CLint,in vivo, correlation was not necessarily good.  By contrast, using human CLint,in vitro cor. with the rat and/or dog scaling factors yielded better predictions of CLint,in vivo that were mostly within 2-fold of the actual values.  Furthermore, successful predictions of human CLoral and hepatic extn. ratio (EH) were obtained by use of the human CLint,in vitro cor. with animal scaling factors.  The new variant method is a simple one, incorporating addnl. information from animal studies and providing a more reliable prediction of human hepatic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcc19l5ypTILVg90H21EOLACvtfcHk0liVBzMt4MWpWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntVGqurs%253D&md5=b8eb1ad7992ce8193cf1a35862823d49</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaritomi%26aufirst%3DY.%26aulast%3DTerashita%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKagayama%26aufirst%3DA.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520human%2520hepatic%2520clearance%2520from%2520in%2520vivo%2520animal%2520experiments%2520and%2520in%2520vitro%2520metabolic%2520studies%2520with%2520liver%2520microsomes%2520from%2520animals%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2001%26volume%3D29%26spage%3D1316%26epage%3D1324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Bowers, K. J.; Chow, E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregersen, B. A.; Klepeis, J. L.; Kolossvary, I.; Moraes, M. A.; Sacerdoti, F. D.; Salmon, J. K; Shan, Y.; Shaw, D. E.</span><span> </span><span class="NLM_article-title">Scalable algorithms for molecular dynamics simulations on commodity clusters</span>. Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa, Florida, November 11–17,2016,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+J.+Bowers&author=E.+Chow&author=H.+Xu&author=R.+O.+Dror&author=M.+P.+Eastwood&author=B.+A.+Gregersen&author=J.+L.+Klepeis&author=I.+Kolossvary&author=M.+A.+Moraes&author=F.+D.+Sacerdoti&author=J.+K+Salmon&author=Y.+Shan&author=D.+E.+Shaw&title=Scalable+algorithms+for+molecular+dynamics+simulations+on+commodity+clusters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DK.%2BJ.%26atitle%3DScalable%2520algorithms%2520for%2520molecular%2520dynamics%2520simulations%2520on%2520commodity%2520clusters%26jtitle%3DProceedings%2520of%2520the%2520ACM%252FIEEE%2520Conference%2520on%2520Supercomputing%2520%2528SC06%2529%252C%2520Tampa%252C%2520Florida%252C%2520November%252011%25E2%2580%259317%252C2016%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Harder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damm, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maple, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reboul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupyan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlgren, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaus, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerutti, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krilov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">OPLS3: a force field providing broad coverage of drug-like small molecules and proteins</span> <span class="citation_source-journal">J. Chem. Theory Comput.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">296</span><span class="refDoi"> DOI: 10.1021/acs.jctc.5b00864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=281-296&author=E.+Harderauthor=W.+Dammauthor=J.+Mapleauthor=C.+Wuauthor=M.+Reboulauthor=J.+Y.+Xiangauthor=L.+Wangauthor=D.+Lupyanauthor=M.+K.+Dahlgrenauthor=J.+L.+Knightauthor=J.+W.+Kausauthor=D.+S.+Ceruttiauthor=G.+Krilovauthor=W.+L.+Jorgensenauthor=R.+Abelauthor=R.+A.+Friesner&title=OPLS3%3A+a+force+field+providing+broad+coverage+of+drug-like+small+molecules+and+proteins&doi=10.1021%2Facs.jctc.5b00864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins</span></div><div class="casAuthors">Harder, Edward; Damm, Wolfgang; Maple, Jon; Wu, Chuanjie; Reboul, Mark; Xiang, Jin Yu; Wang, Lingle; Lupyan, Dmitry; Dahlgren, Markus K.; Knight, Jennifer L.; Kaus, Joseph W.; Cerutti, David S.; Krilov, Goran; Jorgensen, William L.; Abel, Robert; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-296</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and validation of the OPLS3 force field for small mols. and proteins are reported.  Enhancements with respect to the previous version (OPLS2.1) include the addn. of off-atom charge sites to represent halogen bonding and aryl nitrogen lone pairs as well as a complete refit of peptide dihedral parameters to better model the native structure of proteins.  To adequately cover medicinal chem. space, OPLS3 employs over an order of magnitude more ref. data and assocd. parameter types relative to other commonly used small mol. force fields (e.g., MMFF and OPLS_2005).  As a consequence, OPLS3 achieves a high level of accuracy across performance benchmarks that assess small mol. conformational propensities and solvation.  The newly fitted peptide dihedrals lead to significant improvements in the representation of secondary structure elements in simulated peptides and native structure stability over a no. of proteins.  Together, the improvements made to both the small mol. and protein force field lead to a high level of accuracy in predicting protein-ligand binding measured over a wide range of targets and ligands (less than 1 kcal/mol RMS error) representing a 30% improvement over earlier variants of the OPLS force field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY_jrOhcBRgrVg90H21EOLACvtfcHk0ljeyZpzXl-zuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCjtbfE&md5=42663f8cfa84b80a67132bbb13b9b7ce</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00864%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DDamm%26aufirst%3DW.%26aulast%3DMaple%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DReboul%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLupyan%26aufirst%3DD.%26aulast%3DDahlgren%26aufirst%3DM.%2BK.%26aulast%3DKnight%26aufirst%3DJ.%2BL.%26aulast%3DKaus%26aufirst%3DJ.%2BW.%26aulast%3DCerutti%26aufirst%3DD.%2BS.%26aulast%3DKrilov%26aufirst%3DG.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOPLS3%253A%2520a%2520force%2520field%2520providing%2520broad%2520coverage%2520of%2520drug-like%2520small%2520molecules%2520and%2520proteins%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D281%26epage%3D296%26doi%3D10.1021%2Facs.jctc.5b00864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Lomize, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomize, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogozheva, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosberg, H. I.</span><span> </span><span class="NLM_article-title">OPM: orientations of proteins in membranes database</span> <span class="citation_source-journal">Bioinformatics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1093/bioinformatics/btk023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=10.1093%2Fbioinformatics%2Fbtk023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=16397007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVeksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2006&pages=623-625&author=M.+A.+Lomizeauthor=A.+L.+Lomizeauthor=I.+D.+Pogozhevaauthor=H.+I.+Mosberg&title=OPM%3A+orientations+of+proteins+in+membranes+database&doi=10.1093%2Fbioinformatics%2Fbtk023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">OPM: Orientations of Proteins in Membranes database</span></div><div class="casAuthors">Lomize, Mikhail A.; Lomize, Andrei L.; Pogozheva, Irina D.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">623-625</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Orientations of Proteins in Membranes (OPM) database provides a collection of transmembrane, monotopic, and peripheral proteins from the Protein Data Bank whose spatial arrangements in the lipid bilayer have been calcd. theor. and compared with exptl. data.  The database allows anal., sorting, and searching of membrane proteins based on their structural classification, species, destination membrane, nos. of transmembrane segments and subunits, nos. of secondary structures, and the calcd. hydrophobic thickness or tilt angle with respect to the bilayer normal.  All coordinate files with the calcd. membrane boundaries are available for downloading.  The Internet site for the database is: http://opm.phar.umich.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1WjpHiq7e8LVg90H21EOLACvtfcHk0ljeyZpzXl-zuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVeksro%253D&md5=8a9590a32e912509a53ca0bfc7ede4ad</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtk023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtk023%26sid%3Dliteratum%253Aachs%26aulast%3DLomize%26aufirst%3DM.%2BA.%26aulast%3DLomize%26aufirst%3DA.%2BL.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DOPM%253A%2520orientations%2520of%2520proteins%2520in%2520membranes%2520database%26jtitle%3DBioinformatics%26date%3D2006%26volume%3D22%26spage%3D623%26epage%3D625%26doi%3D10.1093%2Fbioinformatics%2Fbtk023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3P0G" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3P0G','PDB','3P0G'); return false;">PDB: 3P0G</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i38"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01197">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_34400"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01197">10.1021/acs.jmedchem.6b01197</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Proposed model of compound <b>15</b> binding to the homology model of β<sub>3</sub>-AR after MD refinement (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_001.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_002.csv">CSV</a>)</p></li><li><p class="inline">Methods for the solubility assay, permeability assay, cytochrome P450 inhibition assay, human α<sub>1B</sub> or α<sub>1D</sub>-AR agonist assay, homology modeling of the β<sub>3</sub>-AR, and docking; sequence alignment of human β<sub>3</sub>-, α<sub>1A</sub>-, β<sub>1</sub>-, and β<sub>2</sub>-AR; summary of individual −pEC<sub>50</sub> and docking score values for β<sub>3</sub>-AR; RMSD analysis of the compound <b>15</b> with β<sub>3</sub>-AR within MD simulations (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_001.pdb">jm6b01197_si_001.pdb (364.43 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_002.csv">jm6b01197_si_002.csv (0.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01197/suppl_file/jm6b01197_si_003.pdf">jm6b01197_si_003.pdf (479.99 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01197&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-8%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01197" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01197" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998794cbed3cca","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
